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Abstract
Ang II generated at tissue sites stimulates both AT1 and AT2 receptors. This local 
generation depends largely on angiotensinogen and renin and/or prorenin taken up 
from blood, the latter uptake possibly involving the recently discovered (pro)renin 
receptor. ACE is generated locally, and appears to be the main, if not the only, Ang 
II-generating enzyme. Ang II has a whole range of metabolites, the most important of 
which are Ang-(1-7), Ang III and Ang IV. The enzymes generating these metabolites, 
including ACE2, have recently been characterized, as well as their putative (non-
AT1/AT2) receptors, like the Mas and AT4 receptor.  Stimulation of AT2 receptors most 
likely contributes to the benefi cial effect of RAS blockers, in particular during AT1 
receptor antagonism. These receptors are upregulated under pathophysiological 
conditions, and are generally believed to counteract the effects of AT1 receptor 
stimulation. However, not all studies agree on this aspect, and thus it remains to be 
seen how the effect of drugs that completely suppress the RAS, i.e., renin inhibitors, 
compare to those that allow/require AT2 receptor stimulation, like ACE inhibitors and 
AT1 receptor antagonists.
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Introduction
The renin-angiotensin system (RAS) plays an important role in the regulation of blood pressure and body fl uid homeostasis. Traditionally, the RAS has been 
viewed as a circulating system (“circulating” RAS). However, it is now well-established 
that angiotensin (Ang) generation also occurs at tissue sites (“tissue” RAS). The 
complexity of the system has increased even further now that we know that Ang II 
activates more than one receptor, that Ang II has metabolites which activate their 
own receptors, and that there may even be receptors for renin and prorenin. This 
review summarizes the latest insights on tissue angiotensin generation and focuses 
in particular on the activation of the Ang II type 2 (AT2) receptor by locally generated 
Ang II. 
The renin angiotension system
Renin, prorenin and (pro)renin receptors
Renin belongs to the family of aspartyl proteases and has only one known substrate, 
angiotensinogen, the precursor of all angiotensin peptides. Structure analysis 
revealed that renin consists of 2 homologous lobes which form a cleft containing 
the active site. Renin has an inactive precursor, prorenin, in which the active site is 
covered by the prosegment. 
The renin gene was cloned in the 1980s in human, rat and mouse. Most species have 
one renin gene (ren-1c), although some mouse strains have two renin genes, ren-1d 
and a submandibular variant, designated as ren-2. The ren-2 gene is encoding for a 
nonglycosylated prorenin, as opposed to the ren-1 gene which can be glycosylated 
at three asparagine residues. The renin gene is located on chromosome 1 in human 
and mouse, whereas it is localized on chromosome 13 in rat. 
The renin gene encodes for pre-prorenin consisting of a presegment of 23 amino 
acids, a prosegment of 43 amino acids and the actual renin protein of 340 amino 
acids2. The presegment functions as a signal peptide directing prorenin to the 
secretory pathway. Recently, a splice-variant of the renin gene was discovered 
which lacks the signal peptide and part of the prosegment. This truncated prorenin 
displays enzymatic activity because the truncated prosegment only partially covers 
the enzymatic cleft. It is thought to remain intracellular3, although truncated prorenin 
has also been demonstrated extracellularly.4
Mice lacking the ren-1d gene are characterized by sexually dimorphic hypotension 
(leading to a signifi cant reduction of blood pressure in female mice), absence of dense 
secretory/storage granule formation in juxta-glomerular cells, altered morphology of 
the kidney, and a signifi cant increase of plasma prorenin levels5. Deletion of the ren-
2 gene resulted in increased renin and decreased prorenin levels6, but no changes 
in blood pressure, nor morphological changes occurred.  
Transgenic mice overexpressing human renin did not develop hypertension 
whereas transgenic mice expressing both human renin and human angiotensinogen 
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showed a signifi cantly increased blood pressure.7 The plasma concentrations of 
Ang I and Ang II were 3-5-fold increased in double transgenic mice as compared to 
either control mice or transgenic mice overexpressing human renin. These results 
demonstrate that human renin does not crossreact with mouse angiotensinogen, 
thereby illustrating the unique species specifi ty of the RAS. 
Figure 1. Proteolytic and non-proteolytic activation of prorenin. Aog, angiotensinogen; Ang, angiotensin. 
See text for explanation.
Prorenin can be activated through cleavage of the prosegment (proteolytic 
activation) or via a conformational change induced by low pH or low temperature 
(non-proteolytic activation)8 (Figure 1). Proteolytic activation is an irreversible 
process in which the prosegment is cleaved, e.g., by kallikrein, trypsin or plasmin. 
In vivo, proteolytic activation is probably mediated by a proconvertase in the renin-
producing cells of the juxta-glomerular apparatus of the kidney. Non-proteolytic 
activation of prorenin is a reversible process in which prorenin is converted from the 
‘closed’ (inactive) to the ‘open’ (active) conformation by unfolding of the prosegment 
from the enzymatic cleft.9 Acid activation leads to complete activation of prorenin 
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whereas exposure to cold (‘cryoactivation’) only leads to partial activation (~15%). 
Kinetic studies have shown that an equilibrium exists between the closed and open 
conformations of prorenin, and that under physiological conditions (pH 7.4, 37oC) 
<2% of prorenin is in the open conformation.8
The kidneys are the main source of circulating (pro)renin. However, following a 
bilateral nephrectomy, prorenin, in contrast with renin, remains detectable. This 
suggests that prorenin is also produced outside the kidney. Potential extrarenal 
prorenin-producing tissues are the eye, adrenal, ovary and testis.3,10-12 Normally, the 
concentration of prorenin in human plasma is 10 times higher than that of renin. The 
reasons for this excess are unknown, as prorenin does not seem to be activated 
outside the kidney.13 One possibility is that prorenin has functions unrelated to 
angiotensin generation. In this regard, it is of interest to note that it has recently been 
suggested that prorenin binds to a ‘(pro)renin receptor’, thereby activating second 
messenger pathways in a manner that is independent of Ang II.14,15 (Pro)renin 
receptors may also mediate the uptake of renin and/or prorenin into tissues that do 
not synthesize renin and prorenin themselves, like the heart and the vessel wall. 
To date, two (pro)renin-binding receptors have been identifi ed: the mannose-6-
phosphate (M6P) receptor16 and the above-mentioned (pro)renin receptor. The M6P 
receptor is identical to the insulin-like growth factor II (IGFII) receptor and binds 
IGFII, M6P-containing proteins such as prorenin and renin, and retinoic acid at 
distinct sites.17,18 Prorenin and renin are both rapidly internalized after binding to this 
receptor, and internalized prorenin is proteolytically converted to renin. However, 
binding to this receptor did not result in angiotensin generation, either intra- or 
extracellularly. This, in combination with the fact that intracellularly generated renin 
was found to be degraded within a few hours, suggests that M6P/IGFII receptors 
function as clearance receptors for (pro)renin. Alternatively, since binding of M6P-
containing proteins to M6P/IGFII receptors results in the activation of second 
messenger pathways involving G-proteins19, (pro)renin may act as an M6P/IGFII 
receptor agonist. 
The (pro)renin receptor was cloned by Nguyen and co-workers.15 Prorenin and 
renin bind equally well to this receptor, without being internalized or degraded. 
Interestingly, the catalytic activity of bound renin was increased 5-fold, and receptor-
bound prorenin became fully active in a non-proteolytic manner. Thus, apparently, 
this receptor allows prorenin to generate angiotensins at tissue sites. Importantly, 
binding of (pro)renin to the (pro)renin receptor in human mesangial cells also 
induced Ang II-independent effects, such as an increase in DNA synthesis, activation 
of the mitogen-activated protein kinases (MAPKs) extracellular signal-regulated 
kinase (ERK)1 (p44)/ERK2 (p42), and plasminogen-activator inhibitor-1 release. 
Furthermore, in cardiomyocytes, prorenin activated the p38 MAPK/heat shock 
protein 27 pathway, resulting in changes of actin fi lament dynamics.14 These non-
angiotensin-mediated effects may underlie the blood pressure-independent cardiac 
hypertrophy in rats with a hepatic prorenin overexpression.20
Finally, Peters and co-workers demonstrated ren-2 prorenin internalization in 
cardiomyocytes of transgenic rats expressing the mouse ren-2 gene in the liver.21 
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Since ren-2 prorenin is nonglycosylated, this phenomenon cannot be mediated 
by M6P/IGFII receptors. The internalization contrasts with the observations on the 
recently cloned (pro)renin receptor. Thus, there may be a third (pro)renin receptor, 
the identity of which is currently unclear. 
Angiotensinogen
Angiotensinogen, the precursor of all angiotensin metabolites, is the only known 
substrate for renin. The angiotensinogen gene encodes for a glycoprotein of 453 
amino acids with a molecular weight of ~60 kDa. The gene is located as a single copy 
on, respectively, chromosome 19 in rats, chromosome 8 in mice and chromosome 
1 in humans. In 1983, Doolittle reported a signifi cant sequence homology of 
angiotensinogen to α1-antitrypsin (23%), ovalbumin (21%) and antithrombin III 
(18%).22 These proteins are members of the serine proteinase inhibitor family 
and are closely associated with acute infl ammation reactions. Acute infl ammation 
induces gene expression via acute-response which increases the angiotensinogen 
concentration in plasma23. The similarity between the structural organization of the 
angiotensinogen and α1-antitrypsin genes suggests that both genes have evolved 
from a common ancestor.24
Although angiotensinogen mRNA has been detected in brain, adipocytes, heart and 
the reproductive system, its main source is the liver.25 Hepatocytes constitutively 
secrete angiotensinogen into the extracellular fl uid, without intracellular storage. 
Blood plasma/extracellular fl uid functions as the major reservoir for angiotensinogen. 
Angiotensinogen plasma concentrations (~1 µM) approximate the Michaelis-
Menten constant of the renin reaction, which makes RAS activity sensitive to small 
changes in angiotensinogen concentration. Deletion of the angiotensinogen gene 
in mice leads to hypotension, low body weight gain after birth, and an abnormal 
morphology of kidney and heart.26 In turn, overexpression of angiotensinogen led to 
the development of hypertension.27
ACE and ACE2
Two isoforms of ACE exist: somatic ACE and testis (germinal) ACE. Somatic ACE 
is abundantly expressed throughout the body, whereas testis ACE is exclusively 
expressed in the testis. Cloning of the ACE gene provided a better understanding 
of the relationship between somatic and testis ACE. Both forms are transcribed 
from the same gene by using different promoters.28 In humans the ACE gene is 
located on chromosome 17. Somatic ACE has 2 homologous domains which share 
60% sequence homology. Both domains contain a catalytically active site29 and 
are situated at the N- and C-terminal side of ACE. According to their position they 
are designated as N- and C-domain. The majority of somatic ACE is membrane-
bound on endothelial cells. Circulating ACE is derived from ACE-expressing cells 
by proteolytic cleavage at the juxta-membrane stalk region.30 Testis ACE possesses 
only one catalytic domain which is identical to the C-domain of somatic ACE. Studies 
selectively blocking the C- and N-domain of somatic ACE revealed that conversion 
of Ang I to Ang II by membrane-bound ACE depends on the C-domain, whereas both 
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domains contribute to this conversion in soluble ACE.31 Degradation of bradykinin 
at tissue sites also required both domains.32 Deletion of both somatic and testis 
ACE (ACE-/-) in mice led to hypotension, male infertility and changes in kidney 
morphology.33 Vascular expression of germinal ACE in Ace null mice restored renal 
morphology but did not normalize blood pressure, thus demonstrating that germinal 
ACE cannot functionally substitute for somatic ACE.34
Recently, a homologue of somatic ACE called ACE2 was discovered.35 ACE2 shares 
42% homology with the C- and N-terminal domains of somatic ACE. The gene 
encoding ACE2 is located on the X chromosome and ACE2 is mainly expressed 
in endothelial cells of heart, kidney and testis. Like somatic ACE, ACE2 can be 
released into the circulation after proteolytic cleavage.36 Unlike somatic ACE, ACE2 
has only one catalytically active site which can convert Ang I and Ang II to Ang (1-
9) and Ang-(1-7), respectively.35,37 These data suggest a potential role of ACE2 in 
the counterregulation of high blood pressure by inactivation of Ang II. Indeed, in a 
model of Ang II-dependent hypertension, blood pressures were substantially higher 
in ACE2-defi cient mice than in wildtype controls.38 Mice lacking the ACE2 gene were 
originally described to develop an abnormal heart function with severely impaired 
contractility39, but this was not confi rmed in a follow-up study.38 Remarkably, ACE2 
also functions as a receptor for the virus causing severe acute respiratory syndrome, 
thereby stressing the importance of ACE2 in a manner unrelated to the RAS.40
Angiotensin II receptors
Initially, it was thought that the responses to Ang II were mediated by a single Ang 
II receptor. At the end of the 1980s, the discovery of specifi c Ang II receptor ligands 
such as losartan, PD12377, PD123319 and CGP42112 made it possible to identify 
several Ang II receptor subtypes. We now know that the biological actions of Ang II 
in man are mediated by at least two types of Ang II receptors: Ang II type 1 (AT1) and 
AT2 receptors (Figure 3).
AT1 receptor
AT1 receptors mediate virtually all the known physiological actions of Ang II, such as 
vasoconstriction, inotropy, chronotropy, aldosterone release, noradrenaline release 
and growth stimulation. The AT1 receptor gene encodes for a protein of 359 amino 
acids with a molecular weight of 41 kDa. The gene was fi rst cloned in 1991 from 
rat vascular smooth muscle cells41 and bovine adrenal gland.42 Cloning and genetic 
analysis of the human AT1 receptor gene revealed that the human AT1 receptor gene 
is located on chromosome 3 and can produce two isoforms by alternative splicing. 
Both isoforms have similar binding - and functional properties. 
In rodents two subtypes of the AT1 receptor have been identifi ed: AT1A and AT1B.
43 
The origin of these subtypes lies in a gene duplication which occurred after the 
divergence of rodents from the human/artiodactyls group about 24 million years ago. 
AT1A and AT1B share 94% sequence homology and are located on chromosome 17 
and 2 in rat and chromosome 13 and 3 in mice, respectively. Not surprisingly, both 
subtypes have similar ligand binding affi nities and signal transduction properties 
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but varying expression levels in different tissues. The AT1A receptor predominates 
in heart, kidney, lung, liver and vascular smooth muscle, whereas the AT1B receptor 
is mainly expressed in the adrenal and pituitary gland.44 To date, there are no 
pharmacological antagonists which clearly discriminate AT1A and AT1B receptors. 
Studies in mice using targeted gene manipulation provided more insight in 
the functional role of both subtypes in vivo. Deletion of the AT1A receptor gene 
signifi cantly decreased resting blood pressure in both heterozygous AT1A
+/- and 
homozygous AT1A
-/- receptor mice.45 Ang II infusions resulted in a diminished pressor 
response in AT1A
+/- receptor mutants whereas this response was virtually abolished 
in AT1A
-/- mutants. Additionally, both the expression levels of renin mRNA and plasma 
renin activity were markedly increased in AT1A receptor knockout mice.
46 Deletion of 
the AT1B receptor gene did not affect resting blood pressure, nor altered the pressure 
response to Ang II.47 Taken together, these fi ndings indicate the important role of 
the AT1A receptor in mediating the pressure response in mice. AT1A or AT1B receptor 
defi ciency is not associated with an impaired development or survival, but double 
knockout mice lacking both receptors display a phenotype similar to that observed 
in angiotensinogen knockout mice.48 These observations, together with the fact 
that Ang II does cause a pressor response in AT1A knockout mice after enalapril 
pretreatment49, suggest a compensatory role for the AT1B receptor. Additionally, in 
vitro studies demonstrated that the AT1B receptor is the most important regulator of 
Ang II contractile responses in the mouse aorta and femoral artery.50
The AT1 receptor belongs to the seven-transmembrane G-protein-coupled receptor 
superfamily, and couples to a wide variety of second messenger systems, including 
the phospholipase C/inositol-1,4,5-triphosphate/diacylglycerol/protein kinase C 
pathway, the phospholipase A2/arachidonic acid pathway, the phospholipase D/
phosphatidyl-choline/phosphatidic acid pathway, and tyrosine kinases such as the 
MAP kinases ERK1/2, p38 and c-jun N-terminal kinase.51
AT1 receptor stimulation results in a rapid internalization of the Ang II-AT1 receptor 
complex, followed by either receptor degradation in lysosomes or receptor recycling 
to the cell surface.51 Internalized Ang II has been proposed to activate cytoplasmic 
or nuclear receptors prior to its intracellular degradation.52 Furthermore, Zou and 
co-workers recently demonstrated that mechanical stretch resulted in AT1 receptor 
activation in a ligand-independent manner. Interestingly, the consequences of such 
activation could be prevented by an AT1 receptor blocker.
53
Several reports have described crosstalk between AT1 receptor and other receptors, 
e.g. the bradykinin type 2 (B2) receptor, the AT2 receptor, and the α1–adrenoceptor. 
AT1 and B2 receptors form stable heterodimers with an enhanced G-protein activation 
and altered receptor sequestration.54 AT1 receptor-α1-adrenoceptor crosstalk 
enhances the response to α1-adrenoceptor agonists.55 Interestingly, although 
the postjunctional AT1 receptor interacting with the α1–adrenoceptor is of the AT1A 
subtype, the prejunctional AT1 receptor which facilitates noradrenaline release from 
sympathetic nerve endings is of the AT1B subtype.
56
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AT2 receptor
In contrast to the well-characterized AT1 receptor, the function of the AT2 receptor 
is much less understood. In general, it is assumed that AT2 receptors counteract 
the responses mediated by the AT1 receptor.
57-61 AT2 receptors are involved in 
physiological processes like development and tissue remodeling (by inhibiting cell 
growth and by stimulating apoptosis), regulation of blood pressure (vasodilatation), 
natriuresis and neuronal activity. 
Evidence for AT2 receptor mediated vasodilatation is largely based on two 
approaches: an indirect approach, showing an enhanced response to Ang II in the 
presence of AT2 receptor blockade or gene disruption
57,58,60,62, and a direct approach 
showing AT2 receptor-induced responses by applying either the (partial) AT2 receptor 
agonist  CGP42112A or Ang II in the presence of an AT1 receptor blocker.
63,64
The AT2 receptor gene was fi rst cloned in 1993.
65 The AT2 receptor gene shares 34% 
sequence homology with its AT1 receptor counterpart and encodes for a protein of 
363 amino acids with a molecular mass of 41 kDa. It is located on the X chromosome 
in both humans and rodents. In fetal tissues the AT2 receptor is the predominant 
subtype. This situation changes rapidly after birth, resulting in the AT1 receptor 
becoming the dominant subtype in most adult tissues.66 Yet, in adults, AT2 receptors 
can still be detected in a variety of tissues, including uterus, ovary, adrenal medulla, 
heart, blood vessels and brain.67 Here it is important to consider that the distribution 
of the AT2 receptor depends on age and species, but is also subject to changes in 
expression during pregnancy and pathological conditions such as hypertension, 
heart failure and vascular injury (see below).67,68
In 1995, two groups reported that deletion of the AT2 receptor in mice led to an 
increased pressor response to Ang II.57,60 Additionally, Ichiki et al. reported a 
signifi cant increased blood pressure in hemizygous AT2
-/Y receptor mice whereas 
blood pressure was not signifi cantly increased in a similar model described by 
Hein and co-workers. Mutants lacking the AT2 receptor gene showed a lower body 
temperature and impaired exploratory behavior. Remarkably, despite its wide 
expression in the fetus, the AT2 receptor does not seem to be required for embryonic 
development, as no morphological and developmental differences were found 
between homozygous AT2
-/-  or hemizygous AT2
-/y receptor mice and their wildtype 
controls. Possibly, AT2 receptor knockout mice display a delayed expression of 
calponin and h-caldesmon after birth.69 During pregnancy, Ang II levels are elevated. 
Because the fetus is also exposed to these high Ang II levels, it has been postulated 
that the AT2 receptor plays a role in the regulation of Ang II responsiveness in order 
to prevent fetal hypertension.70
Like AT1 receptors, AT2 receptors belong to the G protein-coupled receptor 
superfamily. However, in contrast to the AT1 receptor, the AT2 receptor is not 
internalized upon binding of Ang II.66 Two major pathways have been described 
for AT2 receptor signalling
71: (a) activation of protein phosphatases causing protein 
dephosphorylation and (b) activation of the nitric oxide (NO)/guanosine cyclic 
3’, 5’-monophosphate (cGMP) pathway. Up to now, three specifi c phosphatases 
have been linked to AT2 receptor activation: MAPK phosphatase 1, SH2-domain-
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containing phosphatase 1 and protein phosphatase 2A. Growth factors, including 
Ang II via the AT1 receptor, mediate their growth promoting actions through tyrosine 
kinase receptors and several kinase-driven phosphorylation steps. Activation of the 
AT2 receptor counteracts these growth-promoting actions by dephosphorylation 
through subsequent activation of phosphatases. In addition to the inhibitory effect on 
growth, dephosphorylation (e.g., of ERK1/2) also seems to play an important role in 
the stimulation of apoptosis.72
Figure 2. AT2 receptor-mediated relaxation involves either intracellular activation of kininogenase and 
subsequent bradykinin type 2 (B2) receptor activation, or a direct activation of NO synthase (NOS). 
Several studies have shown that AT2 receptor-mediated vasodilation is an 
endothelium-dependent phenomenon involving B2 receptors, NO and cGMP73,74 
(Figure 2). Initially, in vitro studies using endothelial cells showed that the stimulatory 
effect of Ang II on cGMP production, a downstream signaling product of NO 
production, was abolished by blocking both B2 receptors and nitric oxide synthase 
(NOS).73 Subsequent in vivo studies confi rmed that the AT2 receptor-induced rise 
in cGMP involves bradykinin and NO.74 In vitro studies in endothelial cells reported 
that intracellular acidosis, as a result of AT2 receptor activation, stimulates bradykinin 
formation by activating kininogenases.75 Katada and Majima were able to show 
production of bradykinin after AT2 activation in rat mesenteric arteries, suggesting 
that the B2 receptor mediates vasodilatation by endogenous bradykinin released 
upon AT2 receptor activation.
76 In agreement with this concept, deletion of the B2 
receptor enhanced the Ang II-induced hypertensive response in vivo.77 Additional 
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studies concluded that NO production following AT2 receptor stimulation may also 
occur independently of B2 receptors, through direct NOS activation
78, possibly 
involving the calcineurin/nuclear factor of activated T cells pathway.79
As both AT2 and B2 receptors are co-expressed in various tissues, the hypothesis 
was raised that both receptors form heterodimers which can interact through receptor 
crosstalk. Recent studies in rat pheochromocytoma cells, applying fl uorescence 
resonance energy transfer, confi rmed this hypothesis.80 Heterodimer formation 
appeared to be dependent on the receptor number that was expressed, but also 
required AT2 receptor stimulation. As a consequence of heterodimer formation, 
it is possible that AT2 receptor activation results in B2 receptor activation without 
intermediate bradykinin synthesis.58
In addition to its interaction with the B2 receptor, AT2 receptors are also known to 
interact with their AT1 counterpart. Transfection studies in fetal fi broblasts showed 
that AT1 and AT2 receptors form heterodimers in which the AT2 receptor functions 
as a specifi c AT1 receptor antagonist.
61 Possibly, AT2 receptor-induced vasodilatation 
depends on simultaneous AT1 receptor activation, as no AT2 receptor-mediated 
responses were noted in the absence of AT1 receptors.
62
Furthermore, it is important to consider that data obtained in absence of the AT2 
receptor are complex because AT2 receptors downregulate AT1 receptors in a 
ligand-independent manner81 and AT2 receptor knockout mice display an increased 
AT1 receptor expression.
82 In addition to its interaction with AT1 receptors, the AT2 
receptor also downregulates renin biosynthesis, thereby inhibiting the formation of 
Ang II.83
Angiotensin-derived metabolites and their receptors
Ang I and II are metabolized by a whole range of peptidases (‘angiotensinases’). 
Although initially it was thought that all metabolites other than Ang II were inactive, 
it is now clear that at least several of these metabolites have functions of their own, 
which are sometimes mediated via non-AT1/AT2 receptors. The most important of 
these peptides are Ang-(1-7), Ang-(2-8) (Ang III) and Ang-(3-8) (Ang IV) (Figure 3). 
Ang-(1-7) can be formed from Ang I by the action of neutral endopeptidase or prolyl 
endopeptidase but also from the Ang I degradation products Ang (1-9) and Ang II.37 
Ang-(1-7) is generally believed to counteract the response of Ang II although there 
are reports of similar or distinct actions from Ang II.84 Ang-(1-7) induces relaxation 
in several vascular beds. The fact that this relaxation could be blocked by the 
selective Ang-(1-7) antagonist A-779 [D-Ala7-Ang-(1-7)] suggested the involvement 
of a specifi c Ang-(1-7) receptor.84 Indeed, in 2003 the Mas proto-oncogene, a G 
protein-coupled receptor, was proposed to be the receptor for Ang-(1-7).85 Ang-(1-
7) potentiates bradykinin-induced responses32 and releases NO86 via Mas receptor 
stimulation. Mas receptor mRNA expression has been detected in heart, testis, 
kidney and brain.87 Mice defi cient for the Mas-receptor lack the antidiuretic action 
of Ang-(1-7) after an acute water load, and their aortas no longer relax in response 
Chapter 1
20
to Ang-(1-7).85 Mas-/- mice are also characterized by an impaired heart function, 
indicating an important role of the Mas receptor in the maintenance of the structure 
and function of the heart.88 Although the Mas-receptor is now held responsible 
for most of the responses to Ang-(1-7), there are several other pharmacological 
mechanisms and receptors that are affected by Ang-(1-7). As a slow substrate for 
ACE, Ang-(1-7) may also function as an ACE inhibitor, resulting in decreased Ang 
II formation and potentiation of bradykinin-induced vasodilatation32. Furthermore, 
Ang-(1-7) acts as an AT1 receptor antagonist at low concentrations
89, and exerts  AT1 
receptor agonistic effects at high concentrations90. A link between Ang-(1-7) and the 
AT2 receptor has recently been proposed, because infusion of Ang-(1-7) during AT1 
receptor blockade unmasked a vasodepressor response in conscious SHR rats that 
could be attenuated by blockade of AT2 receptors, B2 receptors and NOS
91. Possibly, 
Mas-AT1 and/or Mas-AT2 receptor heterodimers exist.
92,93 Through the action of 
aminopeptidase A, Ang II is converted to Ang III, which in turn can be converted to 
Ang IV by aminopeptidase N.94 Ang III mediates some of the classical responses 
of Ang II (such as stimulation of aldosterone secretion and vasoconstriction) and 
this most likely involves binding to AT1 and AT2 receptors.  The affi nity of Ang III for 
these receptors is somewhat lower than that of Ang II.95 The responses to Ang III are 
less effi cacious than those of Ang II, possibly due to its accelerated metabolism in 
the circulation. The latter relates to the wide distribution of aminopeptidase N that 
initiates the hydrolysis of Ang III but not Ang II. It is thought that Ang III might be the 
fi nal mediator of some of the actions of Ang II. For example, the central action of Ang 
II on vasopressin secretion in rats is dependent on Ang III, as this effect was absent 
after specifi c blockade of aminopeptidase A.96 Additionally, Ang III, and not Ang II, 
mediates the excretion of Na+ excretion through AT2 receptors in the presence of 
AT1 receptor blockade.
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Ang IV was initially believed to have no biological activity. This was based on two 
important fi ndings: both AT1 and AT2 receptors display a poor affi nity for Ang IV, and 
Ang IV does not elicit the characteristic Ang II responses like Ang III. The discovery 
of a specifi c Ang IV binding site, designated as the AT4 receptor, changed this view.
98 
After purifi cation, the receptor was identifi ed as insulin-regulated aminopeptidase99, 
a protein which is abundantly found in vesicles containing the insulin-sensitive 
glucose transporter (GLUT4).100 AT4 receptor expression occurs in brain, spinal cord, 
heart, kidney, colon, prostate, adrenal gland, bladder and vascular smooth muscle 
cells.68,95 Ang IV and the AT4 receptor appear to be involved in the facilitation of 
memory and learning.101 Ang IV infusions cause vasorelaxation in cerebral and renal 
vascular beds, possibly by increasing NOS activity.102 On the other hand, there are 
also studies showing that Ang IV, because of its weak agonistic activity towards the 
AT1 receptor, induces vasoconstriction.
90 The close association of the AT4 receptor 
with GLUT4 suggests that Ang IV might modulate glucose uptake. 
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Tissue angiotensin generation
As soon as it was realized that angiotensin production at tissue sites is of greater 
importance than angiotensin generation in the circulation, many investigators 
started to unravel how and where such local angiotensin production might occur. 
Initially, it was thought that all components required for local Ang II production (i.e., 
renin, angiotensinogen and ACE) would be produced at tissue sites. Infusions of 
radiolabeled angiotensins, allowing the quantifi cation of uptake of blood-derived 
angiotensin in tissues, confi rmed that the majority of tissue Ang I and II is produced 
at tissue sites, and not derived from blood.103
Figure 3. Schematical overview of the generation of angiotensin I and its metabolites. NEP, neutral 
endopeptidase; PEP, prolyl endopeptidase; PCP, prolyl carboxypeptidase; APA, aminopeptidase A; APN, 
aminopeptidase N. 
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ACE is well-known to be abundantly expressed in virtually every tissue of the body, 
its main site being the surface of endothelial cells. Thus, its local synthesis is beyond 
doubt. Although angiotensinogen mRNA has been detected outside the liver, direct 
proof for actual angiotensinogen synthesis at important sites of local angiotensin 
production (e.g., heart and vessel wall) is lacking. For instance, the isolated 
perfused heart does not release angiotensinogen.104 Therefore, the majority of 
tissue angiotensinogen is probably of hepatic origin. The fact that angiotensinogen 
is neither internalized, nor binds to membranes, combined with the observation that 
angiotensinogen-synthesizing cells release angiotensinogen to the extracellular 
space105, rather than storing it intracellularly, indicates that angiotensin generation 
must occurs extracellularly. Thus, tissue angiotensin generation is restricted to the 
interstitial space and/or the cell surface (Figure 4). 
Following a bilateral nephrectomy, tissue renin and angiotensin levels drop to levels at 
or below the detection limit.106-108 This suggests that the majority of tissue renin is not 
locally produced, but kidney-derived, and that without renin, there is no angiotensin 
production. The presence of renin in cardiac membrane fractions106 suggested 
that circulating renin, in addition to its diffusion into the interstitial space108,109, may 
bind to renin-binding proteins or receptors at tissue sites. The recent discovery of 
several of such receptors, as discussed above, supports this concept.  An interesting 
additional observation is that these receptors also bind prorenin, and that prorenin, 
upon binding, becomes catalytically active. In view of the much higher prorenin than 
renin levels, an attractive concept is that prorenin rather than renin contributes to 
tissue angiotensin generation. Studies with (pro)renin receptor blockers in diabetic 
rats confi rmed this concept.110
Unexpectedly however, these blockers did not affect tissue angiotensin levels in 
control rats, although the prorenin levels of the latter rats were only ≈2-fold lower 
than those of the diabetic rats. Moreover, despite the fact that prorenin is still present 
in circulating blood after a nephrectomy106, tissue angiotensin levels are close to 
zero. This suggests that, if prorenin contributes to tissue angiotensin production, 
this involves prorenin of renal rather than extrarenal origin. Currently, the only 
known difference between renal and extrarenal prorenin relates to their degree of 
glycosylation. 
In vitro studies using the isolated perfused rat Langendorff heart fully confi rmed the 
idea of renin and angiotensinogen uptake underlying tissue angiotensin production. 
During buffer perfusion, no release of RAS components could be demonstrated in 
the coronary effl uent or interstitial fl uid.104 After adding renin to the perfusion fl uid, 
renin started to accumulate in the interstitial fl uid, reaching steady-state levels in this 
compartment that were identical to its levels in the coronary circulation. Findings on 
angiotensinogen were similar. Stopping the exposure to renin revealed a biphasic 
washout curve, in agreement with the concept that renin is not only present in 
extracellular fl uid but also binds to receptors. Angiotensinogen washout was mono-
phasic. Angiotensin synthesis only occurred during simultaneous perfusion with 
renin and angiotensinogen. Interestingly, in hearts of transgenic rats overexpressing 
angiotensinogen, angiotensin release continued after stopping the renin perfusion, 
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i.e., when renin was no longer present in the coronary circulation.111 This was due to 
the fact that receptor-bound renin continued to generate Ang I. 
At steady state, the cardiac tissue levels of Ang I were as high as expected assuming 
that Ang I is restricted to the extracellular fl uid.112,113 In contrast, the tissue Ang II levels 
were much higher. Pretreatment with an AT1 receptor antagonist greatly reduced 
the cardiac tissue Ang II levels during renin + angiotensinogen perfusion. This 
suggests that locally generated Ang II accumulates at tissue sites through binding 
to AT1 receptors. Subsequent subcellular fractionation studies confi rmed that tissue 
Ang II, but not Ang I, is located intracellularly.113,114 This is due to the fact that AT1 
receptor-bound Ang II is rapidly internalized, after which intracellular degradation 
occurs. Based on these observations, it is not surprising that the tissue Ang II content 
correlates directly with tissue AT1 receptor density.
115
A wide range of in vitro studies has provided evidence for the existence of enzymes 
other than renin and ACE generating Ang I and II, including cathepsin D, kallikrein, 
tonin and chymase.116,117 The in vivo importance of these alternative pathways is 
questionable. The fact that Ang I and II are virtually absent in plasma and tissue 
of nephrectomized animals (including humans) argue against a role of non-renin 
angiotensinogen-converting enzymes in vivo. A similar situation exists for chymase 
which is present in the cardiac interstitium, mast cells and endothelial cells. In vitro 
studies have provided evidence for an important role of chymase in the conversion 
of Ang I to Ang II116,118, but in vivo evidence for chymase-dependent Ang II generation 
could not be obtained.119 Moreover, angiotensinogen and ACE knockout mice have 
similar phenotypes120,121, and ACE deletion reduced the Ang II levels in both tissue 
and circulation by up to 99%.122 Thus, at least in mice, ACE is the main, if not only 
Ang II-generating enzyme in vivo. 
AT2 receptors and pathophysiology
As discussed above, AT2 receptor expression is low or undetectable in adult tissues, 
in contrast with its high expression in fetal tissues. However, AT2 receptors re-appear 
under pathophysiological conditions. 
For instance, in the kidney, AT2 receptor expression increases when infl ammation, 
apoptosis, and proteinuria occur.123 Interestingly, transgenic AT2 receptor-
overexpressing mice displayed less glomerular injury, proteinuria and transforming 
growth factor β expression in a subtotal nephrectomy model.124 This suggests 
that the re-appearance of AT2 receptors under pathological conditions is part of a 
protective mechanism, for instance related to enhanced NO production.125 However, 
not all studies confi rm the counterregulatory, protective actions of AT2 receptors in 
the kidney. Duke and co-workers report that AT2 receptors mediate vasoconstriction 
in the renal medulla of 2-kidney, 1-clip rats, as opposed to the vasodilator effects 
mediated by AT1 receptors in this model.126
In the heart, a wide range of animal studies revealed increased AT2 receptor 
expression under pathological conditions, e.g. during pressure overload, 
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hypertension and ischemia, and post-myocardial infarction.59,73,127,128 Studies in 
failing human hearts confi rmed the animal data, and simultaneously showed a 
downregulation of AT1 receptors.
129,130 From studies with AT1 receptor antagonists 
it is widely accepted that AT1 receptors play a major role in the post-myocardial 
remodeling process, mediating both fi brosis and hypertrophy.131 Since the benefi cial 
effects of AT1 receptor blockade following myocardial infarction were diminished in 
AT2
-/Y receptor mice132, it is reasonable to assume that the increased Ang II levels 
that will occur during AT1 receptor blockade (see below) exert benefi cial effects via 
AT2 receptor stimulation. Indeed, transgenic mice overexpressing AT2 receptors in 
the heart displayed improved cardiac hemodynamics post-myocardial infarction in 
an NO-dependent manner.133,134 Furthermore, treatment with either an AT2 receptor 
antagonist or a B2 receptor antagonist reduced the benefi cial effects of AT1 receptor 
blockade in wildtype mice following myocardial infarction.135 Therefore, the benefi cial 
effects of AT2 receptors in the heart involve the B2 receptor/NO/cGMP pathway. 
In contrast with these observations, a few studies have shown that AT2 receptors, 
like AT1 receptors, induce cardiac hypertrophy and fi brosis.
136,137 To explain these 
discrepant data, it has been hypothesized that AT2 receptor upregulation is benefi cial 
in the early pathological phase, by counteracting hypertrophy and fi brosis, but that 
chronic stimulation of the AT2 receptor (for instance by the high Ang II levels that will 
occur during AT1 receptor blockade) has deleterious effects on cardiac recovery.
138
Knowledge on the effects of AT2 receptors in the human heart comes from 
polymorphism studies, although the data are often contradictory. AT2 receptor gene 
variants have been linked to both cardiac hypertrophy and coronary ischemia139-
141, without knowing however whether this is based on inceased or decreased AT2 
receptor density. AT2 receptor-mediated vasodilation in isolated human coronary 
microarteries increases with age.58 Since endothelial function decreases with age, 
this could point to increased AT2 receptor expression in the face of decreased 
endothelial function, again in agreement with the concept that AT2 receptor density 
increases under pathological conditions. AT2 receptor expression also increased 
in peripheral resistance arteries of hypertensive diabetic patients during treatment 
with an AT1 receptor blocker, and this resulted in enhanced Ang II-induced 
vasodilation.142
Recent studies have shown that AT2 receptors are also expressed in various 
carcinomas.143 Assuming that AT1 receptors contribute to tumor growth and 
vascularization144, one may predict that, here too, AT2 receptors will counteract the 
effects of the AT1 receptor stimulation, thus inhibiting growth and vascularisation.
145 
However, proangiogenic effects of AT2 receptors have also been described, occurring 
in conjunction with AT1 receptor activation.
146
RAS blockade and AT2 receptor stimulation
Blocking the RAS is possible at three levels: renin, ACE and the AT receptors. Beta-
adrenoceptor blockers, by antagonizing the renin-releasing β1-adrenoceptors in the 
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juxta-glomerular cells, were the fi rst drugs to suppress the RAS. These drugs will 
lower renin147, Ang I and Ang II, thereby reducing the degree of AT1 and AT2 receptor 
stimulation (Table 1).
Table 1. Effects of various RAS blockers on renin, angiotensins and AT receptor stimulation.
Subsequently, the ACE inhibitors were introduced. These drugs will lower Ang II. 
Given the wide variety of available angiotensinases, this will not lead to substantial 
Ang I accumulation, but rather result in metabolism of Ang I through different 
(compensatory) pathways, e.g. by neutral endopeptidase. As a consequence, Ang-
(1-7) levels will rise during ACE inhibition, thereby allowing Ang-(1-7) to contribute 
to the benefi cial effects of ACE inhibitors.32 Simultaneously, due to the interference 
with Ang II generation, the negative feedback loop system regulating renin release is 
affected, and thus, the kidneys will release more renin. Therefore, depending on the 
degree of ACE inhibition, Ang II levels may rise again, sometimes to levels above 
baseline.1,107 For instance, at 90% ACE inhibition, a 10-fold rise in renin is suffi cient 
to fully restore Ang II levels, whereas a 20-fold rise in renin would increase Ang II 
twofold above its baseline levels. In addition, prolonged ACE inhibition is known to 
upregulate ACE. Given these compensatory mechanisms, it is not surprising that 
it has proven diffi cult to show that blood plasma and tissue Ang II levels remain 
suppressed during continuous ACE inhibition.1
Indeed, in pigs treated with captopril for 3 weeks post-myocardial infarction, cardiac 
Ang II levels were increased as compared to untreated control pigs (Figure 5). 
Although this Ang II may theoretically stimulate AT1 and AT2 receptors, it must be 
kept in mind that such receptor stimulation may occur less effi ciently than normal. 
Without ACE inhibitor treatment, ACE generates Ang II in a highly effi cient manner, 
in close proximity of AT receptors. During chronic ACE inhibition, the increase in Ang 
I generation will still allow Ang II generation, either by non-inhibited ACE or by non-
ACE converting enzymes like chymase.148 However, this type of Ang II generation 
is less effi cient, because it does not result in a high level of regional AT receptor 
stimulation. In particular, Ang II generated by chymase (which is localized in the 
adventitia) will be subject to rapid metabolism in the interstitial space on its way 
to AT receptors113,149 and thus is less likely to result in a high regional AT receptor 
occupancy. Therefore, a low overall AT receptor occupancy will occur, below the 
minimum per cell required to induce an effect.
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AT1 receptor blockers, available since the early 1990s, will also cause a rise in 
renin. Ang I and II in blood and tissues (as well as their metabolites) will increase in 
parallel with renin, and although this will not result in AT1 receptor stimulation, non-
AT1 receptors (including AT2 receptors and Mas) may now be stimulated excessively. 
As discussed above, it is feasible that, at least part of the benefi cial effect of AT1 
receptor blockers is due to such AT2 receptor stimulation.
64
Finally, renin inhibitors will soon be clinically available. These drugs lower both Ang 
I and II, and evidence for this, at least in blood plasma, is already available.150,151 
Whether renin inhibitors also decrease tissue Ang I and II levels is not yet known. 
This relates to the fact that renin inhibitors primarily block human renin, and not (or 
to a much lesser degree) rat, mouse or porcine renin. Thus, renin inhibitors cannot 
be tested easily in well-established animal models. Theoretically, the decreased Ang 
I and II levels during renin inhibition will prevent AT1 and AT2 receptor stimulation, as 
well as the stimulation of any other receptor by angiotensin metabolites. Although 
renin will rise during renin inhibitor treatment (like it does during any RAS blocker 
treatment), this renin cannot be enzymatically active due to the presence of the 
renin inhibitor. Thus, renin inhibitors may offer a more complete suppression of the 
RAS, although this also implies that the putative benefi cial effects mediated by AT2 
or Mas receptors will now no longer occur. So far, this does not appear to diminish 
the effects of renin inhibitors, at least on blood pressure.152
Figure 5. Plasma and cardiac tissue angiotensin levels in pigs that were either untreated or treated 
with the ACE inhibitor captopril or the AT1 receptor antagonist eprosartan for 3 weeks after a myocardial 
infarction. *P<0.05 vs. untreated. Data are derived from1.
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Aim of this thesis
Although the benefi cial cardiovascular effects of ACE inhibitors and AT1 receptor 
blockers are beyond doubt, it is clear that the renin-angiotensin system (RAS) still 
holds many secrets. A full understanding of this system might lead to the discovery 
of novel therapeutic targets and improved treatment strategies. To further unravel 
the complexities of the RAS, this thesis therefore has addressed the following three 
issues: 
1. Somatic ACE contains two catalytic domains, the C- and N-domain. Their exact 
contribution to the generation of angiotensin II and the degradation of bradykinin 
in blood and tissues is unknown. In addition, although the so-called ACE insertion/
deletion (I/D) polymorphism has received wide attention in the past decade, it 
is still uncertain to what degree the D allele (which results in higher ACE levels) 
truly associates with cardiovascular disease(s) and/or the effectiveness of RAS 
blockade. Of particular importance is the fi nding that DD subjects do not have 
higher angiotensin II levels than II subjects. Using selective ACE C- and N-domain 
inhibitors, we fi rst quantifi ed the contribution of both domains to angiotensin I and 
bradykinin hydrolysis. Next, we evaluated the possibility that the absence of an 
association between the ACE I/D polymorphism and angiotensin levels relates to 
differences in the contribution of the ACE C- and N-domain (Chapters 2 and 3).
2. Angiotensin II mediates its effects through 2 receptors, AT1 and AT2. In rodents, 
but not in humans, two AT1 receptor subtypes have been identifi ed: AT1A and AT1B. In 
addition, angiotensin I and II have several metabolites (angiotensin III, angiotensin 
IV and angiotensin-(1-7)) which may exert effects of their own, possibly via non-
classical AT receptors. To get a better understanding of the contribution of each 
of these (AT/non-AT) receptors, and to determine their physiological agonist(s), 
we made use of classical pharmacological in vitro and in vivo models, selective 
AT receptor (ant)agonists and mice defi cient in one, two or all three AT receptors 
(Chapter 4-6).
3. Renin inhibitors have now entered the clinical arena. Animal and clinical data 
suggest that the (short-term) blood pressure-lowering effect of renin inhibition equals 
that of ACE inhibition and AT1 receptor blockade. Whether blocking the initial, rate-
limiting step of the RAS also offers long-term (end-organ) protection still needs to be 
investigated. We therefore compared the cardiovascular effi cacy of the renin inhibitor 
aliskiren, the AT1 receptor blocker irbesartan and the ACE inhibitor captopril in a 
well-established physiological model, the spontaneously hypertensive rat, focusing 
in particular on coronary function and cardiac hypertrophy (Chapter 7).
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Abstract
Somatic ACE contains two domains (the C- and N-domain) capable of catalyzing 
angiotensin I and bradykinin hydrolysis. Here we investigated the effect of increasing 
concentrations of the selective ACE C- and N-domain inhibitors RXPA380 and 
RXP407 on angiotensin I-induced vasoconstriction of porcine femoral arteries (PFAs) 
and bradykinin-induced vasodilation of preconstricted porcine coronary microarteries 
(PCMAs). Ang I concentration-dependently constricted PFAs. RXPA380, at 
concentrations >1 μmol/L, shifted the Ang I concentration-response curve (CRC) 10-
fold to the right, and this was comparable to the maximal shift observed with the 
ACE inhibitors (ACEi) quinaprilat and captopril. RXP407 did not affect the Ang I CRC 
at concentrations up to 0.1 mmol/L. Bradykinin concentration-dependently relaxed 
PCMAs. 10 μmol/L RXPA380 and 0.1 mmol/L RXP407 potentiated bradykinin, both 
inducing a leftward shift of the bradykinin CRC that equalled ≈50% of the maximal 
shift observed with quinaprilat. Angiotensin I added to blood plasma, obtained from 
healthy volunteers, disappeared with a half life of 42±3 minutes. Quinaprilat increased 
the angiotensin I half life ≈4-fold, indicating that 71±6% of angiotensin I metabolism 
was due to ACE. RXPA380 (10 μmol/L) and RXP407 (0.1 mmol/L) increased the 
angiotensin I half life ≈2-fold, thereby suggesting that both domains contribute to 
conversion in plasma. In conclusion, tissue angiotensin I-II conversion depends 
exclusively on the ACE C-domain, whereas both domains contribute to conversion 
by soluble ACE and to bradykinin degradation at tissue sites. Since tissue ACE 
(and not plasma ACE) determines the hypertensive effects of angiotensin I, these 
data not only explain why N-domain inhibition does not affect angiotensin I-induced 
vasoconstriction in vivo, but also why ACEi exert blood pressure-independent effects 
at low (C-domain blocking) doses.
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Introduction
Angiotensin (Ang) I-converting enzyme (ACE) is a dipeptidyl carboxypeptidase that generates Ang II and inactivates bradykinin, two peptides that play a key 
role in the regulation of blood pressure. Somatic ACE has two homologous domains, 
each containing an active center. According to their position (N- or C-terminal), 
these domains are designated as the N- and C-domain, respectively. Bradykinin 
potentiation by ACE inhibitors correlates directly with ACE C- and N-domain 
blockade32,153 i.e., half maximal potentiation is observed during blockade of one 
domain, and full potentiation occurs during blockade of both domains. In contrast, 
selective inhibition of the N-domain with the phosphinic peptide RXP407 did not 
affect the blood pressure responses to Ang I bolus injections in mice154, nor did 
targeted inactivation of the N-domain in mice affect blood pressure or plasma Ang II 
levels155. Although this suggests that the C-domain is the dominant Ang I-converting 
site, a recent study153 demonstrated that selective inhibition of either the N-domain or 
the C-domain fully prevents conversion of systemically administered Ang I in mice. 
Moreover, in the latter study it was simultaneously demonstrated that, when using 
soluble ACE, full inhibition of Ang I cleavage is obtained only during blockade of both 
ACE active sites. Thus, Ang I-II conversion by membrane-bound and soluble ACE 
appears to obey to different mechanisms, and C-domain-selective ACE inhibitors 
like quinaprilat156, Ang (1-7)157 and the new phosphinic peptide RXPA380153 may fully 
suppress tissue Ang I-II conversion at concentrations that neither fully block Ang I-II 
conversion in plasma nor fully potentiate bradykinin. 
To study this possibility, we compared the inhibitory effects of the the C-domain-
selective inhibitors RXPA380,153 quinaprilat,156 and Ang (1-7)157 (selectivity for C-
domain vs. N-domain resp. ≈1000-, 200- and 10-fold) and the N-domain-selective 
inhibitors captopril158 and RXP407154 (selectivity for N-domain vs. C-domain 
resp. ≈20- and 300-fold) towards membrane-bound and soluble ACE. Ang I-II 
conversion by membrane-bound ACE was quantifi ed by investigating Ang I-induced 
contractions of porcine femoral arteries (PFAs). These contractions do not involve 
enzymes other than ACE159,160 Ang I-II conversion by soluble ACE was studied by 
quantifying Ang II generation following the addition of Ang I to human blood plasma. 
Bradykinin potentiation was studied in porcine coronary (micro)arteries (PCAs, 
PCMAs). We excluded the possibility that the Ang (1-7)-induced potentiation of 
bradykinin32,161 is mediated via the recently cloned Ang (1-7) receptors.85 Finally, 
we studied the consequences of C-domain inhibition towards bradykinin in human 
coronary microarteries (HCMAs). The consequences of such inhibition towards Ang 
I-II conversion could not be studied in HCMAs, because in isolated human coronary 
vessels, Ang I conversion depends on chymase rather than ACE.118,162
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Material and methods
Tissue and blood collection
HCMAs were obtained from 6 heart-beating organ donors (3 men, 3 women; age 
13-61 years) who died of non-cardiac causes (3 subarachnoidal bleeding, 2 head 
trauma, 1 post-anoxic encephalopathy) <24 hours before the heart was taken to the 
laboratory. Hearts were provided by the Rotterdam Heart Valve Bank after removal 
of the valves for transplantation purposes. The study was approved by the Ethics 
Committee of the Erasmus MC. Immediately after circulatory arrest, the hearts were 
stored in an ice-cooled sterile organ-protecting solution.118,162 Upon arrival in the 
laboratory, tertiary branches of the left anterior descending coronary artery (diameter 
280-600 µm, mean 420 µm) were removed and stored overnight in a cold (4°C), 
oxygenated Krebs bicarbonate solution of the following composition (mmol/L): NaCl 
118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 
7.4. PCAs, PCMAs and PFAs were obtained from 32 2-3 month-old pigs (Yorkshire 
x Landrace, weight 10-15 kg) that had been used in in-vivo experiments studying the 
effects of calcitonin-gene related peptide receptor (ant)agonists under pentobarbital 
(600 mg i.v.) anaesthesia, and from 14 slaughterhouse pigs. The Ethics Committee 
of the Erasmus MC dealing with the use of animals for scientifi c experiments 
approved the protocol for this investigation. Arteries were either removed at the end 
of the experiment or after the heart had been brought to the laboratory in cold Krebs 
bicarbonate solution. Vessels were stored overnight in cold, oxygenated Krebs 
bicarbonate solution. Blood (50 mL) was collected from 6 healthy volunteers (4 men, 
2 women; age 25-41 years) as described before.163 Plasma was stored at -70°C.
Functional Studies
Following overnight storage, PCAs and PFAs were cut into segments of ≈4 mm length 
and mounted in 15-mL organ baths. HCMAs and PCMAs were cut into segments of 
≈2 mm length and mounted in Mulvany myographs (J.P. Trading) with separated 
6-mL organ baths.164 HCMAs rather than large human coronary arteries were used, 
because only the former relax to bradykinin.165 PCMAs were used in the bradykinin 
studies involving RXPA380 and RXP407 because of the limited availability of these 
drugs. All baths contained Krebs bicarbonate solution at 37°C, and were aerated 
with 95% O2 and 5% CO2. Endothelial integrity was verifi ed by observing relaxation 
to 10 nmol/L substance P after preconstriction with the thromboxane A2 analogue 
U46619. Subsequently, to determine the maximum contractile response, the tissue 
was exposed to 100 mmol/L KCl. The segments were then allowed to equilibrate 
in fresh organ bath fl uid for 30 minutes in the presence or absence of RXPA380, 
RXP407, quinaprilat, captopril, Ang (1-7) and/or D-Ala-Ang (1-7). Thereafter, 
HCMAs, PCMAs and PCAs were preconstricted with U46619 (10-100 nmol/L) and 
concentration-response curves (CRCs) were constructed to bradykinin. In PFAs, 
Ang I and II CRCs were constructed. The cyclo-oxygenase inhibitor indomethacin 
(5 µmol/L) was present during all experiments in HCMAs to suppress spontaneously 
occurring contractions and relaxations.
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Metabolism Studies
To study Ang I-II conversion in plasma, 2.5 pmol Ang I was added to blood plasma 
diluted 1:2 or 1:20 in phosphate buffer (pH 7.4) in the presence or absence of 
increasing concentrations of RXPA380, RXP407, quinaprilat, captopril or Ang 
(1-7). The mixture was incubated at 37°C, and 200 µL samples were taken at 0, 
5, 10 and 30 minutes (1:2 diluted plasma) or at 0, 60, 120 and 240 minutes (1:20 
diluted plasma). The samples were immediately mixed with inhibitor solution,118,162 
and stored at -80°C until analysis. Ang I and II were measured with sensitive 
radioimmunoassays.162
Data analysis
Data are given as mean±SEM. CRCs were analysed as described before162 to obtain 
pEC50 (-
10log[EC50]) values. Statistical analysis was by ANOVA, followed by post hoc 
evaluation according to Dunnett. P<0.05 was considered signifi cant.
Results
Figure 1. Relaxations of U46619-preconstricted HCMAs (left) and PCAs (right) to bradykinin in the 
absence (control, open circles) or presence of 10 µmol/L quinaprilat (closed circles), 1 µmol/L Ang (1-7) 
(closed squares), 10 µmol/L Ang (1-7) (closed triangles), and 10 µmol/L Ang (1-7) + 10 µmol/L D-Ala-
Ang (1-7) (open triangles). Data (mean+SEM of 4-6 experiments) are expressed as a percentage of the 
contraction induced by U44169.
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Bradykinin-Induced Relaxations
Bradykinin relaxed U46619-preconstricted HCMAs (n=6), PCAs (n=4) and 
PCMAs (n=14) (pEC50 8.3±0.2, 7.4±0.3, and 8.5±0.2, respectively; Figures 1 and 
2). Quinaprilat (10 µmol/L) shifted the bradykinin CRC in all three vessel types 
≈10-fold to the left (pEC50 9.5±0.2, 8.5±0.1, and 9.7±0.2, respectively; P<0.01 vs. 
control for all). Ang (1-7) also shifted the bradykinin CRC in HCMAs to the left, and, 
at a concentration of 10 µmol/L, its effect (pEC50 9.1±0.3; P<0.05 vs. control) was 
Figure 2. Top panels: Relaxations of U46619-preconstricted PCMAs to bradykinin in the absence 
(control) or presence of the inhibitors RXPA380 (left) and RXP407 (right). For comparison, the effect of 10 
µmol/L quinaprilat is also shown. Data (mean±SEM of 4-7 experiments) are expressed as a percentage 
of the contraction induced by U44169. Bottom panels: Change in -log[EC50] of the bradykinin CRC in 
the presence of increasing concentrations of RXPA380 or RXP407. An increase in –log[EC50] represents 
a leftward shift of the bradykinin CRC. Con, control. Signifi cant differences (P<0.05) vs. control were 
obtained at the highest two concentrations only.
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comparable to that of 10 µmol/L quinaprilat (Figure 1). The leftward shift of 10 µmol/L 
Ang (1-7) in PCAs (pEC50 7.9±0.5, P<0.05 vs. control) was not affected by the Ang 
(1-7) receptor antagonist D-Ala-Ang (1-7) (10 µmol/L) (Figure 1), nor did this drug 
exert additional effects on top of quinaprilat (n=4, data not shown). 
RXPA380 and RXP407, at concentrations of 10 µmol/L and higher, induced a 
leftward shift of the bradykinin CRC in PCMAs that equalled 50% or more of the 
maximal shift observed with quinaprilat (Figure 2).
Angiotensin I-Induced Constrictions
Figure 3. Constrictions of PFAs to Ang I in the absence (control, open circles) or presence (closed circles) 
of 100 µmol/L RXPA380, 10 µmol/L quinaprilat, 10 µmol/L Ang (1-7), 100 µmol/L captopril (middle), or 100 
µmol/L RXP407. Although a wide range of inhibitor concentrations was tested (see also Figure 4), for the 
sake of clarity only the CRC obtained in the presence of the highest inhibitor concentration is shown in 
each panel. Data (mean±SEM of 5-8 experiments) are expressed as a percentage of the contraction to 
100 mmol/L K+.
Ang I constricted PFAs (pEC50=8.1±0.1, n=32; Figure 3) to maximally 40-60% of 
the contraction to 100 mmol/L K+. RXPA380 (n=6), quinaprilat (n=8) and captopril 
(n=5) shifted the Ang I CRC to the right in a concentration-dependent manner, and a 
maximum (≈10-fold) shift occurred at concentrations of 1 µmol/L, 10 nmol/L and 100 
µmol/L, respectively (Figures 3 and 4). Ang (1-7), up to a concentration of 1 µmol/L, 
did not shift the Ang I CRC to the right (n=6; Figure 4), although it did reduce the 
maximum constrictor effect of Ang I by >60% at the latter concentration. At a tenfold 
higher concentration, Ang (1-7) virtually abolished all Ang I-induced effects (Figure 
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3). This high Ang (1-7) concentration also reduced the maximum effect of Ang II (from 
96±23% to 14±4% of the response to 100 mmol/L K+, n=3), thereby indicating that 
its blocking effects towards Ang I are due to Ang II type 1 (AT1) receptor antagonism 
rather than ACE inhibition. RXP407, up to a concentration of 100 µmol/L, did not 
signifi cantly affect the Ang I CRC (Figures 3 and 4).
Figure 4. Top panels: Change in –log[EC50] of the Ang I CRC in the presence of increasing concentrations 
of RXPA380, quinaprilat, Ang (1-7), captopril, or RXP407. A decrease in –log[EC50] represents a rightward 
shift of the Ang I CRC. Data (mean±SEM of 5-8 experiments) were obtained in PFAs (see also Figure 3). 
The fi rst data point represents –log[EC50] in the absence of inhibitor (i.e., control). Signifi cant differences 
(P<0.05) vs. control were obtained for RXPA380, quinaprilat, Ang (1-7) and captopril at concentrations ≥ 
1 µmol/L, 1 nmol/L, 10 µmol/L, and 0.1 µmol/L, respectively. Bottom panels: Inhibition of ACE-dependent 
Ang I-II conversion in the presence of increasing concentrations of RXPA380, quinaprilat, Ang (1-7), 
captopril, or RXP407. Data (mean±SEM of 4 experiments) were obtained in human blood plasma (see also 
Figure 5). The fi rst data point represents conversion in the absence of inhibitor (i.e., control). Signifi cant 
differences (P<0.05) vs. control were obtained for RXPA380, quinaprilat, Ang (1-7), captopril, and RXP407 
at concentrations ≥ 10 µmol/L, 10 nmol/L, 10 µmol/L, 0.1 µmol/L, and 100 µmol/L, respectively. Note the 
difference in inhibition profi le between the top and bottom panels.
Angiotensin I Metabolism in Human Blood Plasma
The half life of Ang I added to human plasma (diluted 1:2 in phosphate buffer) was 
7±0.2 minutes (n=4). Quinaprilat, captopril and Ang (1-7) increased the Ang I half 
life in 1:2 diluted plasma in a concentration-dependent manner to maximally 35±9, 
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29±4 and 32±6 minutes, respectively (n=4 for each; Figure 5). From these data it 
can be calculated166 that, in the absence of inhibitors, 75±3% of the Ang I metabolism 
in human plasma is due to Ang I-II conversion by ACE (Figure 4). The highest 
quinaprilat and captopril concentrations that were tested in this study fully prevented 
the appearance of Ang II in the incubation mixture (data not shown). Ang (1-7), at 
concentrations up to 1 µmol/L, did not affect the generation of Ang II or the half life 
of Ang I. Higher concentrations of Ang (1-7) interfered with the Ang II (but not the 
Ang I) assay,163 thus not allowing us to demonstrate that these concentrations also 
suppressed the generation of Ang II. However, the latter is highly likely in view of the 
similar increase in Ang I half life in the presence of the highest Ang (1-7) concentration 
as in the presence of the highest quinaprilat and captopril concentrations. 
Figure 5. Metabolism of Ang I in human plasma incubated at 37°C in the absence (control, open circles) 
or presence (closed symbols) of 100 µmol/L RXPA380, 10 µmol/L quinaprilat, 100 µmol/L Ang (1-7), 
100 µmol/L captopril, or 100 µmol/L RXP407. Although a wide range of inhibitor concentrations was 
tested (see also Figure 4), for the sake of clarity only the results obtained in the presence of the highest 
inhibitor concentration are shown in each panel. Data (mean±SEM of 4 experiments) are expressed as a 
percentage of the Ang I levels at t=0.
Importantly, the quinaprilat concentration that maximally shifted the Ang I CRC to the 
right (10 nmol/L; Figure 4) reduced Ang I conversion by plasma ACE by only 50%, 
and a 100-fold higher (P<0.01) quinaprilat concentration (1 µmol/L) was needed to 
fully suppress conversion (Figure 4). Conversely, the captopril concentration required 
to block plasma ACE by 50% (IC50) was ≈5-fold lower (P=NS) than the captopril 
concentration required to cause a half-maximal shift of the Ang I CRC (pIC50 6.5±0.2 
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vs. 6.0±0.3). No such comparisons could be made for Ang (1-7), because of its AT1 
receptor-blocking capacities in the organ bath experiments.
RXPA380 and RXP407, up to concentrations of 100 µmol/L, did not affect Ang I 
metabolism in 1:2 diluted plasma (n=4, data not shown). Subsequent measurement 
of these inhibitors in plasma revealed strong plasma protein binding, which 
reduced their free concentrations by >100-fold (V. Dive, unpublished observations). 
Therefore, to minimize the problems arising from protein binding, we studied the 
effects of these inhibitors in 1:20 diluted plasma. Under these conditions the half 
life of Ang I was 42±3 minutes (n=4; Figure 5). Quinaprilat (10 µmol/L) increased 
the Ang I half life to 166±22 minutes (P<0.01), thereby demonstrating that 71±6% 
of the Ang I metabolism in these samples is due to ACE (P=NS vs. 1:2 diluted 
samples). RXPA380 and RXP407 increased the Ang I half life in 1:20 diluted plasma 
in a concentration-dependent manner to maximally 156±19 (P=NS vs. quinaprilat) 
and 80±9 (P<0.01 vs. quinaprilat) minutes, respectively (Figure 5). Only the highest 
RXPA380 concentration (but not the highest RXP407 concentration) fully prevented 
the appearance of Ang II in the incubation mixture (data not shown). Importantly, the 
RXPA380 concentration that was required to fully block Ang I-II conversion in plasma 
(100 µmol/L) was 100 times higher (P<0.01) than the concentration required to fully 
shift the Ang I CRC to the right (Figure 4).
Discussion
The present study shows that low (C-domain selective) concentrations of RXPA380 
and quinaprilat are suffi cient to fully prevent Ang I-induced contractions of PFAs (i.e., 
to cause a maximum rightward shift of the Ang I CRC), whereas high concentrations 
(capable of blocking both the C- and N-domain) are required to fully block Ang I-II 
conversion in human blood plasma. Selective N-domain inhibition with RXP407 did 
not affect Ang I-induced constrictions, and reduced Ang I-II conversion in plasma by 
≈50%. Taken together, these data suggest that only the C-domain contributes to Ang 
I-II conversion by membrane-bound ACE, and that both domains contribute to Ang II 
generation by soluble ACE. In contrast, bradykinin degradation by membrane-bound 
ACE depends on both domains, because, in agreement with the biphasic quinaprilat-
induced leftward shift observed previously in PCAs,32 RXPA380 as well as RXP407 
shifted the bradykinin CRC to the left, and a maximum leftward shift was observed 
only when both domains were blocked. Using the same selective inhibitors, it has 
already been shown that both domains contribute to bradykinin degradation by 
soluble ACE.153 
Our data on captopril, a modestly selective N-domain inhibitor,158 are in full 
agreement with the above concept of C-domain-dependent Ang I-II conversion by 
membrane-bound ACE. When using this inhibitor, the concentrations required to 
shift the Ang I CRC to the right, if anything, were higher than the concentrations 
required to block Ang I-II conversion by circulating ACE. This directly opposes our 
fi ndings with quinaprilat and RXPA380. The lack of a signifi cant difference in the 
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present study most likely relates to the modest (≈20-fold) selectivity of captopril 
towards the N-domain.158
We also evaluated the effects of Ang (1-7), an angiotensin metabolite that selectively 
blocks the ACE C-domain.157 Studies investigating the metabolism of Ang I in 
isolated human and porcine vessels have already shown that, under the present 
experimental conditions, Ang (1-7) will not be generated in suffi cient amounts to 
exert effects.118,159,160,162 First we investigated the potentiating capacity of Ang (1-7) 
towards membrane-bound ACE in HCMAs. To this end we constructed bradykinin 
CRCs rather than Ang I CRCs, because, due to the presence of chymase in human 
coronary arteries, ACE inhibition will not result in a signifi cant rightward shift of the 
Ang I CRC in human vessels.118,162 As expected, Ang (1-7) shifted the bradykinin to 
the left in a concentration-dependent manner, reaching the same maximal leftward 
shift as quinaprilat at a concentration of 10 µmol/L. The inhibitory capacities of 
Ang (1-7) towards human ACE were further supported by the fact that this inhibitor 
increased the Ang I half life in human blood plasma to exactly the same degree as 
the ACE inhibitors quinaprilat and captopril. Second, we excluded the possibility 
that the Ang (1-7)-induced leftward shift of the bradykinin CRC depends on the 
activation of Ang (1-7) receptors rather than ACE inhibition, using the selective Ang 
(1-7) receptor antagonist D-Ala-Ang (1-7).85 As shown in Figure 1, this antagonist 
did indeed not affect the Ang (1-7)-induced leftward shift of the bradykinin CRC in 
PCAs, although it does block the direct vasodilator effects of Ang (1-7) in the isolated 
rabbit afferent arteriole.167 Finally, we studied the effects of Ang (1-7) towards Ang I-
induced constrictions in PFAs. PCAs are not suitable for such experiments, because 
of their limited reactivity to Ang II.162 In agreement with our fi ndings on quinaprilat, 
Ang (1-7) markedly shifted the Ang I CRC to the right, at concentrations that in PCAs 
selectively blocked the ACE C-domain.118 However, it simultaneously reduced the 
maximum effect of Ang I, and identical observations were made towards Ang II.168,169 
This suggests that the Ang (1-7) concentrations that  selectively block the C-domain 
are also capable of blocking AT1 receptors, thereby not allowing us to demonstrate 
the functional consequence of selective C-domain inhibition by Ang (1-7) towards 
Ang I.
Our observation that N-domain inhibition does not block Ang I-II conversion by 
membrane-bound ACE is in full agreement with a previous study demonstrating no 
effect of the N-domain selective inhibitor RXP407 on the blood pressure responses 
to Ang I in mice.154 In apparent contrast with our current data, as well as with the 
data on Ang I pressor responses in mice, Georgiadis et al.153 observed that RXP407, 
at N-domain selective doses, did block the conversion of systemically administered 
Ang I in mice. This discrepancy may be explained  in several ways. First, it could 
relate to in vitro Ang II generation at the time of blood sampling.170 To avoid such 
in vitro generation, blood samples need to be collected with a syringe containing 
an angiotensinase inhibitor cocktail rather than mixing the samples with the 
inhibitor cocktail after they have been collected. This approach was not followed by 
Georgiadis et al..153 Consequently, in their experimental setup, Ang II generation by 
plasma ACE may have continued ex vivo in the absence of inhibitors, but not (or to 
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a lesser degree) in the presence of RXP407 and RXPA380, thereby leading to the 
conclusion that both types of inhibitors are capable of blocking Ang II generation 
from systemically applied Ang I. Second, based on a recent study showing enhanced 
ACE-mediated outside-in signaling in the presence of ACE inhibitors,171 one may 
speculate that ACE-induced signaling is determined by the N-domain. Consequently, 
RXP407, but not RXPA380, might exert effects through ACE that need to be taken 
into consideration when investigating Ang I-induced vasoconstriction.
Future perspective
This study is the fi rst to show that low concentrations of (C-domain selective) ACE 
inhibitors are suffi cient to fully inhibit Ang II generation by membrane-bound ACE. 
Although the molecular mechanism of this effect is currently not known, the fact 
that such low concentrations did not fully block plasma ACE offers an explanation 
for earlier studies showing that low doses of ACE inhibitors exert benefi cial effects 
in the absence of blood pressure reduction.172,173 Selective inhibition of tissue Ang 
II generation (in addition to AT1 receptor blockade) might also explain why the 
benefi cial effects of Ang (1-7) differ from those of ACE inhibitors in heart failure.174
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Abstract
ACE I/D polymorphism-related differences in ACE concentration do not result in 
differences in angiotensin levels. In this study we investigated whether this relates 
to differences in the contribution of the ACE C- and N-domain, we quantifi ed, using 
the C-domain-selective inhibitors quinaprilat and RXPA380, and the N-domain-
selective inhibitor RXP407, the contribution of both domains to the metabolism of 
angiotensin I, bradykinin, the C-domain-selective substrate Mca-BK(1-8), and the 
N-domain-selective substrate Mca-Ala, in serum of II’s, DD’s, and  ‘hyperACE’ 
subjects (i.e., subjects with increased ACE due to enhanced shedding). During 
incubation with angiotensin I, the highest angiotensin II levels were observed in sera 
with the highest ACE activity. This confi rms that ACE is rate-limiting with regard to 
angiotensin II generation. C-domain-selective concentrations of quinaprilat fully 
blocked angiotensin I-II conversion in DD’s, whereas additional N-domain blockade 
was required to fully block conversion in II’s. Both domains contributed to bradykinin 
hydrolysis in all subjects, and the inhibition profi le of RXP407 when using Mca-Ala 
was identical in II’s and DD’s. In contrast, the RXPA380 concentrations required to 
block C-domain activity when using Mca-BK(1-8) were three-fold higher in II’s than 
DD’s. The contributions of the C- and N-domain differ between DD’s and II’s, and 
RXPA380 is the fi rst inhibitor capable of distinguishing D-allele ACE from I-allele 
ACE. The lack of angiotensin II accumulation in DD’s in vivo is not due to the often 
quoted concept that ACE is a non-rate limiting enzyme. It may relate to the fact that 
in II’s both the N- and C- domain generate angiotensin II, whereas in DD’s only the 
C-domain converts angiotensin I. 
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Introduction
Membrane-bound (‘tissue’) ACE is the main, if not the only, contributor to angiotensin (Ang) I-II conversion in vivo.163,175 A fraction of membrane-bound 
ACE is released into the extracellular fl uid (shedding), but this ‘soluble’ ACE 
contributes little to Ang II generation.176 Somatic ACE has two domains, each 
containing an active center. According to their position (N- or C-terminal), these 
domains are designated as the N- and C-domain, respectively. Selective C-domain 
inhibition fully blocks Ang I-induced vasoconstriction.31 Thus, the Ang II that reaches 
vasoconstrictor Ang II type 1 (AT1) receptors following its local generation from Ang 
I118 requires the ACE C-domain. This implies that either the N-domain of tissue ACE 
does not contribute to Ang II generation or that it is responsible for the generation 
of Ang II that is released from tissues sites to act elsewhere.153 The N-domain 
negatively affects shedding and the catalytic activity of the C-domain.177,178
The ACE I/D polymorphism determines part of the interindividual variability in tissue 
and soluble ACE, carriers of the D allele displaying higher tissue and serum ACE 
levels.179-181 This is most likely due to the fact that the D allele leads to higher ACE 
mRNA expression.182. Remarkably, the ≈60% higher ACE levels in subjects with the 
DD genotype (as compared to II’s) did not result in a 60% higher regional conversion 
rate nor in an alteration in the levels of circulating Ang II in DD’s.183-186. Ang II levels 
also did not differ in mice with different numbers of Ace gene copies187,188, and 
compensatory renin regulation, as well as changes in the levels of Ang I-degrading 
enzymes, have been shown to explain the lack of effect of ACE titration on Ang II in 
mice. D allele-related changes in renin or differences in Ang I degradation did not 
occur in humans184,189 and, thus, alternative explanations must be put forward for the 
absence of a D allele-related change in Ang II in man. 
In the present study, we set out to investigate the possibility that the contributions of 
the ACE C- and N-domain are different in D vs. I allele carriers. We made use of serum 
obtained from the II and DD subjects that displayed the lowest and highest serum 
ACE activity in a cohort of several hundred British army recruits. For comparison, we 
also used serum of ‘hyperACE’ subjects, i.e., subjects who, due to a point mutation 
in the stalk region of ACE (which enhances shedding), display serum ACE levels that 
are several fold above the levels in the general population.190 Importantly, hyperACE 
subjects have normal plasma levels of Ang II and exhibit no clinical abnormalities. 
Finally, using porcine coronary arteries (PCAs), we studied whether Ang II release 
from tissue sites depends on the ACE N-domain. To distinguish the contribution 
of the two domains, we used the C-domain-selective inhibitors quinaprilat and 
RXPA380 and the N-domain-selective inhibitor RXP407.31,32,153
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Material and methods
Tissue and blood collection
PCAs were obtained from slaughterhouse pigs. Arteries were removed after the 
heart had been brought to the laboratory in cold Krebs bicarbonate solution of the 
following composition (mmol/L): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 
1.2, NaHCO3 25 and glucose 8.3; pH 7.4. Vessels were stored overnight in cold, 
oxygenated Krebs bicarbonate solution. 
Serum was obtained from the 24 II and 25 DD subjects displaying the lowest and 
the highest serum ACE activity among a cohort of several hundred healthy British 
Army recruits (age 20 years) who were recruited to a study examining the role of 
genetic variation and environmental factors on cardiac growth in response to 
exercise. Genotyping occurred as described before.191 Serum was also obtained 
from 15 hyperACE subjects (10 ID, 5 DD; 10 men and 5 women, age 25-69 years). 
Serum was stored at -80oC. The studies were approved by the UK Defence Medical 
Services Clinical Research (Ethics) Committee and the Ethics Committee of the 
UMCN St. Radboud.
Vascular studies
Following overnight storage, PCAs were cut into segments of ~4 mm length. 
The segments were incubated in 1 mL oxygenated Krebs bicarbonate solution at 
37oC, aerated with 95% O2 and 5% CO2 in the absence or presence of increasing 
concentrations of RXPA380, RXP407 or quinaprilat for 30 minutes. Next, 100 
pmol Ang I was added to the incubation fl uid and the incubation was continued 
for 1 hour. Immediately thereafter, the incubation fl uid was collected, mixed 
with inhibitor solution, and stored at -80oC. Ang II was measured with a sensitive 
radioimmunoassay.118
Serum studies    
ACE activity was measured with a commercial kit (ACE Color, Fujirebio) using Hip-
His-Leu (HHL) as substrate. Ang I-II conversion was studied by adding 10 pmol 
Ang I to serum diluted 1:20 (II and DD subjects) or 1:50 (hyperACE subjects) in 
phosphate buffer (pH 7.4; fi nal volume 1 mL). The mixture was incubated at 37oC, 
and 200 µL samples were taken over a period of 4 hours. Samples were mixed with 
inhibitor solution,118 and stored at -80oC. Ang I and II were measured with sensitive 
radioimmunoassay.118 Bradykinin hydrolysis was studied by adding 250 pmol 
bradykinin to serum diluted 1:100 (II and DD subjects) or 1:300 (hyperACE subjects) 
in phosphate buffer (fi nal volume 2 mL). The mixture was incubated at 37oC. Samples 
(200 µL) were taken over a period of 2 hours, mixed with ethanol, and bradykinin 
was quantifi ed by UV detection (210 nm) after reversed-phase high-performance 
liquid chromatography according to Kuoppala et al.,192 using bradykinin-(1-8) as 
internal standard. All studies with HHL, Ang I and bradykinin were repeated in the 
presence of increasing concentrations of quinaprilat. Finally, the inhibitory effects 
of RXP407 and RXPA380 were evaluated in serum diluted 1:20 (RXP407) or 1:100 
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(RXPA380) in 50 mmol/L HEPES buffer as described by Jullien et al.,193 using the 
N- and C-domain-selective substrates Mca-Ala-Ser-Asp-Lys-DpaOH (Mca-Ala) and 
Mca-Arg-Pro-Pro-Gly-Phe-Ser-Pro-DpaOH (Mca-BK(1-8)) at a concentration of 15 
and 10 µmol/L, respectively.  
Data analysis
Data are given as mean±SEM, and n-values represent the number of subjects. 
First order rate constants of Ang I and bradykinin metabolism by non-ACE enzymes 
(‘degradation’; k1) and ACE (conversion; k2) in serum were calculated as described 
before,160 and corrected for the dilution factor. In short, the Ang I and bradykinin 
elimination in the absence of quinaprilat represents both degradation and conversion 
(kelimination = k1 + k2), whereas elimination in the presence of the highest quinaprilat dose 
(which fully blocks ACE) represents degradation only (kelimination = k1). By subtracting 
k1 from the kelimination at each quinaprilat concentration, k2 could be determined 
at each condition.  Fractional conversion (i.e., the percentage of metabolism due to 
ACE) at each condition was subsequently calculated as k2 * 100/(k1 + k2). Statistical 
analysis was by t-test. P<0.05 was considered signifi cant.
Results
Vascular studies
The Ang II levels in the incubation 
fl uid after 1 hour of incubation at 
37oC corresponded with ~5% of 
the Ang I levels that were added at 
t=0. RXPA380, but not RXP407, 
decreased Ang II in a concentration-
dependent manner (Figure 1), 
reaching the same degree of 
inhibition as 10 µmol/L quinaprilat at 
a concentration of 0.1 mmol/L. Thus, 
Ang II release from porcine coronary 
arteries depends exclusively on the 
ACE C-domain.
Serum studies
HHL. Serum ACE activity in II, DD 
and hyperACE subjects was 19+1, 
44+2 (P<0.001 vs. II), and 95+7 U/L 
(P<0.001 vs. DD), respectively. The 
inhibition profi le of quinaprilat, tested 
in duplicate in serum pools containing 
serum of 10 subjects, was identical 
Figure 1. Angiotensin II levels in incubation fl uid 
following incubation of PCA segments in 1 mL fl uid with 
100 pmol Ang I in the absence or presence of increasing 
concentrations of RXP407 (open symbols) or RXPA380 
(closed symbols). Results obtained with 10 µmol/L 
quinaprilat (quin) are shown for comparison. Data are 
mean±SEM of 4 experiments. *P<0.05 vs. control.
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in all groups (Figure 2). Quinaprilat 
concentrations of 1 µmol/L and higher 
were required to fully block HHL 
conversion. 
Angiotensin I. The half life of Ang I 
added to serum of II (n=5) and DD 
(n=5) subjects (diluted 1:20) was 
73+10 and 25+2 min (P<0.002), 
respectively (Figure 3). Peak Ang II 
levels were higher in subjects with the 
DD genotype (P<0.05). Quinaprilat 
increased the Ang I half life to 
maximally 246±60 and 170±37 min 
(P=NS for difference), respectively, 
and fully suppressed Ang II generation 
at concentrations >100 nmol/L. From 
these data it can be calculated that the 
fi rst order rate constant of conversion 
in serum is ~4 times lower in II’s than 
DD’s (0.13+0.01 vs. 0.47+0.02 1/
min; P<0.001; Figure 4), and that, in 
the absence of quinaprilat, 65+6% 
Figure 2. Inhibitory effect of quinaprilat on ACE-
mediated HHL conversion in serum of II, DD and 
hyperACE subjects. Data are means of duplicate 
measurements in pools containing serum of 10 
subjects. 
and 83+3% of Ang I metabolism is due to Ang I-II conversion by ACE (P<0.05). The 
fi rst order rate constant of degradation (representing Ang I metabolism by non-ACE 
pathways) was similar in both groups (0.08+0.02 vs. 0.10+0.02 1/min; Figure 4). The 
inhibitory profi le of quinaprilat was monophasic in DD’s (fully blocking conversion at 
10 nmol/L), and biphasic in II’s (blocking conversion by 64+6% at 10 nmol/L (P<0.02 
vs. DD), and fully at 1 µmol/L) (Figure 5). Since 10 nmol/L quinaprilat selectively 
blocks the C-domain, and 1 µmol/L quinaprilat blocks both domains,31,32 these data 
indicate that the C-domain is the only Ang I-II-converting domain in DD subjects, 
and that both domains contribute to Ang I-II conversion in II subjects. The half life of 
Ang I added to serum of hyperACE (n=6) subjects (diluted 1:50) was 25+2 minutes 
(Figure 3). Peak Ang II levels were higher than in DD subjects (P<0.05), despite the 
2.5-fold larger dilution of serum. Quinaprilat increased the Ang I half life to maximally 
592+184 minutes, and fully suppressed Ang II generation at concentrations >100 
nmol/L. From these data it can be calculated that the fi rst order rate constant of 
conversion in serum of hyperACE subjects is 1.36+0.12 1/min (P<0.001 vs. DD’s; 
Figure 4), and that, in the absence of quinaprilat, 94+2% (P<0.02 vs. DD’s) of Ang 
I metabolism is due to Ang I-II conversion by ACE. The fi rst order rate constant of 
degradation (0.09+0.03 1/min) was similar to that in II and DD subjects. The inhibitory 
profi le of quinaprilat was biphasic in hyperACE subjects, blocking conversion by 
43+3% at 10 nmol/L (P<0.05 vs. II, P<0.001 vs. DD), and fully at 1 µmol/L) (Figure 
5). These data indicate that both ACE domains contribute to Ang I-II conversion in 
hyperACE subjects.
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Bradykinin. The half life of bradykinin added to serum of II (n=5) and DD (n=5) 
subjects (diluted 1:100) was 66+4 and 26+2 min (P<0.005), respectively (Figure 6). 
Quinaprilat increased the bradykinin half life to maximally 270+24 and 433+99 min 
Figure 3. Metabolism of angiotensin (Ang) I in serum obtained from II, DD and hyperACE  subjects 
incubated at 37°C in the absence (open symbols) or presence (closed symbols) of quinaprilat. For the 
sake of clarity only data obtained with the highest quinaprilat concentration (10 µmol/L) are shown. Top, 
Ang I levels, bottom, Ang II levels. Data (mean±SEM of 5-6 experiments) are expressed as a percentage 
of the Ang I levels at t=0.
Figure 4. First order rate constants of conversion (open bars) and degradation (closed bars) of angiotensin 
I and bradykinin in serum of II, DD and hyperACE subjects. Data are mean±SEM of 5-6 experiments. 
*P<0.001 vs. II, # P<0.001 vs. DD.
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(P=NS for difference). From these 
data it can be calculated that the fi rst 
order rate constant of conversion in 
serum is ~4 times lower in II’s than 
DD’s (0.81+0.09 vs. 2.59+0.20 1/min; 
P<0.001; Figure 4), and that, in the 
absence of quinaprilat, 75+4% and 
93+1% of bradykinin metabolism is 
due to conversion by ACE (P<0.002). 
The fi rst order rate constant of 
degradation (representing bradykinin 
metabolism by non-ACE pathways) 
was similar in both groups (0.19+0.03 
vs. 0.27+0.03 1/min; Figure 4). The 
inhibitory profi le of quinaprilat was 
identical in II’s and DD’s (Figure 5), 
requiring quinaprilat concentrations 
that blocks both domains to fully 
prevent bradykinin conversion. 
Thus, both ACE domains contribute 
to bradykinin hydrolysis in II and DD 
subjects. The half life of bradykinin 
added to serum of hyperACE (n=5) 
subjects (diluted 1:300) was 24+1 
minutes (Figure 6). Quinaprilat 
increased the bradykinin half life to 
maximally 562+142 minutes. From 
these data it can be calculated that the 
fi rst order rate constant of conversion 
in serum of hyperACE subjects is 
8.52+0.51 1/min (P<0.001 vs. DD’s; 
Figure 4), and that, in the absence 
of quinaprilat, 95+1% of bradykinin 
metabolism is due to conversion by 
ACE. The fi rst order rate constant of 
degradation (0.46+0.10 1/min) was 
similar to that in II and DD subjects. 
The inhibitory profi le of quinaprilat in 
hyperACE subjects was identical to 
that in II and DD subjects (Figure 5). 
RXPA380 and RXP407. The inhibition 
profi le of RXP407 was identical 
in II and DD subjects, and closely 
resembled that obtained when using 
Figure 5. Fractional conversion of Ang I (open symbols) 
and bradykinin (closed symbols) in serum obtained from 
II, DD and hyperACE subjects incubated at 37°C in the 
presence of increasing concentrations of quinaprilat. 
Data (mean±SEM of 5-6 experiments) are expressed 
as a percentage of the conversion in the absence of 
quinaprilat.
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Figure 6. Metabolism of bradykinin in serum obtained from II, DD and hyperACE subjects incubated at 
37°C in the absence (open symbols) or presence (closed symbols) of quinaprilat. For the sake of clarity 
only data obtained with the highest quinaprilat concentration (10 µmol/L) are shown. Data (mean±SEM of 
5 experiments) are expressed as a percentage of the bradykinin levels at t=0.
(a)
(b)
(c)
(d)
1000100101 104 105
(RXPA380) nmol/l
0
20
40
60
80
100
101000100101
4
10
5
%
 In
h
ib
it
io
n
(RXP407) nmol/l
0
20
40
60
80
100
Figure 7. Inhibition profi les (% inhibition) of human ACE with the N-domain-selective inhibitor RXP407 (A, 
B) or the C-domain-selective inhibitor RXPA380 (C, D) in serum obtained from 13 DD (top panels) and 10 
II (bottom panels) subjects. Each symbol represents an individual measurement. Profi les were simulated 
using the following Ki values: panel A, 10 nmol/L for the N-domain, and 3 µmol/L for the C-domain; panel 
B, 10 nmol/L for the N-domain, and 5 µmol/L for the C-domain; panel C, 50 nmol/L for the C-domain, and 
50 µmol/L for the N-domain; panel D, 150 nmol/L for the C-domain, and 50 µmol/L for the N-domain. 
Please note that the RXP407 curves in DD and II subjects are identical, whereas the RXPA380 curve has 
shifted to the right in II vs. DD subjects.
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purifi ed human ACE (Figure 7).193 The curve consisted of two parts, refl ecting the 
titration of the N- and C-domain, respectively. The RXPA380 curve in II and DD 
subjects also consisted of two parts, now refl ecting the titration of the C- and N-
domain, respectively (Figure 7). However, with this inhibitor, the bottom part of the 
curve (resembling C-domain inhibition) was shifted 3-fold to the right (IC50 150 vs. 
50 nmol/L) in II subjects as compared to DD subjects. Thus, a C-domain-selective 
inhibitor is able to distinguish DD and II subjects.
Discussion
This study shows that, in porcine membrane-bound ACE, the C-domain is the 
predominant Ang I-II converting domain, being responsible for both the generation 
of Ang II that acts locally31 and the release of Ang II from tissue sites. Secondly, this 
study raises the possibility that the N-domain contributes to Ang II generation in I 
allele carriers, thereby offering an explanation for the lack of effect of the D allele-
related rise in ACE on Ang II generation. A further difference between II and DD 
subjects was observed when studying the inhibitory effect of the C-domain-selective 
inhibitor RXPA380. Finally, we detected the highest degree of Ang II generation in 
sera with the highest ACE levels. This suggests that the often quoted concept that 
ACE is non-rate limiting with regard to Ang II generation is incorrect. 
In agreement with our previous in vivo studies,184 no D allele-related increase in Ang 
I degradation was detected in serum. This conclusion contrasts with the observation 
in mice that Ace gene titration is accompanied by changes in the metabolism of Ang 
I by non-ACE enzymes.188 However, these titration studies, unlike the D allele, did 
result in changes in Ang II generation, as evidenced by compensatory changes 
in renin187,188 and, thus, they may not be truly representative for the functional 
consequences of the ACE I/D polymorphism. Based on the present data, it appears 
that such studies should also incorporate the varying contribution of the two ACE 
domains. The underlying assumption for this conclusion is that the current results 
(obtained with soluble ACE) also apply to membrane-bound ACE. If indeed the I 
allele, but not the D allele, allows Ang I-II conversion by the N-domain of membrane-
bound ACE, it is obvious that the (on average) 60% higher ACE levels in DD’s will not 
result in a higher Ang II-generating capacity than in II’s. Rather, the capacity might 
be somewhat lower, because 100 I-allele ACE molecules maximally posses 200 Ang 
I-converting sites, as opposed to 160 Ang I-converting sites for 160 molecules of 
D-allele ACE. Only by studying DD subjects with ACE levels that are much (i.e, far 
more than 60%) higher than in II’s, an increase in Ang I-II conversion will be found. 
However, such extreme differences occur rarely, as demonstrated by the fact that 
it took several hundred recruits to select the DD’s and II’s for the present study. 
Consequently, it is not surprising that previous studies investigating ACE I/D-related 
changes in Ang I-II conversion 183-185 did not fi nd differences. 
A further difference between II and DD subjects was noted when studying the 
inhibitory effect of the C-domain-selective inhibitor RXPA380, using the C-domain 
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selective substrate Mca-BK(1-8). The IC50 for C-domain inhibition under these 
circumstances was 3-fold higher in II’s than in DD’s. No such difference was observed 
when studying the inhibitory effect of the N-domain-selective inhibitor RXP407 in 
combination with the N-domain-selective substrate Mca-Ala, nor when studying 
the inhibitory effect of quinaprilat in combination with HHL as substrate. In the latter 
case inhibition was observed only at quinaprilat concentrations that were no longer 
C-domain-selective (i.e., they also blocked the N-domain). Thus, it seems that the 
contributions of the C- and N-domain do differ between DD’s and II’s. Differences 
can only be observed under specifi c conditions, and most optimally when using C-
domain-selective inhibitors in combination with C-domain-selective substrates. 
What might underlie the contribution of the N-domain to Ang II generation in II’s but 
not DD’s? Based on the insertion (which concerns a 287 base pair Alu repeat in intron 
16 of the ACE gene), no molecular differences are to be expected between I and D 
ACE. Complete genomic sequencing of the ACE gene has revealed 17 sites that 
are in absolute linkage disequilibrium with the I/D polymorphism, 15 of which were 
noncoding sites and 2 were synonymous coding variants.194 Thus, further genomic 
studies are required to identify other polymorphisms that may cause this difference. 
The mechanism may involve the 14-residue bridge responsible for interdomain 
cooperativity178,195 in view of the fact that the N-domain negatively regulates the 
catalytic activity of the C-domain.177,178 Alternatively, the difference may be due to 
posttranslational modifi cation (involving differences in glycosylation) and/or a factor 
in serum capable of interfering with ACE activity, e.g., an endogenous N-domain 
inhibitor. Such natural inhibitors have also been described for other enzymes, e.g. 
neutral endopeptidase196 and NO synthase.197        
Interestingly, whereas the C-domain appears to be the principal Ang I-converting 
domain, both domains contributed equally to bradykinin hydrolysis in II and DD 
subjects, in full agreement with previous studies.32,157,188 Therefore, with regard to 
bradykinin, ACE I/D polymorphism-related differences are to be expected, even in 
populations where the ACE levels in DD’s are on average only 60% higher than in 
II’s. Small studies demonstrating increased bradykinin metabolism in DD subjects, 
in vitro as well as in vivo, support this view198,199. Importantly, the latter data are 
also in agreement with the fi ndings on bradykinin levels in mice with varying ACE 
concentrations,187 in contrast with the opposite fi ndings on angiotensins in humans 
and mice described above.
Finally, our data in serum of hyperACE subjects largely resembled those in II’s. 
This is due to the fact that the majority of our hyperACE subjects was of the ID 
genotype, thus allowing the contribution of both ACE domains to Ang I-II conversion. 
Importantly, the ACE levels in these subjects were even higher than in DD’s, and 
this resulted in the highest degree of Ang I conversion of all groups. Thus, contrary 
to the concept that ACE is non-rate limiting with regard to Ang I conversion, our data 
show clearly that the higher ACE, the more Ang I is converted to Ang II, and the 
higher [Ang II] will be. It is important to realize that the high serum ACE levels in 
hyperACE subjects are the consequence of increased shedding. Unlike the situation 
in DD subjects181 they are not  accompanied by similarly high tissue ACE levels. 
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Thus, given the fact that circulating Ang II is generated by membrane-bound (and 
not circulating) ACE,163 hyperACE subjects do not display increased Ang II levels in 
blood plasma.190
Future studies investigating the ACE I/D polymorphism should take into account that 
the contributions of both ACE domains to Ang I-II conversion may differ between I 
and D allele carriers. As a result, regional Ang I-II conversion, plasma renin and Ang 
II levels will be identical in II and DD subjects, and animal models with varying ACE 
expression are unsuitable to study the consequences of the ACE I/D polymorphism. 
Since the two domains do not make a distinction in bradykinin hydrolysis, it seems 
reasonable to propose that differences in kinin levels are more likely to underlie 
the observed association of the ACE I/D polymorphism with cardiovascular 
disorders.200,201 Since the polymorphism also determines the effectiveness of ACE 
inhibitor therapy,202 it is important to test this concept on a large-scale basis.
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Abstract
Angiotensin (Ang) II type 2 (AT2) receptors are believed to counteract Ang II type 1 
(AT1) receptor-mediated effects. Here we investigated AT2 receptor-mediated effects 
on coronary and cardiac contractility in C57BL/6 mice.
Hearts were perfused according to Langendorff. Baseline coronary fl ow (CF) and 
left ventricular systolic pressure (LVSP) were 2.7±0.1 ml 1/min and 111±3 mm Hg 
(n=50), respectively. 
Ang II (n=14) concentration-dependently decreased CF and LVSP, by maximally 
41±4% and 25±3%, respectively (pEC50’s 7.41±0.12 and 7.65±0.12). The AT1 
receptor antagonist irbesartan (n=4) abolished all Ang II-induced changes, whereas 
the AT2 receptor antagonist PD123319 (n=6) enhanced (P<0.05) the effect of Ang 
II on CF (to 59±1%) and LVSP (to 44±2%), without altering its potency. A similar 
enhancement was observed in the presence of NO synthase inhibitor Nω-nitro-L-
arginine methyl ester HCl (L-NAME; n=4). On top of L-NAME, PD123319 no longer 
affected the response to Ang II (n=4).
The AT2 receptor agonist CGP42112A (n=4) did not affect CF or LVSP, nor did 
CGP42112A (n=4) alter the constrictor response to the α1-adrenoceptor agonist 
phenylephrine. Furthermore, Ang II exerted no effects in hearts of AT1A
-/- mice 
(n=5), whereas its effects in hearts of AT1A
+/+ wildtype control mice (n=7) were 
indistinguishable from those in hearts of C57BL/6 mice. 
In conclusion, Ang II exerts opposite effects on coronary and cardiac contractility 
in the mouse heart via activation of AT1A and AT2 receptors. AT2 receptor-mediated 
effects depend on NO and occur only in conjunction with AT1A receptor activation.
AT2 receptors and mouse coronary vasodilation
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Introduction
The renin-angiotensin system (RAS) plays an important role in the regulation of blood pressure, cardiovascular remodelling and maintaining body fl uid volume. 
The main effector peptide of the RAS, angiotensin (Ang) II, activates Ang II type 1 
(AT1) and Ang II type 2 (AT2) receptors. Two subtypes of AT1 receptors have been 
identifi ed in rodents (AT1A and AT1B) which share 94% sequence homology, whereas 
the AT2 receptor only shares 34% sequence homology with these subtypes.
43,65,203 
AT1 receptors mediate the well-known vasoconstrictor, inotropic, chronotropic, 
aldosterone-releasing, noradrenaline-releasing and growth-stimulatory effects of 
Ang II, and AT2 receptors are generally assumed to counteract these actions.
57-60,204-
207 It is believed that AT2 receptor-mediated vasodilation is an endothelium-dependent 
phenomenon, involving bradykinin type 2 receptors, nitric oxide (NO) and guanosine 
cyclic 3’, 5’ –monophosphate (cGMP).74-76,208,209
However, not all studies confi rm the counterregulatory actions of AT2 receptors.
136,210-
212 Findings on AT2 receptor-mediated effects that contrasted with the above concept 
have been attributed to disparities in genetic background138 or blood pressure.212 
Furthermore, in many studies conclusions on AT2 receptor-mediated counteracting 
effects were drawn based on indirect evidence, i.e., the occurrence of an enhanced 
response to Ang II following AT2 receptor antagonism or gene disruption.
57,59,60,208. The 
interpretation of data obtained in the absence of AT2 receptors is complex, because 
AT2 receptors downregulate AT1 receptors in a ligand-independent manner
81, and 
AT2 receptor-null mice display increased AT1 receptor expression.
82
In the present study we set out to characterize AT2 receptor-mediated effects in the 
coronary vascular bed of the mouse heart, using the Langendorff model. Despite 
the many AT2 receptor-related studies in transgenic mice, such data are currently 
not available. AT2 receptor-mediated responses were studied by comparing Ang 
II-induced responses in the absence and presence of the AT2 receptor antagonist 
PD123319, and by selectively stimulating AT2 receptors. The latter was accomplished 
in three ways. First, we investigated the effects of Ang II in the presence of the AT1 
receptor antagonist irbesartan. Second, we studied the effects of the AT2 receptor 
agonist CGP42112A63,213,214, both at baseline and during phenylephrine-induced 
vasoconstriction. Third, we evaluated the response to Ang II in AT1A
-/- mice, i.e., 
mice lacking Ang II-induced vasoconstriction.45 We also investigated whether NO 
mediated the AT2 receptor-dependent responses, using the NO synthase (NOS) 
inhibitor Nω-nitro-L-arginine methyl ester HCl (L-NAME).  
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Material and methods
Animals
Male C57BL/6 mice (26±0.6 gram; n=50) were obtained from Harlan (Zeist, The 
Netherlands). Male AT1A
+/+ (31±1 gram; n=7) and AT1A
-/- mice (27±2 g; n=5) were 
bred on a 129xC57BL/6 background at the animal facilities of the Charité, Campus 
Benjamin Franklin, Berlin, Germany.49 All experiments were performed under 
the regulation and permission of the Animal Care Committee of the Erasmus MC, 
Rotterdam, The Netherlands.
Drugs
Ang II, CGP42112A, PD123319, bradykinin, endothelin-1, phenylephrine, and L-
NAME were purchased from Sigma (Zwijndrecht, The Netherlands). Irbesartan 
was a kind gift of Sanofi -Synthelabo BV (Gouda, The Netherlands). Irbesartan (10 
mmol/L) was dissolved in ethanol whereas all other chemicals were dissolved in 
water. Stock solutions were stored in aliquots at -80ºC and diluted in modifi ed Krebs-
Henseleit (KH) perfusion buffer (composition in mmol/L: NaCl 118, KCl 4.7, MgSO4 
1.2, KH2PO4 1.2,CaCl2 1.2, D-glucose 11, NaHCO3 25, pyruvic acid 2) on the day 
of the experiment. All perfusion solutions were passed through a 0.46 µm cellulose 
acetate fi lter (Millipore, Billerica, Massachusetts, USA) prior to their application in 
the Langendorff setup.
Langendorff preparation
Mice were heparinized using heparin (200 IU; i.p) and subsequently killed by cervical 
dislocation.215 The heart was rapidly excised and placed in ice-cold modifi ed KH 
buffer, gassed with 95% O2 and 5% CO2.
215,216 The aorta was immediately cannulated 
with a 19G needle (with a small circumferential grove close to the blunt tip) and 
perfused with gassed KH buffer according to Langendorff at a constant perfusion 
pressure of 80 mm Hg217. Two needle electrodes were placed at the right atrium 
and the hearts were paced at ~600 bpm (5 Hz, 4 ms duration, 4 Volt) using a Grass 
stimulator (Grass Instruments Co., Quincy, Massachusetts, USA).   
Left ventricular systolic pressure (LVSP) was measured with a water-fi lled balloon 
(made of domestic food wrap) connected to a disposable pressure transducer 
(Braun, Melsungen, Germany). The left atrium was removed and the balloon was 
inserted into the left ventricle.217,218 The left ventricular end-diastolic pressure was 
set at 3-5 mmHg by adjusting the balloon volume. Coronary fl ow (CF) was measured 
with a fl ow probe (Transonic systems, Ithaca, New York, USA). 
Experimental protocol
After a stabilization period of 10-15 minutes, baseline values of CF and LVSP were 
obtained. Next, bolus injections (100 µL) of modifi ed KH buffer were applied three 
times to determine injection-induced changes in CF and LVSP. Subsequently, bolus 
injections (100 µL) of Ang II, CGP42112A, bradykinin or endothelin-1 (concentration 
range in the injection fl uid 0.1 nmol/L – 0.1 mmol/L) were applied, in the absence 
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or presence of irbesartan (1 µmol/L in the perfusion buffer), PD123319 (1 µmol/L) 
and/or the NOS inhibitor L-NAME (10 mmol/L). All blockers were present in the 
perfusion buffer starting 15 minutes before the fi rst bolus injection. CGP42112A-
induced effects were also studied in combination with the α1-adrenoceptor agonist 
phenylephrine, by injecting 1 mmol/L phenylephrine alone or simultaneously with 0.1 
µmol/L CGP42112A. 
Data analysis
CF and LVSP data were recorded and digitalized using WinDaq waveform recording 
software (Dataq Instruments, Akron, Ohio, USA). After a manual selection of 
the desired signals pre- and post-injection, data were analyzed using Matlab 
(Mathworks Inc, Natick, Massachusetts, USA). Six consecutive beats were selected 
for determination of CF and LVSP. 
Data are given as mean±SEM and represent percentage change from baseline. 
Concentration-response curves (CRCs) were analysed as described219, using 
Graph Pad Prism 3.01 (Graph Pad Software Inc., San Diego, California, USA), to 
obtain pEC50 (-
10logEC50) and Emax values. The pEC50 values refer to the agonist 
concentration in the injection fl uid and do not refl ect the actual concentrations seen 
by the receptor. Statistical analysis between groups was performed by Student’s 
t test or one-way analysis of variance (ANOVA), followed by post hoc evaluation 
according to Dunnet. P<0.05 was considered signifi cant. 
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Studies in C57BL/6 mice
Ang II (n=14) concentration-dependently decreased CF and LVSP, by maximally 
41±4% and 25±3%, respectively (pEC50’s 7.41±0.12 and 7.65±0.12; Figure 1). 
Ang II concentrations >1 µmol/L did not result in effects that were larger than those 
observed at 1 µmol/L, in agreement with the concept of receptor desensitization220-
222. The Ang II effects were maximal within 10-20 and 20-30 seconds for CF and 
LVSP, respectively. Values returned to baseline after 0.5-1 minute. 
Figure 1.  Left panels, effects of Ang II bolus injections (100 µL) on coronary fl ow and LVSP in the mouse 
Langendorff heart in the absence (control; n=14) or presence of 1 µmol/L irbesartan (n=4) or 1 µmol. 
PD123319 (n=6). Right panels, Effects of Ang II bolus injections on coronary fl ow and LVSP in the mouse 
Langendorff heart in the presence of 1 µmol/L L-NAME with or without 1 µmol/L PD123319 (n=4 for both 
conditions). The x-axis displays the Ang II concentration in the injection fl uid. Data are mean±SEM and 
represent percentage change from baseline. KH, bolus injection of Krebs-Henseleit buffer. *P<0.05 vs. 
control.
Results
Baseline hemodynamic values and effect of KH buffer injection
Baseline CF values were 2.7±0.1 (n=50), 2.7±0.2 (n=5) and 2.5±0.2 (n=8) ml/min in 
C57BL/6 mice, AT1A
-/- mice and AT1A
+/+ wild type control mice, respectively. Baseline 
LVSP values were 111±3, 114±8 and 99±4 mm Hg, respectively. KH buffer injections 
did not signifi cantly affect these baseline parameters (Figures 1-4). 
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Phenylephrine (n=4) decreased CF and LVSP (Figure 2, P<0.05). CGP42112A (n=4) 
did not diminish the constrictor and inotropic response to phenylephrine, nor did this 
AT2 receptor agonist (n=4) exert constrictor or inotropic effects of its own (Figure 2). 
Bradykinin (n=6) increased CF by maximally 42±6% and marginally affected LVSP 
(Figure 3). 
Figure 2. Left panels, effects of CGP42112A (n=4) bolus injections (100 µL) on coronary fl ow and LVSP 
in C57BL/6 mice. The x-axis displays the concentration in the injection fl uid. KH, bolus injection of Krebs-
Henseleit buffer. Right panels, effects of a phenylephrine bolus injection (100 µL of a solution containing 1 
mmol/L phenylephrine), with or without 0.1 µmol/L CGP42112A (n=4 for both conditions), on coronary fl ow 
and LVSP in the mouse Langendorff heart. Data are mean±SEM and represent percentage change from 
baseline.
Irbesartan (n=4) abolished all Ang II-induced changes. In contrast, PD123319 (n=6) 
enhanced the effect of Ang II on CF (to 59±1%; P<0.05 vs. control) and LVSP (to 
44±2%; P<0.05 vs. control), without altering its potency (pEC50’s 7.41±0.12 and 
7.49±0.20, respectively). L-NAME (n=4) similarly enhanced (P<0.05) the effect of 
Ang II on CF (to 57±1%) and LVSP (to 35±2%), without altering its potency (pEC50’s 
6.95±0.34 and 7.22±0.13, respectively; Figure 1). PD123319 (n=4) no longer 
enhanced the effect of Ang II on top of L-NAME, thereby indicating that its effect 
depends on NO. 
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Studies in AT1A-/- mice
Ang II (n=5) did not affect CF or LVSP in AT1A
-/- mice, whereas the Ang II (n=7) 
response in AT1A
+/+ wild type control mice was indistinguishable from that in C57BL/6 
mice (Figures 1, 4 and 5). Endothelin-1 (0.1 nM) decreased CF in both AT1A
-/- and 
AT1A
+/+ wild type control mice (Figure 5). The endothelin-1-induced decreases in CF 
and LVSP (47±15% and 41±10%, respectively) were comparable to those induced 
by 1 mmol/L phenylephrine (Figure 4).  
Figure 3.  Effect of bradykinin bolus injections (100 µl) on coronary fl ow and LVSP in the mouse 
Langendorff heart. Data are mean±SEM of 6 experiments and represent percentage change from 
baseline. KH, bolus injection of Krebs-Henseleit buffer.
Figure 4. Effects of Ang II bolus injections on coronary fl ow and LVSP in AT1A-/- (n=5) and the corresponding 
AT1A
+/+ (wildtype control; n=7) mice. The x-axis displays the concentration in the injection fl uid. Data are 
mean±SEM and represent percentage change from baseline. KH, bolus injection of Krebs-Henseleit 
buffer. *P<0.05 vs. AT1A
+/+.
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Discussion
This study is the fi rst to support the concept of AT2 receptor-mediated vasodilation 
in the mouse coronary vascular bed. Evidence for such vasodilation was obtained 
indirectly, i.e., as an enhanced constrictor response to Ang II in the presence of the 
AT2 receptor antagonist PD123319. Data are in full agreement with previous studies 
on this matter in human58, porcine223, rabbit224 and rat59 coronary arteries. 
Vasodilation did not occur when exposing the mouse heart to Ang II in the presence 
of irbesartan (a condition allowing selective AT2 receptor stimulation, which has 
been used successfully in previous studies58,64,206), nor during exposure of the heart 
to the AT2 receptor agonist CGP42112A. This was not due to an inability to detect 
vasodilation, since bradykinin exerted its well-known vasodilator effects in our 
Langendorff setup. Furthermore, Ang II exerted no effect in hearts of AT1A
-/- mice, 
although these mice do express AT2 receptors.
225,226 This demonstrates fi rst that the 
AT1A receptor is the receptor responsible for coronary vasoconstriction, in agreement 
Figure 5. Representative tracings showing the effects of a bolus injection (100 µl; arrow) containing 1 µM 
Ang II or 0.1 nM endothelin-1 (ET-1) on coronary fl ow in AT1A
+/+ (wildtype control; left panels) and AT1A
-/- 
(right panels) mice.
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with the observation that deletion of the AT1A receptor
45, but not of the AT1B receptor
47, 
virtually abolishes the in vivo vasoconstrictor response to Ang II and reduces blood 
pressure. Secondly, it demonstrates that stimulation of AT2 receptors in the absence 
of AT1A receptors also does not result in vasodilation.
It has been suggested that AT2 receptor-mediated vasodilatation can only be 
observed in hypertensive (and not normotensive) animals.63 Thus, concomitant 
vasoconstriction might be a prerequisite to observe AT2 receptor-mediated 
vasodilatation. However, in contrast with this concept, CGP42112A did not affect 
the vasoconstrictor response to the α1-adrenoceptor agonist phenylephrine in the 
mouse heart. 
It appears therefore that AT2 receptor-mediated effects depend on simultaneous 
AT1A receptor activation, for instance because both receptors heterodimerize
61, or 
because interaction occurs at the post-receptor level. Heterodimerization would 
require the simultaneous occurrence of both receptors in the same (smooth muscle) 
cell, and although this concept has been tested in smooth muscle cells of transgenic 
mice75,227, most studies suggest that AT2 receptors are restricted to endothelial 
cells58,228,229, whereas AT1 receptors are mainly located on smooth muscle cells.     
AT2 receptor-mediated responses, in contrast with AT1 receptor-mediated constriction, 
depend on both endothelial and smooth muscle cells, and involve a cascade starting 
with endothelial bradykinin type 2 receptor activation and subsequent NO synthesis, 
and fi nally resulting in guanylyl cyclase activation in smooth muscle cells.75,208,209 In 
agreement with the important contribution of NO to the vasodilator effect of the AT2 
receptor, L-NAME enhanced the Ang II response to the same degree as PD123319, 
and PD123319 no longer enhanced the effect of Ang II in the presence of L-NAME. 
The question then arises why direct, AT2 receptor-mediated vasodilation could 
not be observed in the present study. First, although several groups have 
demonstrated such vasodilation in various species (including humans), both in vitro 
and in vivo58,64,76,230,231, we are not aware of studies in mice showing Ang II-induced 
vasodilation. Thus, the simplest explanation is that mice differ from other species, 
in that their coronary AT2 receptors are not limited to endothelial cells. Indeed, 
Utsunomiya et al. observed abundant AT2 receptor protein immunoreactivity in the 
media of mouse coronary arteries.232 Second, Widdop et al. have suggested that 
the sensitivity of some experimental preparations is too low to observe AT2 receptor-
induced vasodilation.66 However, based on the robust (≈50%) PD123319-induced 
increase of the coronary constrictor response to Ang II, a considerable degree of 
vasodilation should have occurred in our preparation during selective AT2 receptor 
stimulation, and such robust vasodilation was in fact present when exposing the heart 
to bradykinin, the putative mediator of the AT2 receptor-mediated relaxation. Finally, 
application of Ang II via bolus injections differs greatly from the local production of 
Ang II in close proximity of AT1 and AT2 receptors
118,159,233 that occurs in vivo, and 
thus, one further possibility is that arterial Ang II delivery is an inappropriate tool to 
observe AT2 receptor-mediated vasorelaxation. 
PD123319 enhanced the negative inotropic response to Ang II in the mouse heart. 
This suggests that AT2 receptors counteract the AT1 receptor-mediated negative 
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inotropic effects in mouse cardiomyocytes. However, selective AT2 receptor 
stimulation did not affect cardiac inotropy. Combined with the observation that AT2 
receptors do not occur in cardiomyocytes232, a more likely explanation is that the 
inotropic effects of Ang II in the mouse heart are a consequence of its effects on 
coronary fl ow rather than the consequence of direct stimulation of AT1 and/or AT2 
receptor on cardiomyocytes. This may be different under pathological conditions, 
e.g. following myocardial infarction, when AT2 receptors improve left ventricular 
systolic function.133
In summary, our study provides evidence for opposite effects of AT1A and AT2 
receptors in the coronary vascular bed of normotensive mice. AT2 receptor-mediated 
effects depended on NO and occurred only in conjunction with AT1A receptor 
activation. The latter observation suggests that AT1A and AT2 receptors display an 
interaction, either directly (due to receptor heterodimerization) or at the post-receptor 
level. Such interaction might be of particular importance under conditions where the 
RAS is stimulated, e.g., during sodium depletion or in subjects with renovascular 
hypertension. A similar functional interaction has been described between the 
angiotensin-(1-7) receptor Mas and AT1 and AT2 receptors.
92 Future investigations 
should elucidate the exact site of AT1A-AT2 receptor interaction and whether the 
interaction is altered under pathological conditions.
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Abstract
Angiotensin (Ang) II, the main effector peptide of the renin-angiotensin system, 
activates two distinct receptors, the Ang II receptors type 1 (AT1) and type 2 (AT2). 
In rodents, two AT1 subtypes have been identifi ed (AT1A, AT1B). To determine 
receptor-specifi c functions and possible Ang II effects independent of its three 
known receptors we generated mice, which are defi cient in either one of the Ang II 
receptors, in two, or in all three (triple-knockouts). Triple-knockouts were vital and 
fertile, but survival was impaired and plasma Ang II level was increased similarly to 
the elevated one observed in AT1A-defi cient mice. AT2 deletion increased baseline 
mean arterial pressure (MAP), while mice lacking AT1A were hypotensive. Blood 
pressure further dropped in mice lacking both AT1 subtypes to values comparable 
to that in triple-knockouts. All combinations lacking the AT1A were distinguished by 
a reduced heart rate. AT1A deletion impaired the in vivo pressor response to Ang II 
bolus injection, whereas defi ciency for AT1B and/or AT2 had no impact. However, the 
additional lack of AT1B in AT1A-defi cient mice further impaired the vasoconstrictive 
capacity of Ang II. While general vasoconstrictor properties were not changed as 
shown by bolus injection of endothelin-1 and phenylephrine, Ang II failed to alter 
MAP in triple-knockouts, indicating that there are no other receptors involved in 
Ang II-mediated pressor effects. Our data identify mice defi cient in all three Ang II 
receptors as an ideal tool to better understand structure and function of the renin-
angiotensin system and to search for Ang II effects independent of AT1 and AT2.
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Introduction
The renin-angiotensin system (RAS) plays a vital role in regulating the physiological function of the cardiovascular system. The primary effector of the 
RAS is the octapeptide angiotensin (Ang) II. Ang II is a potent regulator of blood 
pressure and water and electrolyte homeostasis.234 Ang II mediates its functions 
through stimulation of two pharmacologically defi ned receptors, the Ang II receptor 
type 1 (AT1) and type 2 (AT2).
235 Molecular cloning of AT1
41 and AT2
236 has shown 
that both receptors belong to the family of G-protein-coupled receptors (GPCR). The 
two Ang II receptor subtypes have a low sequence homology (~35%), with highest 
similarity in the 7 predicted trans-membrane domains.236 In rodents, two isoforms 
of the AT1, AT1A and AT1B, have been identifi ed. The two murine AT1 isoforms are 
products of two independent genes, but share substantial sequence homology (~95% 
identity).237 The AT1 is present in almost all tissues and most of the known actions of 
Ang II are mediated through its stimulation. The AT1A isoform is predominating in 
most of the organs, including e.g. heart, aorta, kidney, lung, and brain,44 whereas 
the AT1B is abundantly expressed in pituitary gland and adrenal cortex.
44,238 AT2 
expression in adult tissue is restricted to a few organs, as brain, adrenal, heart, 
vascular endothelium, kidney, and ovary,239 whereas it is widely distributed in fetal 
tissues.240 The predominant expression of AT2 in fetal tissues suggests a role of 
these receptors in differentiation and developmental processes.241
It was demonstrated in genetically modifi ed mice, lacking either the AT1A or AT1A, 
that blood pressure control is dominated by the AT1A isoform. The baseline blood 
pressure was signifi cantly decreased in mice lacking the AT1A,
45 whereas AT1B-
defi cient animals were normotensive.47,242 Interestingly, AT2-knockout mice showed 
an increase in blood pressure under basal conditions,60 supporting the hypothesis 
of its AT1-counteracting effects in blood pressure regulation.
62 The vasoconstrictor 
effect of exogenous Ang II was almost completely blunted in AT1A-knockout mice,
45 
while animals lacking AT1B showed normal responsiveness to Ang II.
242 In AT2-
knockout mice, Ang II stimulation led to a signifi cant pronounced vasoconstriction, a 
further indicator for AT1-counteracting effects of AT2 on blood pressure regulation.
60 
The kidney abnormalities observed in mice lacking angiotensinogen (Agt)26,243 or 
angiotensin-converting enzyme (ACE),121,175 like cortical thinning, focal areas of 
atrophy, and thickened walls of renal vessels, were less pronounced in AT1A-knockout 
mice45,244 and absent in AT1B and AT2-knockout mice,
47,60 whereas mice lacking AT1A 
and AT1A showed a similar phenotype as Agt- and ACE-knockout mice.
48,242
In the present study we generated mice, defi cient for one, two, or all three Ang 
II receptor subtypes, to investigate the relative infl uence of each subtype on 
blood pressure regulation, coronary contractility and normal renal development. 
Furthermore, we wanted to clarify if there are Ang II effects on blood pressure control 
and cardiac function not related to one of the known Ang II receptor subtypes.
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Material and methods
Animals
AT1A (-/-//+/+//+/+),
45  AT1B (+/+//-/-//+/+),
242 and AT2 (+/+//+/+//-/-) 
60single-knockout 
mice were used to generate the recently described AT1A/AT1A-double-knockout mice 
(-/-//-/-//+/+),242 the herein newly described mice exclusively expressing AT1A (+/+//-
/-//-/-) or AT1B (-/-//+/+//-/-), or mice defi cient for all three Ang II receptors (triple-
knockouts; -/-//-/-//-/-). To generate homozygous wild-type (+/+//+/+//+/+), double-
knockout, and triple-knockout mice, the heterozygous offspring was intercrossed 
and bred on a 129xC57BL/6 background at the animal facilities of the Charité, 
Campus Benjamin Franklin, Berlin, Germany. For basal cardiac phenotyping and 
Ang II infusion a set of seven-month old animals was used. A second set of 6-
month old male mice was used for measurement of plasma levels of Ang II. A third 
set was used for morphohistological analysis at the endpoint of twelve months. In 
addition, age-matched animals lacking Agt120 were used for histological comparison. 
Experiments were performed according to the regulations of the Animal Care 
Committee of the Erasmus MC, in accordance with the Guiding Principles of the 
American Physiological Society or according to the guidelines of the Federal Law 
on the Use of Experimental Animals in Germany and were approved by the local 
authorities.
Polymerase chain reaction (Genotyping)
Genotyping was performed by polymerase chain reaction (PCR) with specifi c 
primers for each genotype. PCR for AT1A and AT2 were described earlier.
245 For AT1B-
specifi c PCR two pairs of primers that amplifi ed products specifi c for the AT1B wild-
type (P1: 5´ CCA GGG CAA GAT TCA GAA GG 3´ and P2: 5´ CCA ACA AAG AGA 
CAT GAT C 3´) or knockout (P3: 5´ CCT GCG TGC AAT CCA TCT TGT TCA ATG 3´ 
and P2) allele were designed and used. Agt-defi cient animals were genotyped as 
described previously.246
RNA isolation and RNase protection assay
RNA of frozen organs was isolated using TRIzol reagent following the manufacturers 
protocol, as described previously.247,248 AT1A, AT1A, and AT2 expression was 
analyzed by RNase protection assays using commercially available Ambion RPA 
II kit (Ambion (Europe) Ltd., Huntingdon, UK), according to the protocol of the 
manufacturer. Thirty µg total RNA were hybridized with one of the following probes: 
Probe MMAT1A: A recently described vector249 was used to transcribe a radioactive 
probe complementary to a 352-bp fragment specifi c for AT1A mRNA. Probe MMAT1: 
A 255-bp fragment, from genomic mouse DNA amplifi ed by PCR using the primers 
5´ CTC AGC ATC GAC CGC TAC C 3´ and 5´ GAA CAG GAA GCC CAG G 3´, was 
subcloned in a T-vector (Promega GmbH, Mannheim, Germany). A T7 polymerase 
transcribed a radioactive probe complementary to a 170-bp fragment specifi c for 
AT1A mRNA and a 255-bp fragment specifi c for AT1B mRNA. Probe MMAT2: A 468-
bp fragment from genomic mouse DNA, amplifi ed by PCR using the genotyping 
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primers,245 was subcloned in a T-vector. SP6 polymerase transcribed a radioactive 
probe complementary to a 258-bp-mRNA fragment specifi c for AT2. Probe rL32: 
A commercially available rL32 probe template (PharMingen International, USA), 
complementary to a 127-bp fragment of rL32 mRNA, was used as a housekeeping 
control as described earlier.247,250 RNA samples were hybridized with 40,000 cpm 
of the radio labeled probe for MMAT1A, MMAT1, or MMAT2 and 20,000 cpm of the 
radio labeled probe for rL32 as the housekeeping gene. The hybridized fragments 
protected from RNase A + T1 digestion, were separated by electrophoresis on a 
denaturing gel (5% polyacrylamid, 8 mol/L urea) and analyzed using a FUJIX BAS 
2000 Phospho-Imager system (Raytest GmbH, Straubenhardt, Germany).
Blood pressure measurement
Mice of all genotypes were weighed and anesthetized with pentobarbital (60 mg/
kg; i.p.). The left carotid artery and right jugular vein were cannulated using a PE-
10 (0.011”IDx0.025”OD) catheter. Heart rate and mean arterial pressure (MAP) 
were monitored continuously with a disposable pressure transducer (TSE Systems 
GmbH, Bad Homburg, Germany) connected to the catheter situated in the left carotid 
artery. After a stabilization period of 5-15 minutes, hemodynamic baseline values 
were determined. Heart rate and MAP data were recorded and digitalized using 
the Invasive Blood Pressure Monitoring System recording software (TSE Systems 
GmbH, Bad Homburg, Germany). The hemodynamic response to Ang II (0.5 µmol/L 
in a 100 µL bolus injection) was evaluated in animals of all eight genotypes. After 
heart rate and MAP had returned to baseline (within ~10 minutes), the response 
to 0.5 mmol/L phenylephrine (PE; 100 µL) was determined, and this protocol was 
repeated for 2 µmol/L endothelin-1 (ET-1; 100 µL). At the end of the hemodynamic 
studies, kidneys and hearts were rapidly excised and weighed. Ratios of kidney 
weight/body weight (KW/BW) and heart weight/body weight (HW/BW) were used as 
indices of organ hypertrophy.
Langendorff heart 
Mice were killed by cervical dislocation.215 The heart was rapidly excised and placed 
in ice-cold modifi ed Krebs-Henseleit (KH) buffer (composition in mmol/L: NaCl 118, 
KCl 4.7, MgSO4 1.2, KH2PO4 1.2,CaCl2 1.2, D-glucose 11, NaHCO3 25, pyruvic acid 
2), gassed with 95% O2 and 5% CO2.62,215,216 The aorta was immediately cannulated 
with a 19G needle (with a small circumferential grove close to the blunt tip) and 
perfused with gassed KH buffer according to Langendorff at a constant perfusion 
pressure of 80 mmHg.217 Two needle electrodes were placed at the right atrium and 
the hearts were paced at ~600 bpm (5 Hz, 4 ms duration, 4 Volt) using a Grass 
stimulator (Grass Instruments Co., Quincy, Massachusetts, USA). Left ventricular 
systolic pressure (LVSP) was measured with a water-fi lled balloon (made of domestic 
food wrap) connected to a disposable pressure transducer (Braun, Melsungen, 
Germany). The left atrium was removed and the balloon was inserted into the left 
ventricle.217,218 The left ventricular end-diastolic pressure was set at 3-5 mmHg by 
adjusting the balloon volume. Coronary fl ow (CF) was measured with a fl ow probe 
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(Transonic systems, Ithaca, New York, USA). After a stabilization period of 10-15 
minutes, baseline values of CF and LVSP were obtained. Next, bolus injections 
(100 µL) of modifi ed KH buffer were applied three times to determine injection-
induced changes in CF and LVSP. Subsequently, bolus injections (100 µL) of Ang II 
(concentration range 0.1 nmol/L-0.1 mmol/L) were applied.
Angiotensin II levels in blood plasma
Blood (130-610 μL, mean 278 μL) was collected from the abdominal aorta in 2.5 mL 
of 4 mol/L guanine thiocyanate.187 Both were stored at -80oC until further processing. 
Ang II was determined by radioimmunoassay following SepPak extraction and high-
performance liquid chromatography separation as described before.106 
Histology
Kidneys were isolated and fi xed in 10% formalin. The kidneys were embedded 
in paraffi n and sectioned at 2 µm. Serial sections of kidneys were stained with 
haematoxylin-eosin (HE) or periodic acid-Schiff (PAS) as described previously.251
Statistics
Results are represented as mean+SEM or median and interquartile range. For 
determination of intergroup differences, Kruskal-Wallis test was used (Graph Pad 
Prism 3.01; Graph Pad Software Inc., San Diego, California, USA). The Mann-
Whitney U test was employed to analyze the differences in parameters among the 
groups. Signifi cance was considered from a value of P<0.05.
Results
Generation of animals lacking one, two, or all three known Ang II 
receptors
Crossbreeding of animals defi cient for AT1A (-/-//+/+//+/+), AT1B (+/+//-/-//+/+), or AT2 
(+/+//+/+//-/-) was used to generate mice lacking two (AT1A/AT1B: -/-//-/-//+/+, AT1A/AT2: 
-/-//+/+//-/-, and AT1B/AT2: +/+//-/-//-/-) or all three (-/-//-/-//-/-) known Ang II receptors. 
Homozygosity in the eight genotype combinations possible has been proven by PCR 
after weaning and before experiments. Figure 1A shows exemplarily PCR results 
identifying a wild-type (+/+//+/+//+/+) mouse (upper panel) and a triple-knockout 
(lower panel). All eight receptor combinations were vital and fertile, although survival 
in AT1A/AT1B-double- and in the triple-knockout mice was signifi cantly impaired until 
weaning (Figure 1B). However, mortality was not increased in these mice from 
weaning to the defi ned endpoint of twelve months (data not shown).
Regulation of Ang II receptors in different knockout variants
To clarify the impact of the genetic modifi cations on the expression level of the three 
Ang II receptors, we measured receptor-specifi c mRNA in the heart. Figure 1C shows 
representative RPA blots of heart RNA using an AT1A-specifi c probe (MMAT1A). All 
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Table 1. D
ata sum
m
ary of the basal characterization of anim
als defi cient for one, tw
o, or all three A
ng II receptor subtypes (B
W
: body w
eight; H
W
: heart 
w
eight; K
W
: kidney w
eight; M
A
P
: m
ean arterial pressure; H
R
: heart rate; C
F: coronary fl ow
; LV
S
P
: left ventricular systolic pressure; * P
<0.05; ** P
<0.01; *** 
P
<0.001 vs. +/+//+/+//+/+; # P
<0.05; ## P
<0.01 vs. -/-//+/+//+/+; &
 P
<0.05 vs. -/-//-/-//+/+; n≥6).
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3.0+0.3 
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3.1+0.1 
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2.5+0.3
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m
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98.5+3.7 
114.3+6.8 
98.2+6.3 
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112.6+7.1 
86.0+6.2 
72.3+6.7
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animals not defi cient for AT1A (+/+//++//+/+, +/+//-/-//+/+, +/+//+/+//-/-, and +/+//-/-//-
/-) have been characterized by detectable AT1A-specifi c bands, whereby AT1A-RNA 
expression was signifi cantly increased only in animals exclusively expressing 
AT1A (Figure 1D; +/+//-/-//-/-). Investigating the samples with a probe discriminating 
between AT1A and AT1B (MMAT1) revealed the same pattern of regulation for AT1A 
mRNA. However, AT1B- and AT2-specifi c mRNA expression was below RPA detection 
level, independent of the receptor combination used (data not shown) as proven 
with this probe and the specifi c one for AT2 mRNA (MMAT2).
Basal phenotyping
Body weight recording confi rmed previous fi ndings that the lack of just one Ang 
II receptor did not infl uence body weight (Table 1).47,60,242 The newly generated 
double-knockout variants (+/+//-/-//-/- and -/-//+/+//-/-) showed no change in BW, 
whereas AT1A/AT1B-double-knockout mice were characterized by a signifi cant weight 
reduction, as described previously.242 Interestingly, this body weight reduction was 
partially compensated in triple-knockouts. In all variants defi cient for AT1A the HW/BW 
was decreased (Table 1) with the lowest heart weight in AT1A/AT1B-double-knockouts. 
A less pronounced heart weight reduction was seen in AT2-defi cient animals. KW/
BW ratio was unaltered in AT1A- and AT1A-single-knockout mice (Table 1). In contrast 
to them animals defi cient 
for AT2 showed a reduced 
KW/BW ratio. Kidney 
weight was also reduced in 
our newly generated mice 
exclusively expressing 
either AT1A  (+/+//-/-//-/-
) or AT1B (-/-//+/+//-/-). As 
described previously, in 
animals lacking both AT1 
subtypes KW/BW ratio was 
signifi cantly reduced.242 
However, we observed a 
further, profound reduction 
of KW/BW ratio in triple-
knockout animals. To 
investigate the regulation 
of endogenous Ang II, 
depending on expression of 
its receptors, we determined 
Ang II levels in plasma. In 
Figure 2. Ang II levels in blood plasma of mice of all eight genotypes. 
Boxes show median with interquartile range. **P<0.01 vs. 
+/+//+/+//+/+; ## P<0.01 vs. -/-//+/+//+/+; n=2 for +/+//+/+//-/- and n≥5 
for all other groups.
mice lacking only one Ang II receptor, independently of the subtype, plasma Ang II 
levels were not changed signifi cantly (Figure 2). In mice only expressing AT1A, Ang 
II plasma level was unchanged (98.8+34.0 fmol/mL), compared to WT (81.0+9.8 
fmol/mL), whereas mice exclusively expressing AT1B showed a rise in plasma Ang 
II (270.7+80.7 fmol/mL). Mice defi cient for both AT1 subtypes had the highest Ang 
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II plasma concentration (885.8+217.2 fmol/mL). Notably, Ang II levels in triple-
knockouts (315.8+104.7 fmol/mL) ranged between WT and AT1A/AT1B-double-
knockouts without signifi cant differences compared to any other group.
Renal histopathological examination
As described earlier, kidneys of AT2-defi cient animals showed comparable 
morphology to wild-type (Figure 3; upper panel, left) and were characterized by 
inconspicuous histology (Figure 3; middle panel, left).204 Investigations on renal 
pathology also confi rmed the previously described renal phenotype of the double-
knockouts defi cient for the two AT1 subtypes, including cystic dilated cavities, partially 
dilated tubular lumina, multifocal and focally extensive glomeruli atrophy with a 
severely dilated Bowman’s space (Figure 3; lower panel, left), and media hyperplasia 
of small and medium sized vessels.242 Furthermore, kidneys of these AT1A/AT1B-
defi cient mice showed prominent renal mononuclear infi ltrates, partially with 
blastic appearance and a high partially mitotic rate including bizarre mitotic fi gures 
(data not shown). To test whether the renal phenotype in triple-knockouts could 
be discriminated from that of kidneys defi cient in both AT1 subtypes, comparative 
histological analyses were accomplished. The additional defi ciency in AT2 did not 
impact the renal phenotype as the histological phenotype was comparable between 
both genotypes. Nevertheless, the number of kidneys with severe hydronephrosis 
was signifi cantly higher in triple-knockout mice (data not shown). 
We then examined the kidneys of the newly generated double-knockout animals 
expressing exclusively either AT1A or AT1B to investigate if one of the AT1 subtypes 
alone is capable to restore the kidney morphology. Kidneys of mice expressing only 
AT1A had hyperaemic capillary loops, but their glomeruli were well perfused and 
showed distinct basal membranes (Figure 3; middle panel, middle). In contrast, 
kidneys of mice harboring only the AT1b showed a multifocal glomeruli atrophy, 
partially with cystic dilated Bowman’s space (Figure 3; middle panel, right). 
Nevertheless, compared to the severely changed phenotype observed in kidneys 
of AT1A/AT1B-double-knockouts and triple-knockouts, kidneys harboring only the AT1B 
had less damaged glomeruli and the majority was without pathological fi ndings. 
To fi nally investigate whether the renal phenotype in mice lacking all three Ang II 
receptors was comparable to that of mice keeping all receptors but lacking the ligand 
(Ang II), we also analyzed kidneys of mice lacking the angiotensinogen gene (Agt) 
coding for the angiotensin precursor. Morphohistological investigations revealed 
that kidneys of Agt-defi cient mice showed the same malformations (Figure 3, lower 
panel, right) as mice lacking both AT1 subtypes and as the triple-knockouts.
Impact of Ang II receptors on basal hemodynamic parameters
Baseline MAP in AT1A-defi cient mice was markedly reduced (Table 1) compared to 
wild-type animals. The lack of only the AT1B did not have an infl uence on basal MAP, 
whereas the additional AT1B defi ciency in AT1A-knockout mice led to a further drop 
in blood pressure as described previously.242 We also confi rmed the rise in blood 
pressure in AT2-knockout mice.
60 However, in contrast to the AT1B, the lack of AT2 on 
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top of AT1A defi ciency did not modify the hypotensive phenotype. Interestingly, also 
the AT1B defi ciency did not alter the elevated blood pressure observed in AT2-single-
knockouts. The ineffectiveness of AT2 on blood pressure control in animals lacking 
AT1 was further confi rmed in triple-knockouts that did not differ in their MAP from 
AT1A/AT1B-double-knockout mice.
Heart rate in all genotypes lacking AT1A was signifi cantly reduced (Table 1). 
Defi ciency for both AT1A and AT1B led to a further, but not signifi cant reduction in 
heart rate, whereas this reduction reached signifi cance in animals lacking all three 
receptors.
Figure 3. PAS-stained sections of kidneys of WT (+/+//+/+//+/+), AT1A- (-/-//+/+//+/+), AT1B- (+/+//-/-//+/+), 
and AT2-single-knockout mice, mice exclusively expressing AT1A (+/+//-/-//-/-), AT1B (-/-//+/+//-/-) or AT2 (-/-
//-/-//+/+), triple-knockouts (-/-//-/-//-/-), and angiotensinogen-defi cient (Agt -/-) mice. Atrophic glomeruli are 
indicated by an arrow.
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Effects of infusions of vasoactive substances
To clarify the impact of the three Ang II receptors on blood pressure and heart rate 
control, we administered a single bolus injection of Ang II. In wild-type mice, Ang II 
injection caused a fulminant increase in MAP and heart rate (Figure 4A and 4B). In 
AT1A-single-knockout mice, Ang II effects on MAP and heart rate were reduced by 
almost 85% and 65% respectively. In AT1A/AT1B-double-knockout and triple-knockout 
mice the Ang II-stimulated effect on MAP was almost completely blunted, whereas in 
both genotypes the decrease in heart rate was unaffected compared to AT1A-single-
knockouts.
Figure 4. Changes in MAP (A) and HR (B) after a bolus injection of Ang II. MAP: mean arterial pressure; 
HR: heart rate; ΔMAP: change in MAP after injection; ΔHR: change in HR after injection. * P<0.05; ** 
P<0.01; *** P<0.001 vs. +/+//+/+//+/+; # P<0.05; ## P<0.01; ### P<0.001 vs. -/-//+/+//+/+; n≥6.
To prove whether the deletion of AT1A alone or in combination with either AT1B or AT2 
or both led to a general impairment in vasoconstrictive properties in those animals 
we infused two other vasoactive compounds. Firstly, we administered the peptide 
ET-1 as an Ang II-independent vasoconstrictor. ET-1 mediates vasoconstriction by 
stimulation of its own receptors, the endothelin type A and type B receptors. ET-1 
infusion led to a rise in MAP in all eight genotypes without signifi cant differences 
(Figure 5A). Interestingly, the negative chronotropic effect of ET-1 in wild-type 
animals (Figure 5B) changed inversely to a positive chronotropic effect in animals 
defi cient for either AT1A or AT2. In AT1A/AT1B-double-knockout mice ET-1 effects were 
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not inverted but heart rate reduction was less pronounced than in wild-type controls. 
Nevertheless, ET-1 infusion again mediated a positive chronotropic effect in animals 
defi cient for all three Ang II receptor subtypes.
Secondly we used the non-peptidic sympathicomimetic compound PE. In contrast 
to ET-1, PE-stimulated α1-adrenoceptor-mediated increase in MAP was comparably 
reduced in AT1A/AT1B-double- (Figure 6A) and triple-knockout animals compared 
to controls. In wild-type mice, administration of PE reduced heart rate by 12 % 
(Figure 6B). PE effect on heart rate was inverted in AT1A-single-knockout mice to 
a positive chronotropic response, while deletion of AT1B and AT2 alone did not 
infl uence changes in heart rate observed in wild-type animals. Notably, additional 
AT1b defi ciency reversed the positive chronotropic effects of PE infusion seen in 
AT1A-single-knockouts. In contrast to all other genotype variants, PE infusion did not 
mediate any chronotropic effect in animals lacking all three receptor subtypes.
Figure 5. Changes in MAP (A) and HR (B) after a bolus injection of ET-1. MAP: mean arterial pressure; 
HR: heart rate; ΔMAP: change in MAP after injection; ΔHR: change in HR after injection. *** P<0.001 vs. 
+/+//+/+//+/+; n≥6.
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Langendorff heart
No genotype-related differences in baseline CF and LVSP were found (Table 1). In 
hearts of wildtype (+/+//+/+//+/+) mice, bolus injections of Ang II dose-dependently 
decreased CF and LVSP (Figure 7) by maximally 56±5% and 39±4%, respectively 
(pEC50’s 7.51±0.17 and 7.35±0.13). Ang II concentrations >1 µmol/L did not result 
in effects that were larger than those observed at 1 µmol/L, in agreement with the 
concept of receptor desensitization.220-222 
Bolus injections of Ang II exerted no effects in hearts of mice defi cient for AT1A (Figure 
7), whereas effects in mice lacking only AT1B or AT2 were identical to those in wild-
type.Effects in hearts lacking both AT1B and AT2 were also unaltered. These data 
indicate that the cardiac effects of Ang II are entirely AT1A receptor-mediated.
Discussion
Targeting the RAS, specifi cally the effector peptide Ang II, represents a major 
opportunity for delaying or even preventing the progression of cardiovascular 
diseases and, in turn, reducing the risk of morbidity and mortality.252,253 Inhibition 
of Ang II actions is achieved clinically by either blocking with antagonists against 
Figure 6. Changes in MAP (A) and HR (B) after a bolus injection of PE. MAP: mean arterial pressure; HR: 
heart rate; ΔMAP: change in MAP after injection; ΔHR: change in HR after injection. * P<0.05; ** P<0.01; 
*** P<0.001 vs. +/+//+/+//+/+; # P<0.05 vs. -/-//+/+//+/+ n≥6.
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Figure 7. Changes in CF (open symbols) and LVSP (closed symbols) after a bolus injection of Ang II in the 
Langendorff heart according to genotype. Data (mean+SEM of 4-8 experiments) represent percentage 
change from baseline. KH, bolus injection of Krebs-Henseleit buffer. The x-axis displays the Ang II 
concentration in the injection fl uid.
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its type 1 receptors or preventing Ang II generation with ACE inhibitors.254-256 Both 
pharmacological interventions are primarily used for blood pressure control, but 
research of the last decade has demonstrated that they also provide cardiovascular 
protective effects that are independent of blood pressure lowering, as e.g. evidence 
arose that the anti-infl ammatory component of both drugs is part of their success.257
The generation of AT1- and AT2-specifi c antagonists gave a fi rst tool that allowed 
identifying further pathways both drugs may benefi t by, also due to defi ning functions 
specifi c for either AT1 or AT2. Nevertheless, the generation of animals overexpressing 
Ang II type 1 receptors lacking intracellular signaling via heterotrimeric G proteins 
has shown that AT1 can mediate effects, e.g. induction of cardiac hypertrophy and 
bradycardia, independent of Ang II.258 Therefore, animals defi cient for AT1A or AT1B or 
AT2 have been generated also to better discriminate between those ectopic and/or 
Ang II-independent receptor effects and receptor effects requiring the stimulation by 
Ang II. However, none of the single-receptor-knockouts is capable to reproduce the 
severe kidney malformations, pronounced blood pressure lowering, and reduced 
vitality seen in mice lacking Agt and hence lacking the ligand-specifi c receptor 
stimulation. Furthermore, using these animal models could also not fully answer the 
question regarding receptor specifi ty, since it could not be discriminated whether 
the observed phenotype was related to a lack in receptor stimulation due to the 
defi ciency or due to an overstimulation of the residual two receptors. Therefore, we 
fi rstly generated new transgenic mice exclusively expressing either AT1A or AT1B for 
verifi cation of Ang II-mediated AT1 subtype-specifi c effects. Utilizing these animals 
and the previously described mice defi cient for both AT1 subtypes,
242 exclusively 
expressing AT2, we could demonstrate that basal blood pressure and heart rate are 
mainly affected by AT1A, while the role of AT1B differs between both parameters. In 
mice exclusively expressing AT1A, basal blood pressure is slightly increased (~118% 
of wild-type) probably due to a higher expression of AT1A (Figure 1) and/or the missing 
inhibitory properties of AT2 on AT1A signalling.
61,259 The mice solely expressing AT1B 
show a less pronounced decrease in blood pressure (~70% of wild-type) than the 
mice only expressing AT2 (~55% of wild-type), indicating that AT1B is partially capable 
to compensate the lack of AT1A. Although, the reduced blood pressure in all groups 
lacking AT1A may account for the reduced HW/BW-ratio, yet the lower HW/BW ratio 
in AT2 defi cient mice, which have elevated blood pressure, makes this conclusion 
less probable. In animals exclusively expressing AT1A heart rate is unchanged 
compared to wild-type, whereas in mice lacking AT1A and AT1B it is reduced (~-23%). 
Mice uniquely expressing AT1B show a similar reduction in heart rate (~-19%) to 
animals lacking only AT1A (~-15%) or both AT1 subtypes, suggesting that regarding 
the heart rate, the lack of AT1A cannot be compensated by AT1B in contrast to partial 
normalization of blood pressure. This difference may be best explained by the lack in 
valuable level of AT1B in the heart but a signifi cant expression of AT1B in vessels.
44
We also identifi ed the formerly described blood pressure rising260 and positive 
chronotropic261 effects of exogenous Ang II to be primarily mediated by AT1A. Ang 
II effects on blood pressure are normal in animals exclusively expressing AT1A. 
However, the vasoconstrictive properties of Ang II are almost blunted in mice 
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lacking both AT1 subtypes (~7% of wild-type), while the responsiveness to Ang II is 
partially restored in animals exclusively expressing AT1B (~30% of wild-type). The 
Ang II-induced increase in heart rate in wild-type is not altered in animals harboring 
only AT1A compared to wild-type. In mice exclusively expressing either AT1B or AT2, 
and thus lacking the AT1A, the positive chronotropic effect of Ang II is substantially 
reduced (to ~40% and ~44% of wild-type, respectively). The inability of the AT1B in 
compensating the lack in AT1A expression on Ang II-induced positive chronotropic 
actions is similar to the effect described under basal conditions and may also be due 
to the aforementioned reasons.
The importance of the AT1A subtype was further confi rmed by our studies using 
the Langendorff model. Deletion of one, two or all three AT receptors did not affect 
baseline CF or LVSP in comparison to wild-type. The dose-dependent decrease of 
both CF and LVSP in response to Ang II was similar in all genotypes expressing 
the AT1A receptor independently of presence or absence of AT1B and/or AT2. These 
effects were completely abolished in all genotypes defi cient for AT1A. Thus, AT1A 
exclusively mediates the Ang II-induced negative inotropy and vasoconstriction in 
the mouse heart, in full agreement with previously published data.62
In recent investigations it was shown that the chronic infusion of Ang II262 and the 
lack of both AT1 subtypes
263 are regulators of the endothelin system, e.g. affecting 
expression levels of ET-1 and its receptors. However, to our knowledge we are the 
fi rst administrating ET-1 to mice lacking Ang II receptors. The ET-1-mediated rise in 
blood pressure is similar in all eight genotypes. Thus, the previously described up-
regulation of the two ET-1 receptors in mice defi cient for AT1A and AT1B
263 may not 
have an effect on blood pressure in our in vivo experiments. Interestingly, we have 
identifi ed ET-1 effects on heart rate depending on the combination of expressed/
lacking Ang II receptors. However, these distinct regulatory effects of the Ang II 
receptor subtypes on the endothelin system and their clinical relevance need further 
investigation.
This may also count for the regulation of the sympathetic system which can be 
infl uenced by the RAS as it has been described previously.264-267 Our data illustrates 
the importance of AT1 receptors on the regulation of the sympathetic system.
Our fi ndings also show that the previously described abnormal kidney structure, 
including cystic dilatations, atrophic glomeruli, and hydronephrosis, in mice lacking 
either both AT1 subtypes
242 or Agt26 is primarily caused by the lack of Ang II stimulation 
of AT1A. This is best illustrated as the expression of only AT1A preserves a normally 
working, healthy kidney, whereas expression of AT1B alone leads to an intermediate 
phenotype, anticipating the development of hydronephrosis, interstitial infi ltrates, 
and partially the atrophy of glomeruli.
To fi nally discriminate Ang II effects independent of its known receptors AT1 and AT2 
and receptor effects that are Ang II independent, we also generated mice lacking 
all three receptor subtypes. Infusion of Ang II in the triple-knockouts generates 
the same effects on blood pressure and heart rate as in mice lacking both AT1 
subtypes, indicating that the AT2 has no direct effect on these parameters and that 
no unknown Ang II receptors are directly involved in blood pressure and heart rate 
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regulation effected by Ang II. The lack of all three Ang II receptors also results in a 
comparable kidney morphology as seen in Agt-defi cient animals, indicating that AT1 
stimulation by Ang II is a necessity for normal development of the kidney and that 
the lack of other bioactive Ang fragments in Agt-defi cient mice, as e.g. Ang-(1-7) and 
Ang IV, does not infl uence renal pathology and thus may not play a role in kidney 
development. However, the more frequent occurrence of hydronephrosis in triple-
knockouts compared to AT1A/AT1B-double-defi cient animals may suggest a kidney-
protective role for AT2.
Beside their AT1-depending effects on blood pressure reduction, several AT1 
antagonists have postulated pleiotropic effects, e.g. acting as a partial agonist on 
peroxisome proliferator-activated receptor γ, infl uencing platelet aggregation, and 
reducing uric acid levels in plasma.264 Our generated animals lacking all three Ang II 
receptors are an excellent tool for investigation of these additional effects that may 
not involve AT1- or AT2-mediated actions. Thus, the newly generated triple-knockout 
mice are a very promising resource for further RAS-related research, since they can 
visualize effects of Ang II independent of its known receptors and identify effects of 
other Ang metabolites being dependent or independent of the AT1 and AT2.
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Abstract
Aminopeptidases metabolize Angiotensin (Ang) II to Ang-(2-8) (=Ang III) and Ang-
(3-8) (=Ang IV), and carboxypeptidases generate Ang-(1-7) from Ang I and II. 
Angiotensin-converting enzyme (ACE) inhibitors and/or Ang II type 1 (AT1) receptor 
blockers affect the concentrations of these metabolites, and they may thus contribute 
to the benefi cial effects of these drugs, possibly through stimulation of non-classical 
AT receptors. Here, we investigated the effects of Ang II, Ang III, Ang IV and Ang-(1-
7) in the rat coronary vascular bed, with or without AT1 - or Ang II type 2 (AT2) receptor 
blockade. Results were compared to those in rat iliac arteries and abdominal aortas. 
Ang II, Ang III and Ang IV constricted coronary arteries via AT1 receptor stimulation, 
Ang III and Ang IV being ≈20- and ≈8000-fold less potent than Ang II. The AT2 receptor 
antagonist PD123319 greatly enhanced the constrictor effects of Ang III, starting at 
Ang III concentrations in the low nanomolar range. PD123319 enhanced the Ang II-
induced constriction at submicromolar Ang II concentrations only. Ang-(1-7) exerted 
no effects in the coronary circulation, although, at micromolar concentrations, it 
blocked AT1 receptor-induced constriction. AT2 receptor-mediated relaxation did 
not occur in iliac arteries and abdominal aortas, and the constrictor effects of the 
Ang metabolites in these vessels were identical to those in the coronary vascular 
bed. In conclusion, AT2 receptor activation in the rat coronary vascular bed results in 
vasodilation, and Ang III rather than Ang II is the preferred agonist of these receptors. 
Ang II,  Ang  III, Ang IV and Ang-(1-7) do not exert effects through non-classical AT 
receptors in the rat coronary vascular bed, iliac artery or aorta.  
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Introduction
The renin-angiotensin system (RAS) plays an important role in the regulation of blood pressure and body fl uid homeostasis. The main effector peptide of the 
RAS, the octapeptide angiotensin (Ang) II (Ang-(1-8)), formed from the decapeptide 
Ang I (Ang-(1-10)) by Ang-converting enzyme (ACE), exerts its effect through 
activation of Ang II type 1 (AT1) and Ang II type 2 (AT2) receptors. AT1 receptors 
mediate the well-known vasoconstrictor and growth-stimulatory effects of Ang II, and 
AT2 receptors are generally assumed to counteract these actions
57-60,205,206.
Several Ang metabolites other than Ang II are currently believed to have effects 
of their own94, in particular Ang III (Ang-(2-8)), Ang IV (Ang-(3-8)) and Ang-(1-7). 
These metabolites stimulate the two above Ang receptors and/or newly discovered 
receptors85,98. Ang III and Ang IV are formed from Ang II by the aminopeptidases A and 
N, respectively94. Ang-(1-7) is formed from Ang I by neutral endopeptidase or prolyl 
endopeptidase84, and from Ang II by propyl endopeptidase, prolyl carboxypeptidase 
or ACE237,84. 
Ang III stimulates both AT1 and AT2 receptors. Its in-vivo potency is lower than 
that of Ang II268,269, either because it binds with lower affi nity95, and/or because it is 
metabolized faster270. Ang IV is a weak agonist of AT1 receptors 
90 and occurs at low 
levels271. It was therefore initially thought to be biologically irrelevant. The discovery 
of a distinct Ang IV binding site, which was designated as the AT4 receptor because 
of its specifi city for Ang IV, changed this view98. AT4 receptors are expressed in brain, 
heart, kidney and vascular smooth muscle cells68,95, and might mediate the Ang IV-
induced vasorelaxation. Recently, Ang IV was also reported to reverse endothelial 
dysfunction in ApoE-defi cient mice via AT4 and/or AT2 receptor stimulation
272. 
Ang-(1-7) induces relaxation in several vascular beds. The fact that A-779 [D-
Ala7-Ang-(1-7)], a selective Ang-(1-7) antagonist, was able to block this relaxation, 
led to the discovery of a specifi c Ang-(1-7) receptor, the Mas receptor84,85. As a 
slow substrate for ACE, Ang-(1-7) also functions as an ACE inhibitor, resulting in 
decreased Ang II formation and potentiation of bradykinin-induced vasodilatation32. 
Furthermore, depending upon the presence of Ang II, Ang-(1-7) may act both as an 
AT1 receptor agonist 
90 and antagonist89. 
ACE inhibitors and/or AT1 receptor antagonists affect the levels of Ang-(1-7), 
Ang III and/or Ang IV107,273,274, and part of the benefi cial effect of RAS blockade 
might actually be due to these metabolites275. A careful evaluation of their effects 
in the cardiovascular system is therefore of great interest. In the present study we 
investigated the effects of Ang II, Ang III, Ang IV and Ang-(1-7) in the rat coronary 
vascular bed, using selective AT1 and AT2 receptor blockers (irbesartan and 
PD123319, respectively). This bed is of major cardiovascular importance, and 
expresses both AT1 and AT2 receptors
58,62. Results were compared to those in 
isolated vessels (iliac artery and abdominal aorta), in order to allow a comparison 
with previously published data on this topic268,269. 
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Materials and methods
Animals
Male Wistar rats (329+3 gram; n=57) were obtained from Harlan (Zeist, The 
Netherlands). All experiments were performed under the regulation and permission 
of the Animal Care Committee of the Erasmus MC, Rotterdam, The Netherlands. 
Drugs
Ang II, Ang III, Ang IV, Ang-(1-7), (S)-1-{ [4-(di-methylamino)-3-methylphenyl]methyl}-
5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazol[4,5-c]pyridine-6-carboxylic acid 
(PD123319; Ki = 12 nmol/L)
276, 9,11-dideoxy-11α,9α-epoxymethano-prostaglandin 
F2α (U46619) and N
ω-nitro-L-arginine methyl ester HCl (L-NAME) were purchased 
from Sigma (Zwijndrecht, The Netherlands). 2-Butyl-3-[2'-(1H-terazol-5-yl)biphenyl-
4-yl)methyl)]-1,3-diazospironon-1-en-4-one (irbesartan; Ki = 1.6 nM) 
277was a kind 
gift of Sanofi -Synthelabo BV (Gouda, The Netherlands). Irbesartan was dissolved 
in 100% ethanol (10 mmol/L), whereas all other chemicals were dissolved in water. 
Stock solutions were stored in aliquots at -80ºC. On the day of the experiments 
stock solutions used for the Langendorff preparation were diluted with Tyrode’s 
buffer (composition in mmol/L: NaCl 125, KCl 4.7, NaH2PO4·2H2O 0.43, MgCl2 
1.0, CaCl2·H2O 1.3, glucose·H2O 9.1, NaHCO3 20; pH 7.4).  This implies that, at an 
irbesartan concentration of 1 μM (see below), the perfusion fl uid contained 0.01% 
ethanol. Previous studies have shown that such concentrations do not affect cardiac 
hemodynamics278. Stock solutions used for the Mulvany myographs were diluted in 
water.
Tissue collection
Male Wistar rats were anesthetized with pentobarbital (60 mg/kg i.p.). Hearts were 
rapidly excised and placed in ice-cold Tyrode’s buffer, gassed with 95% O2 and 
5% CO2. Subsequently, the iliac arteries and abdominal aorta were removed and 
either used directly or stored overnight in cold, oxygenated Krebs-Henseleit solution 
(composition in mmol/L: NaCl 118, KCl 4.7, CaCl2 2.5, MgCl2 1.2, KH2PO4 1.2, 
glucose 11.1, NaHCO3 25; pH 7.4). Such overnight storage does not affect vascular 
responsiveness162,279. 
Langendorff preparation
The aorta was immediately cannulated with a 21G needle with a small circumferential 
grove close to the blunt tip, and perfused with gassed (95% O2 and 5% CO2) 
Tyrode’s buffer according to Langendorff at a constant perfusion pressure of 80 mm 
Hg. The hearts were paced at ~480 bpm (8 Hz, 4 ms duration, 6 Volt) using a Grass 
stimulator (Grass Instruments Co., Quincy, Massachusetts, USA) by placing one 
needle electrode at the right atrium and one at the apex. 
After removal of the left atrium, a water-fi lled latex balloon (Durex, London, UK) was 
inserted into the left ventricle. The left ventricular end-diastolic pressure was set at 
3-5 mmHg by adjusting the balloon volume. Coronary fl ow was measured with a fl ow 
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probe (Transonic systems, Ithaca, New York, USA). After a stabilization period of 30 
min, baseline values of coronary fl ow were obtained. Next, bolus injections (100 µL) 
of Tyrode’s buffer were applied three times to determine injection-induced changes 
in coronary fl ow. Subsequently, concentration-response curves to Ang II, Ang III, Ang 
IV or Ang-(1-7) (concentration range in the injection fl uid 0.1 nmol/L – 0.1 mmol/L) 
were constructed by applying bolus injections (100 µL), in the absence or presence 
of 1 µmol/L irbesartan, PD123319 or Ang-(1-7) in the perfusion buffer58,62. All blockers 
were present in the perfusion buffer starting 15 min before the fi rst bolus injection. 
Mulvany myographs
Iliac arteries (diameter: 992+15 µm, n=148) and abdominal aortas (diameter: 
1541+21 µm, n=145) were cut into ring segments of approximately 2 mm length 
and mounted in a Mulvany myograph (Danish Myograph Technology, Aarhus, 
Denmark) with separated 6-ml organ baths containing gassed (95% O2 and 5% 
CO2) Krebs-Henseleit buffer at 37
oC. The tension was normalized to 90% of the 
estimated diameter at 100 mm Hg effective transmural pressure164. Following a 
30-min stabilization period, the normalized vessels were exposed to 30 mmol/L 
KCl. The maximal contractile response was determined by exposing the vessels 
to 100 mmol/L KCl. Thereafter, the vessels were pre-incubated for 30 min in fresh 
buffer in absence or presence of 1 µmol/L irbesartan, PD123319 or Ang-(1-7). All 
contraction studies, except those involving PD123319, were performed after a 
pre-incubation of 30 min with the NO synthase inhibitor L-NAME (100 µmol/L), to 
increase the contractile response162. In order to study vasorelaxation, vessels were 
preconstricted with U46619 (10-100 nmol/L) in the absence or presence of 1 µmol/
L irbesartan. Subsequently concentration-response curves (0.1 nmol/L – 1 µmol/L) 
were constructed to either Ang II, Ang III, Ang IV or Ang-(1-7).
Data analysis
Data obtained with the Langendorff preparation were recorded and digitalized using 
WinDaq waveform recording software (Dataq Instruments, Akron, Ohio, USA). After 
a manual selection of the desired signals pre- and post-injection, data were analyzed 
using Matlab (Mathworks Inc, Natick, Massachusetts, USA). Six consecutive beats 
were selected for determination of coronary fl ow. Ang-induced changes in left 
ventricular systolic pressure were not evaluated, since they were within the range 
induced by Tyrode’s buffer injection. Data are given as mean±standard error of the 
mean (SEM) and represent percentage change from baseline. The n number refl ects 
the number of animals. In the Mulvany myographs, contractile responses were 
expressed as a percentage of the contraction to 100 mmol/L KCl, whereas dilatory 
responses were expressed as a percentage of the preconstriction with U46619. 
Concentration-response curves were analysed as described219, using Graph Pad 
Prism 3.01 (Graph Pad Software Inc., San Diego, California, USA), to determine the 
maximum effect (Emax) and pEC50 (=-
10logEC50) values. The pEC50 values refer to the 
agonist concentration in injection fl uid of the Langendorff model and do not refl ect the 
actual concentrations seen by the receptor. In the Mulvany myograph studies, Ang 
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III and Ang IV did not reach Emax at the highest concentrations used. We therefore 
determined the concentration required to obtain 5% of the K+-induced contraction 
(EC5%K
+) in order to calculate pEC5%K
+ values162.  Concentration-response curves 
were compared by two-way ANOVA, followed by post hoc evaluation according to 
Dunnet. Emax, EC50 or pEC5%K
+ values were compared by Student’s t-test in case 
n=2, or when n>2, by one-way ANOVA, followed by post hoc evaluation according to 
Dunnet. P<0.05 was considered signifi cant. 
Results
Langendorff preparation 
Figure 1. Effects of Ang II , Ang III, Ang IV and Ang-(1-7) bolus injections (100 µL) on coronary fl ow in the rat 
Langendorff heart (A).  Effects of Ang II (B), Ang III (C) and Ang IV bolus injections (100 µL), respectively, 
on coronary fl ow in the rat Langendorff heart in the absence or presence of 1 µmol/L irbesartan or 1 µM 
PD123319. The x-axis displays the concentration of the agonist in the injection fl uid. Data are mean±SEM 
of 4-6 experiments and represent percentage change from baseline. T, bolus injection of Tyrode’s buffer. 
*P<0.05 vs. control.
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Figure 2.  Effects of Ang II bolus injections (100 µL) on coronary fl ow in the rat Langendorff heart in the 
absence or presence of 1 µmol/L Ang-(1-7) (A). The x-axis displays the Ang II concentration in the injection 
fl uid. Data are mean±SEM of 4-5 experiments and represent percentage change from baseline. T, bolus 
injection of Tyrode’s buffer. Effects of Ang II in L-NAME (100 µmol/L)-pretreated rat iliac arteries (B) and 
abdominal aortas (C), respectively, in the absence or presence of 1 µmol/L Ang-(1-7). The x-axis displays 
the concentration of the agonist in the organ bath fl uid. Data are mean±SEM of 5-6 experiments and have 
been expressed as a percentage of the response to 100 mmol/L K+.
Baseline coronary fl ow (9.2+0.3 mL/min; n=54) was similar in all groups. Bolus 
injections with Tyrode’s buffer injections did not signifi cantly affect coronary fl ow 
(Fig. 1). Ang II, Ang III and Ang IV concentration-dependently decreased coronary 
fl ow, by maximally 42+3%, 43+4% and 51+5%, respectively, whereas Ang-(1-7) 
had no effect on coronary fl ow (Figure 1A). Ang II and Ang III concentrations >1 
µmol/L did not result in effects that were larger than those observed at 1 µmol/L, in 
agreement with the concept of receptor desensitization220-222. Ang III (pEC50 7.0±0.2, 
n=5) and Ang IV (pEC50 4.7±0.1, n=5) were respectively ~20 and ~8000-fold less 
potent than Ang II (pEC50 8.3±0.6, n=5). Irbesartan abolished all Ang II, Ang III and 
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Ang IV-induced fl ow changes (Figure 1B-D) and did not unmask effects of Ang-(1-
7) (n=3, data not shown). PD123319 enhanced the effect of 10 µmol/L Ang II on 
coronary fl ow (P<0.05; n=6). PD123319 (P<0.05) enhanced the effect of Ang III on 
coronary fl ow at all Ang III concentrations (Emax 61±2%), and the potency of Ang III in 
the presence of PD123319 (pEC50 7.3±0.1, n=5) was no longer different from that of 
Ang II. The effect of Ang IV on coronary fl ow was unaltered in presence of PD123319 
(n=4). Ang-(1-7) (1 µmol/L) signifi cantly (P<0.05) shifted the Ang II curve to the right 
(pEC50 6.9±0.3, n=5; Figure. 2), without changing Emax. 
Mulvany myographs
Figure 3. Effects of Ang II, Ang III, Ang IV and Ang-(1-7) in L-NAME (100 µmol/L)-pretreated rat iliac 
arteries (A). Effects of Ang II (B), Ang III (C) and Ang IV (D), respectively, in L-NAME-pretreated rat iliac 
arteries in the absence or presence of 1 µmol/L irbesartan. The x-axis displays the concentration of the 
agonist in the organ bath fl uid. Data are mean±SEM of 4-31 experiments and have been expressed as a 
percentage of the response to 100 mmol/L K+. *P<0.05 vs. control.
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Ang II, Ang III and Ang IV constricted iliac arteries (Figure 3A + 4A) and abdominal 
aortas (Figure. 5A + 6A) in a concentration-dependent manner, whereas Ang-(1-
7) had no effect. As expected162, the contractile responses in the presence of L-
NAME (Figure. 3 and 5) were much larger than those in the absence of L-NAME 
(Figure 4 and 6). In the iliac arteries, in the presence of L-NAME, Ang III and Ang 
IV (pEC5%K
+’s: 7.8+0.3, n=8 and 5.6+0.2, n=5) were respectively ~12 (P<0.001) 
and ~2000-fold (P<0.0001) less potent than Ang II (pEC5%K
+: 8.9+0.1, n=30). In the 
abdominal aorta, in the presence of L-NAME, Ang III and Ang IV (pEC5%K
+’s: 7.6+0.3, 
n=10 and 5.9+0.2, n=5) were respectively ~12 (P<0.0001) and ~600-fold (P<0.0001) 
less potent than Ang II (pEC5%K
+: 8.7+0.1, n=25). Potencies of Ang II, Ang III and Ang 
IV in the absence of L-NAME were identical to those in the presence of L-NAME. 
The effects of PD123319 in the two vessel types were studied in the absence of L-
Figure 4. Effects of Ang II, Ang III, Ang IV and Ang-(1-7) in rat iliac arteries (A). Effects of Ang II (B), Ang 
III (C) and Ang IV (D), respectively, in rat iliac arteries in the absence or presence of 1 µM PD123319. 
The x-axis displays the concentration of the agonist in the organ bath fl uid. Data are mean±SEM of 5-6 
experiments and have been expressed as a percentage of the response to 100 mmol/L K+.
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NAME, since these are most likely NO-dependent71. The effects of irbesartan were 
studied in the presence of L-NAME, i.e., when contractions were largest. Irbesartan 
abolished all Ang II, Ang III and Ang IV-induced contractions in both vessel types 
(Figure 3B-D and 5B-D, n=5-6), but did not unmask any Ang-(1-7) effects in either 
iliac arteries (n=5, data not shown) or abdominal aortas (n=6; data not shown). Ang-
(1-7) shifted the Ang II concentration-response curves to the right in the iliac artery 
(P<0.05), and decreased the Emax to Ang II in the abdominal aorta, although the latter 
was not signifi cant (Figure 2B and C). PD123319 did not affect the concentration-
response curves to Ang  II, Ang III or Ang IV in either iliac arteries or abdominal 
aortas (Figure 4B-D and 6B-D, n=4-6). 
Figure 5. Effects of Ang III, Ang IV and Ang-(1-7) in L-NAME (100 µmol/L)-pretreated rat abdominal aortas 
(A). Effects of Ang II (B), Ang III (C) and Ang IV (D), respectively, in L-NAME-pretreated rat abdominal 
aortas in the absence or presence of 1 µmol/L irbesartan. The x-axis displays the concentration of the 
agonist in the organ bath fl uid. Data are mean±SEM of 4-28 experiments and have been expressed as a 
percentage of the response to 100 mmol/L K+. *P<0.05 vs. control.
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No relaxant response to Ang II, Ang III, Ang IV or Ang-(1-7) were observed in 
preconstricted iliac arteries and abdominal aortas in the absence or presence of 
irbesartan (n=3-5; data not shown). 
Discussion
This study is the fi rst to compare the effects of Ang II and its metabolites Ang III, Ang 
IV and Ang-(1-7) in the rat coronary circulation. Ang III and Ang IV caused coronary 
constriction via AT1 receptor stimulation, although at lower potency than Ang II. Ang 
III, but not Ang IV, simultaneously induced vasorelaxation via AT2 receptors, and 
Figure 6. Effects of Ang II, Ang III, Ang IV and Ang-(1-7) in rat abdominal aortas (A). Effects of Ang II 
(B), Ang III (C) and Ang IV (D), respectively, in rat abdominal aortas in the absence or presence of 1 
µmol/L PD123319. The x-axis displays the concentration of the agonist in the organ bath fl uid. Data are 
mean±SEM of 4-6 experiments and have been expressed as a percentage of the response to 100 mmol/L 
K+.
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this was already apparent at subnanomolar Ang III concentrations, as opposed 
to the submicromolar concentrations of Ang II that were required to observe such 
relaxation. Ang-(1-7) did not exert effects of its own in the coronary circulation, 
but blocked AT1 receptor-induced constriction at high concentrations. The relative 
constrictor potencies of the 3 angiotensin metabolites in iliac arteries and abdominal 
aortas were identical to those in the coronary vascular bed, and agree with previous 
fi ndings in the rat thoracic aorta and the human saphenous vein268,269. No AT2 
receptor-mediated relaxant effects occurred in these vessels.     
The reduced potency of Ang III and Ang IV as compared to Ang II towards AT1 
receptors can be explained on the basis of the important role of the Asp1 and Arg2 
residues of Ang II in the ‘pre-activation’ process280. These residues interact with 
His183 and Asp281 of the AT1 receptor, stabilizing its conformation, and thus allowing 
optimal binding of the remaining 5 C-terminal residues281,282. Because the Arg2-Asp281 
interaction is of much greater importance than the Asp1-His183 interaction281, Ang III is 
only slightly less potent than Ang II, while Ang IV was up to 8000-fold less potent than 
Ang II in the present study. Studies with constitutively active human AT1 receptors 
(N111G mutant), i.e. receptors which are already in the pre-activated state, have 
shown that, without the need for pre-activation, Ang IV is as potent as Ang II282. 
PD123319 increased the constrictor response to Ang III in the coronary vascular 
bed at all Ang III concentrations tested, whereas it increased the response to Ang 
II at concentrations in the low micromolar range only. In addition, in the presence of 
PD123319, Ang III was as potent as Ang II. This suggests that the 20-fold difference 
in potency between Ang III and Ang II in the coronary vascular bed in the absence 
of PD123319 (as compared to the ≈10-fold difference in iliac arteries and aortas) is 
largely due to Ang III-selective stimulation of dilator AT2 receptors, which counteract its 
AT1 receptor-mediated constrictor effects. Since the PD123319-induced potentiation 
became apparent already at Ang III concentrations <1 nmol/L, Ang III rather than 
Ang II appears to be the preferred AT2 receptor agonist. Similar observations have 
been made in the kidney, where Ang III (and not Ang II) induced natriuresis through 
AT2 receptor activation during AT1 receptor blockade
97. This natriuretic effect was 
enhanced during aminopeptidase N blockade, which further supports the concept 
of Ang III-dependent Ang AT2 receptor stimulation
283. In spontaneously hypertensive 
rats, Ang III induced a depressor response during AT1 receptor blockade
284. This effect 
was blocked by PD123319, L-NAME and the bradykinin type 2 receptor antagonist 
Hoe140, suggesting that it depended on AT2 receptor stimulation, NO and bradykinin 
type 2 receptors. Endothelial B2 receptors and the NO/cGMP pathway have also 
been linked to coronary AT2 receptor stimulation in rats
59, mice62 and humans58. 
In our study, selective AT2 receptor stimulation during AT1 receptor blockade with 
irbesartan did not result in vasodilation. Similar observations were made in mice 
during AT1 receptor blockade, as well as in AT1a knockout mice
62, and collectively, 
these data suggest that AT2 receptor-mediated effects occur only in conjunction with 
AT1 receptor activation, possibly because both receptors interact, either directly (due 
to heterodimerization)61 or indirectly, at the post-receptor level. 
We were unable to observe Ang IV-induced vasorelaxant effects in any of our 
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preparations, suggesting that such effects are limited to certain vascular beds, 
e.g., in the brain and the kidney102. Ang IV did induce vasoconstriction. Since this 
occurred at pharmacological concentrations only, it is unlikely to have physiological 
relevance. 
Unexpectedly, Ang-(1-7) did not cause vasodilation via Mas receptor activation 
in any of our preparations, neither at baseline, nor after preconstriction, or in the 
presence of irbesartan. At micromolar concentrations, Ang-(1-7) did shift the Ang 
II concentration-response curve to the right in the coronary circulation and iliac 
arteries, and a similar trend was observed in the abdominal aorta. This mimics 
previous fi ndings in the rat renal vascular bed 89,285 and the human forearm169, and 
suggests that Ang-(1-7), at pharmacological concentrations, acts as an AT1 receptor 
antagonist. Ang-(1-7) also exerts ACE-inhibitory effects32, and thus the benefi cial 
effects of Ang-(1-7) infusions in rats 174 may be due, at least in part, to RAS blockade. 
Clearly, the attenuation of heart failure induced by the Mas receptor agonist AVE-
0991 286 does not involve Mas receptor-dependent coronary vasorelaxation. Indeed, 
in the mouse heart, the Mas receptor was mainly localized in cardiomyocytes88.
In conclusion, AT2 receptor activation in the rat coronary vascular bed results in 
vasodilation, and Ang III rather than Ang II appears to be the preferred agonist of 
these receptors. Due to the diffi culties of measuring Ang metabolites in a reliable 
manner176,287, epidemiological data linking Ang III levels to cardiovascular outcome 
parameters in humans are currently not available.
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Abstract
Animal and clinical data suggest that the blood pressure-lowering effect of renin 
inhibition equals that of ACE inhibition and angiotensin (Ang) type 1 (AT1) receptor 
blockade. Whether blocking the initial, rate-limiting step of the renin-angiotensin 
system also offers end-organ protection still needs to be investigated. In this study, 
we compared the cardiovascular effi cacy of the renin inhibitor aliskiren (100 mg/
kg/day), the AT1 receptor blocker irbesartan (15 and 30 mg/kg/day) and the ACE 
inhibitor captopril (3 and 6 mg/kg/day) in spontaneously hypertensive rats (SHR). 
All treatments lasted 3 weeks, and during this period mean arterial blood pressure 
(MAP) and heart rate (HR) were continuously monitored by radiotelemetry. After 3 
weeks, the animals were sacrifi ced to determine (1) plasma renin activity (PRA), (2) 
coronary reactivity to bradykinin and Ang II, and 3) cardiac hypertrophy (heart weight 
(HW)/body weight (BW) ratio and cardiomyocyte area). Aliskiren, irbesartan and 
captopril lowered MAP in a dose-dependent manner, without affecting HR. Aliskiren 
decreased PRA by ≈70%, whereas irbesartan and captopril increased PRA in a dose-
dependent manner. The blood pressure-lowering effects of irbesartan 15 mg/kg/day 
and captopril 3 mg/kg/day were comparable to those of aliskiren 100 mg/kg/day, 
and at these doses all drugs increased coronary reactivity to bradykinin, whereas 
only aliskiren and irbesartan decreased the response to Ang II. Simultaneously, at 
these doses, all drugs decreased HW/BW ratio and cardiomyocyte area, although 
signifi cance was reached for the latter only. In conclusion, for a given decrease 
in blood pressure, aliskiren is as least as effective as AT1 receptor blockade and 
ACE inhibition with regard to improvement of endothelial function and cardiac 
hypertrophy. 
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Introduction
The renin-angiotensin system (RAS) plays an important role in the regulation of blood pressure and body fl uid homeostasis. The RAS is not only active in 
the circulation (“circulating RAS”) but also in many tissues, functioning as so-called 
“local” RAS.103 Angiotensin (Ang) II, the main effector peptide of the RAS, when 
generated from Ang I at tissue sites, stimulates both Ang II type 1 (AT1) and Ang II 
type 2 (AT2) receptors. This local synthesis depends on angiotensinogen, renin and/
or prorenin (the inactive precursor of renin) taken up from blood, the latter uptake 
possibly involving the recently discovered (pro)renin receptor.186,288 In contrast, 
the angiotensin-converting enzyme (ACE) required to convert Ang I into Ang II, is 
generated locally.
Under pathological conditions excessive RAS activity may lead to a rise in blood 
pressure and cardiac/renal hypertrophy, resulting in end-organ damage. ACE 
inhibitors are believed to exert their benefi cial effects through blockade of Ang 
II formation from Ang I at tissue sites. However, compensatory feedback loops 
within the RAS will result in an increased release of renin from the kidneys and an 
upregulation of ACE and non-ACE Ang II-generating enzymes, thus making it very 
diffi cult to suppress Ang II levels during continuous ACE inhibition.1,118 Treatment 
with AT1 receptor blockers will also cause a rise in renin, resulting in increased Ang 
I and II levels in blood and tissues.1 It is believed that during AT1 receptor blockade 
the unopposed AT2 receptors will be stimulated excessively due to the rise in 
Ang II levels. In fact, animal data suggest that part of the benefi cial effect of AT1 
receptor blockers is due to AT2 receptor stimulation.
64 AT2 receptors exert effects that 
directly oppose the effects of AT1 receptors, and, as they form heterodimers with 
AT1 receptors, AT2 receptor might even act as natural AT1 receptor antagonists.
61 
Since the AT2 receptor-induced effects could not be observed in the absence of AT1 
receptors,62 the net benefi cial effect of AT2 receptor stimulation may actually be a 
more complete AT1 receptor blockade. 
Renin inhibitors prevent the formation of Ang I and II by targeting the initial and rate-
limiting step of the RAS. They bind to both renin and prorenin.8 Renin, unlike ACE, 
has only one known substrate, and without renin, there are no angiotensins.106 Renin 
inhibitors have a pharmacokinetic advantage over other RAS blockers in that they 
may already bind to renin and/or prorenin on their way to tissue sites (i.e., in blood), 
whereas the other blockers fi rst have to penetrate into tissues in order to exert their 
effect. Although renin will rise during renin inhibitor treatment, like it does during any 
type of RAS blockade, this renin cannot be enzymatically active due to the presence 
of the renin inhibitor. Therefore, renin inhibitors are expected to provide a more 
complete suppression of the RAS with a low likelihood of side-effects. 
The putative benefi cial effects mediated by AT2 receptors will not occur during renin 
inhibition. So far, this does not appear to diminish the effects of renin inhibitors, at 
least on blood pressure,152 possibly because more complete RAS blockade induces 
the same effect as AT2 receptor stimulation, as discussed above. 
Despite its promise, renin inhibition was held back for a long time due to a number 
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of technical problems.289 Early renin inhibitors had limited bioavailability and effi cacy. 
In contrast, the recently developed renin inhibitor aliskiren is a potent and selective 
inhibitor of human renin, with an improved bioavailability as compared to the early 
renin inhibitors.290 Aliskiren lowers both plasma Ang I and II in humans, and prevents 
the rise in plasma Ang I and II during AT1 receptor blockade
150,151.150,151 In short-term 
studies, it reduced blood pressure to the same degree as other RAS blockers.152 
Oparil and co-workers showed that aliskiren treatment on top of AT1 receptor 
blockade led to an additional lowering in blood pressure.291 
The long-term effects of aliskiren (e.g., on cardiac hypertrophy) as well as its effects 
on tissue Ang I and II are not yet known. This relates to the fact that aliskiren primarily 
blocks human renin and is less effective towards renin of other species, thus 
hampering its use in animals. Aliskiren is highly effective in double transgenic rats 
expressing both human renin and angiotensinogen,292 but given the exceptionally 
high Ang II levels in these animals (up to 20 times normal), causing them to die within 
7 weeks without treatment, it is uncertain to what degree such data refl ect “normal” 
in vivo conditions. 
At high doses (100 mg/kg/day), aliskiren does lower blood pressure in spontaneously 
hypertensive rats (SHR).293 In the present study we therefore compared the 
cardiovascular effi cacy of aliskiren with that of the AT1 receptor blocker irbesartan 
and the ACE inhibitor captopril in SHR. First, the effects of these RAS blockers at 
various doses on blood pressure and heart rate were measured by telemetry in 
conscious animals. Based on these data we determined which dose of irbesartan 
and captopril induced a comparable blood pressure-lowering effect as a high 
dose of aliskiren. Next, applying such equi-hypotensive doses of the 3 drugs, we 
determined, after a 3-week treatment, coronary reactivity to bradykinin and Ang II, 
and the degree of cardiac hypertrophy (heart weight (HW)/body weight (BW) ratio 
and cardiomyocyte area). 
Materials and methods
Animals
Male SHR (280-300 gram; n=33) and their normotensive Wistar Kyoto (WKY: 280-
300 gram; n=2) controls were obtained from Harlan (Zeist, The Netherlands). SHR 
and WKY rats were housed in individual cages and maintained on a 12-h light/
dark cycle, having access to standard laboratory rat chow and water ad libitum. All 
experiments were performed under the regulation and permission of the Animal Care 
Committee of the Erasmus MC, Rotterdam, The Netherlands. 
Drugs
Captopril, Ang II, bradykinin and sodium nitroprusside (SNP) were purchased 
from Sigma (Zwijndrecht, The Netherlands). Irbesartan was a kind gift of Sanofi -
Synthelabo BV (Gouda, The Netherlands), and aliskiren (hydrochloride salt) was a 
kind gift of Novartis Pharmaceuticals (Basel, Switzerland). 
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The drugs were prepared for administration via osmotic minipumps as follows: 
Irbesartan (87.5 mg/mL or 175 mg/mL) was dissolved in saline in the presence of 
4% vol/vol NaOH.294 The pH was subsequently adjusted to 7-9 by equilibration with 
carbogen (95% O2, 5% CO2). Captopril (17.5 mg/mL or 35 mg/mL) and aliskiren 
(583.3 mg/mL) were dissolved in saline. 
Ang II and bradykinin for in-vitro use were dissolved in water, and stock solutions 
were stored in aliquots at -80ºC. On the day of the experiments stock solutions 
were further diluted with Tyrode’s buffer (composition in mmol/L: NaCl 125, KCl 4.7, 
NaH2PO4·2H2O 0.43, MgCl2 1.0, CaCl2·H2O 1.3, glucose·H2O 9.1, NaHCO3 20; pH 
7.4).
Telemetry and treatment
Rats were anesthetized by inhalation of isofl urane (Rhodia Organique Fine 
Limited, Avonmouth, Bristol, UK) in air. A radio-telemetry transmitter (TA11PA-C40, 
Datascience Inc., St. Paul, Minnesota, USA) was implanted into the abdominal cavity 
with the fl uid-fi lled catheter placed into the lower abdominal aorta. After surgery rats 
were treated with Temgesic® (buprenorphine, Reckitt and Colman, Hull, UK) for 2 
days (0.1 and 0.05 mg/kg during the fi rst and second day, respectively). After 11 days 
of recovery, telemetry measurement was started to obtain baseline hemodynamic 
parameters. Two days later, osmotic minipumps (2mL4 Alzet, California, USA) were 
implanted subcutaneously under isofl urane anesthesia to infuse either vehicle 
(saline), irbesartan (15 or 30 mg/kg/day), captopril (3 or 6 mg/kg/day) or aliskiren 
(100 mg/kg/day). Three weeks after implantation of the osmotic pumps, telemetry 
measurement was stopped.  
Collection of tissue and blood
In the third to fourth week after implantation of the osmotic pump, animals were 
anesthetized by inhalation of isofl urane. The hepatic portal vein was cannulated 
to collect 1 ml of blood, which was centrifuged for 5 minutes at 13000 rpm. 
Subsequently, plasma was obtained and stored at -80oC. The hearts were rapidly 
excised and placed in ice-cold Tyrode’s buffer, gassed with 95% O2 and 5% CO2. 
Langendorff preparation
The aorta was immediately cannulated with a 21G needle (with a small circumferential 
grove close to the blunt tip) and perfused with gassed (95% O2 and 5% CO2) Tyrode’s 
buffer according to Langendorff at a constant perfusion pressure of 80 mm Hg. Two 
needle electrodes were placed at the right atrium and the hearts were paced at ~480 
bpm (8 Hz, 4 ms duration, 6 Volt) using a Grass stimulator (Grass Instruments Co., 
Quincy, Massachusetts, USA). After removal of the left atrium, a water-fi lled latex 
balloon (Durex, London, UK) was inserted into the left ventricle. The left ventricular 
end-diastolic pressure was set at 3-5 mmHg by adjusting the balloon volume. 
Coronary fl ow (CF) was measured with a fl ow probe (Transonic systems, Ithaca, 
New York, USA). After a stabilization period of 30 minutes, baseline values of CF 
were obtained. Next, bolus injections (100 µL) of Tyrode’s buffer were applied three 
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times to determine injection-induced changes in CF. First a concentration-response 
curve to BK (concentration range in the injection fl uid 0.1 nmol/L - 0.1 mmol/L) 
was constructed by bolus injections (100 µL). Ten minutes later, a concentration-
response curve was constructed to Ang II (concentration range in the injection fl uid 
0.1 nmol/L - 0.1 mmol/L). Finally, the maximum coronary fl ow was determined by an 
injection of SNP (10 mmol/L)
Cardiac hypertrophy 
Following completion of the measurements in the Langendorff model, the hearts 
were collected, and the ventricular heart weight was determined after removal of 
the atria and large vessels. Ventricular hypertrophy was defi ned as the ratio of the 
ventricular HW to BW. Subsequently, ventricles were cut into 3 transversal slices 
and fi xed in a 3.5-4% formaldehyde solution (Boom, Meppel, the Netherlands). 
After fi xation, the slices were dehydrated and paraffi n-embedded. Deparaffi nized 
5 µm thick sections were stained with Gomori’s silver staining in order to visualize 
individual cardiomyocytes.295. Only transversally cut cells showing a nucleus were 
used to determine the cardiomyocyte area. 
Plasma renin activity (PRA)
PRA was measured by incubating plasma for 60 minutes at pH 7.4 and 37oC in the 
presence of a mixture of inhibitors to block Ang I degradation, Ang I-II conversion, 
and prorenin-renin conversion, and to prevent bacterial growth.296 The generated 
Ang I was measured by radioimmunoassay. 
Data analysis
Telemetric data were recorded and digitalized using the Dataquest Acquisition & 
Analysis system (DQ ART 3.1 Silver, Datascience Inc., St. Paul, Minnesota, USA). 
Each animal was sampled for 10 seconds at 10-minute intervals for a period of 23 
days. All recordings were averaged per day and baseline values were calculated 
using the data from the fi rst 2 days of measurement before treatment was started. 
Changes in MAP from baseline were analyzed by comparison of the areas over the 
curve (AOC), as calculated by the trapezoidal method (mm Hg x days).293,297 
Data obtained with the Langendorff preparation were recorded and digitalized using 
WinDaq waveform recording software (Dataq Instruments, Akron, Ohio, USA). After 
a manual selection of the desired signals pre- and post-injection, data were analyzed 
using Matlab (Mathworks Inc, Natick, Massachusetts, USA). Six consecutive beats 
were selected for determination of CF. 
Statistical analysis between groups was performed by Student’s t test or one-way 
analysis of variance (ANOVA), followed by post hoc evaluation according to Dunnet. 
P<0.05 was considered signifi cant.
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Results
Baseline parameters and vehicle treatment
At baseline, the body weights of SHR (278+2 gram, n=26) and WKY rats (260+1, 
n=2) were identical, and SHR displayed a higher MAP and a lower HR than WKY 
rats (Table). Vehicle did not affect MAP or HR in either strain. At the end of the 21 
day-treatment period WKY rats had gained more weight than SHR, in full agreement 
with previous fi ndings.298,299
RAS blockade in SHR
Aliskiren 100 mg/kg/day lowered MAP in comparison to vehicle control (Table and 
Figure 1), without affecting HR (data not shown). MAP was maximally reduced at 
the 4th day after the start of infusion. Thereafter, the effect of aliskiren leveled off, 
but MAP remained reduced at day 7, 14 and 21. Aliskiren reduced PRA on day 7 of 
treatment, and this effect was unaltered on day 21 (Figure 1). 
Figure 1. Left panel, ∆MAP during a 3-week infusion of aliskiren or vehicle in SHR (n=8). Right panel, 
plasma renin activity (PRA) on day 7 and 21 after the start of treatment (n=6-7). Data are mean+SEM. 
*P<0.05 vs. control. 
Irbesartan and captopril reduced MAP at all tested doses, and both drugs increased 
PRA in a dose-dependent manner (Figures 2 and 3). The blood pressure-lowering 
effects of the two highest doses of irbesartan and captopril, estimated from the AOC 
values and the MAP decreases at day 7, 14 and 21 (Table), were larger than that of 
aliskiren, whereas the effects of the two lowest doses of both drugs were comparable 
to that of aliskiren. HR was unaltered during treatment with these lower doses (data 
not shown). On the basis of these fi ndings, all further studies were performed with 
aliskiren 100 mg/kg/day, irbesartan 15 mg/kg/day and captopril 3 mg/kg/day. 
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Langendorff studies
Baseline CF of vehicle-treated SHR (11.9+0.8 mL/min, n=9), vehicle-treated 
WKY rats (8.6+0.2 mL/min, n=2), aliskiren-treated SHR (9.7+0.5 mL/min, n=7), 
irbesartan-treated SHR (8.9+0.6 mL/min, n=4) and captopril-treated SHR (9.7+0.6 
mL/min, n=4) were identical. Bolus injections with Tyrode’s buffer injections did not 
signifi cantly affect CF (Figures 4 and 5). Bradykinin increased CF in vehicle-treated 
WKY rats and SHR (Figure 4), but its effects were much larger in the former (Emax: 
+254±20% vs. +73±20%, P<0.05). Treatment of SHR with aliskiren, irbesartan or 
captopril increased the effect of bradykinin to WKY values (P<0.05 for all). 
Figure 2. Left panel, ∆MAP during a 3-week infusion of irbesartan or vehicle in SHR (n=5-8). Right panel, 
PRA on day 21 after the start of treatment (n=4-7). Data are mean+SEM. *P<0.05 vs. control.
Figure 3. Left panel, ∆MAP during a 3-week infusion of captopril or vehicle in SHR (n=2-8). Right panel, 
PRA on day 21 after the start of treatment (n=2-7). Data are mean+SEM. *P<0.05 vs. control.
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Ang II concentration-dependently decreased CF in vehicle-treated WKY rats and 
SHR (Figure 5), and its effects were larger in the latter (Emax: -62+0.1% vs. -73+4%, 
P<0.05). Treatment of SHR with aliskiren or irbesartan decreased the effect of Ang II 
to WKY values (P<0.05 for both). Captopril treatment of SHR did not alter the effect 
of Ang II. The maximum CF values (determined with SNP) were identical in vehicle-
treated WKY rats and SHR (34.8+3.1 mL/min vs. 31.2+5.8 mL/min; n=2 for both), 
and treatment of SHR with aliskiren, irbesartan or captopril did not alter these values 
(data not shown).
Figure 4. Effect of bradykinin (BK) bolus injections (100 µL) on coronary fl ow in SHR (panels A-D) or WKY 
rats (panel A) after a 3-week treatment with vehicle, aliskiren, irbesartan or captopril. Data (mean+SEM of 
2-7 experiments) were obtained using the Langendorff heart preparation, and represent % change from 
baseline. The concentrations on the x-axis represent the concentration in the injection fl uid. T represents 
the effect of a bolus injection with Tyrode’s buffer. †P<0.05 vs. WKY; *P<0.05 vs. SHR vehicle control.
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Cardiac hypertrophy
The HW/BW ratio (Figure 6) and 
cardiomyocyte area (Figure 7) were 
much larger (P<0.0001) in vehicle-
treated SHR than in vehicle-treated 
WKY rats. Treatment of SHR with 
aliskiren, irbesartan or captopril did 
not signifi cantly affect the HW/BW 
ratio, but reduced the cardiomyocyte 
area (P<0.05). 
Figure 5. Effects of angiotensin (Ang) II bolus injections (100 µL) on coronary fl ow in SHR (panels A-
D) or WKY rats (panel A) after a 3-week treatment with vehicle, aliskiren, irbesartan or captopril. Data 
(mean+SEM of 2-6 experiments) were obtained using the Langendorff heart preparation, and represent % 
change from baseline. The concentrations on the x-axis represent the concentration in the injection fl uid. 
T represents the effect of a bolus injection with Tyrode’s buffer. †P<0.05 vs. WKY; *P<0.05 vs. SHR vehicle 
control.
Figure 6. Ventricular heart weight (HW)/body weight (BW) ratio of SHR and WKY rats after a 3-week 
treatment with vehicle, aliskiren, irbesartan or captopril. Data are mean+SEM of 2-7 experiments. †P<0.05 
vs. WKY. 
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Discussion
This study is the fi rst to compare, head-to-head, the 3 types of RAS inhibition in a 
well-established model, the SHR. This is of importance now that the renin inhibitor 
Figure 7. Gomori-stained sections showing cardiomyocytes in the left ventricular wall of hearts from 
vehicle-treated WKY rats (A), vehicle-treated SHR (B), aliskiren-treated SHR (C), irbesartan-treated SHR 
(D) and captopril-treated SHR (E). The bar in the in picture A represents 50 µm. Panel F summarizes the 
fi ndings on the cardiomyocyte area (mean+SEM of 2-5 experiments) in the 5 groups. †P<0.05 vs. WKY; 
*P<0.05 vs. SHR vehicle control. 
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aliskiren is entering the clinical arena. The data show that, for a given decrease in 
blood pressure, aliskiren improves endothelial function and decreases cardiac 
hypertrophy to minimally the same degree as captopril and irbesartan. In addition, it 
decreases the contractile effects of Ang II to the same degree as irbesartan, although 
it is not an AT1 receptor blocker.  
The aliskiren-induced decrease in blood pressure in SHR in the present study was 
comparable to that observed by Wood et al. in SHR.293 The blood pressure effect 
leveled off at the end of the infusion period, although PRA at that time was still 
suppressed to the same degree as after 7 days of treatment. This indicates that 
the levels of the renin inhibitor, at least in blood, were still suffi ciently high to block 
plasma renin. Future measurements of renin activity and Ang II levels at tissue 
sites should reveal to what degree renin inhibition was also effective at the tissue 
level. A similar degree of leveling off was observed during treatment with the lower 
doses of irbesartan and captopril (which decreased blood pressure to the same 
degree as aliskiren) but not during treatment with the higher doses of these 2 drugs. 
Clearly therefore, RAS blockade was incomplete at the 3 equi-hypotensive doses 
of aliskiren, irbesartan and captopril. The decreases in MAP at these doses were 
not accompanied by changes in HR, in full agreement with previous studies on RAS 
blockade.293,297,300.
As expected, coronary endothelial function (determined as the response to 
bradykinin) was greatly impaired in SHR as compared to WKY.301,302 All 3 RAS 
blockers, despite their modest blood pressure-lowering effects, normalized coronary 
endothelial function in SHR. In the case of captopril, part of this effect may relate to 
its bradykinin-potentiating properties. However, given the much smaller maximum 
effect of bradykinin in SHR, this potentiation cannot fully explain the benefi cial effects 
of the ACE inhibitors. Clearly therefore, RAS blockade per se translates into an 
improved endothelial function, for instance because Ang II suppression diminishes 
oxidative stress.279,303-306
Surprisingly, aliskiren, like irbesartan, decreased the coronary responsiveness to 
Ang II. Theoretically, based on the assumption that a renin inhibitor will suppress 
Ang II, one would have expected an upregulation of AT1 receptors during aliskiren 
treatment, and thus, an increased responsiveness to exogenously applied Ang II. 
Indeed, a tendency for such a leftward shift of the Ang II dose-response curve was 
observed during captopril treatment, which will also lower Ang II. The fact that this 
did not occur during aliskiren treatment may suggest that renin inhibition affects AT1 
receptor expression independently of its effect on Ang II. Indeed, a decrease in renal 
AT1 receptor expression has also been observed in aliskiren-treated diabetic rats.
307 
The mechanism underlying this phenomenon is currently unknown, but it is tempting 
to speculate that it relates to stimulation of the (pro)renin receptor by renin and/or 
prorenin. 
Finally, the equi-hypotensive doses of the 3 RAS blockers did not signifi cantly affect 
the HW/BW ratio. Since this parameter is largely determined by blood pressure (ref), 
it is not surprising, given the modest blood pressure-lowering effects of the 3 drugs, 
that no signifi cant decrease occurred in this study. Nevertheless, cardiomyocyte 
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area did decrease during treatment with aliskiren, irbesartan and captopril, and thus 
measurements of cardiac Ang II and collagen content are required to get a more 
complete picture of the putative antihypertrophic effects of these drugs.  
In summary, for a given decrease in blood pressure, aliskiren is as least as effective 
as AT1 receptor blockade and ACE inhibition with regard to improvement of 
endothelial function and cardiac hypertrophy.
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Summary
Introduction and aim of this thesis (Chapter 1)
The renin-angiotensin system (RAS) plays an important role in the regulation of blood 
pressure and body fl uid homeostasis. Traditionally the RAS has been viewed as a 
circulating system (“circulating” RAS) but it is now well-established that angiotensin 
(Ang) generation also occurs at tissue sites (“tissue” RAS). Angiotensinogen (liver-
derived) is cleaved by renin (kidney-derived) into Ang I which in turn can be converted 
into Ang II by angiotensin-converting enzyme (ACE). As main biological component 
of the RAS, Ang II mediates it effects through the angiotensin type 1 (AT1) and type 2 
(AT2) receptors. In rodents, two AT1 receptor subtypes have been identifi ed: AT1A and 
AT1B. AT1 receptors mediate the well-known vasoconstrictor, inotropic, chronotropic, 
aldosterone-releasing, noradrenaline-releasing and growth-stimulatory effects 
of Ang II, and AT2 receptors are generally assumed to counteract these actions. 
Initially it was thought that all metabolites other than Ang II were inactive, but now it 
is clear that several of these metabolites such as Ang III, Ang IV and Ang-(1-7) have 
functions of their own which are possibly mediated by non-AT1/AT2 receptors. Under 
pathophysiological conditions excessive RAS activity may lead to an increased blood 
pressure and cardiac/renal hypertrophy, resulting in end-organ damage. By now the 
RAS can be blocked at three levels: renin, ACE and the AT1 receptor. ACE inhibitors 
and AT1 receptor blockers already have proven their effectiveness in the treatment 
of hypertension and cardiovascular diseases. ACE inhibitors block the formation of 
Ang II whereas AT1 receptor blockers prevent Ang II to mediate effects through the 
AT1 receptor. It is feasible that at least part of the benefi cial effect of AT1 receptor 
blockers is due to stimulation of the unblocked AT2 receptor. It is thought that the 
newly developed renin inhibitors will provide a more complete suppression of the 
RAS as they block the fi rst rate-limiting step. Clearly, the RAS has not yet revealed 
all of its secrets. Step by step the pieces of the puzzle fall into place and a better 
understanding of the RAS and its components eventually might lead to the discovery 
of novel therapeutic targets and improved treatment strategies.
ACE (Chapter 2 and 3)
Somatic ACE contains two homologous domains (the C- and N-domain) capable 
of hydrolyzing Ang I and bradykinin. Selective C-domain inhibition induced a 
rightward shift of the Ang I concentration-response curve (CRC) in porcine femoral 
arteries (PFAs) whereas selective N-domain inhibition did not affect Ang I-induced 
constriction. In human blood plasma blockade of both domains fully blocked the 
Ang I-II conversion. In contrast, bradykinin degradation by membrane-bound ACE 
depended on both domains, as both selective C- and N-domain blockade shifted the 
bradykinin CRC to the left, with a maximum leftward shift being observed when both 
domains were blocked. Thus, tissue Ang I-II conversion depends exclusively on the 
C-domain, whereas both domains contribute to conversion by soluble ACE and to 
bradykinin degradation at tissue sites.
The ACE insertion/deletion (I/D) polymorphism determines part of the interindividual 
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ACE variability, carriers of the D allele having higher tissue and plasma ACE levels. 
Unexpectedly, the higher ACE concentrations found in DD subjects do not result in a 
higher regional Ang I-II conversion rate and/or higher Ang II levels. Using plasma of 
DD and II subjects, it was observed that selective C-domain blockade fully blocked 
Ang I-II conversion in plasma of DD subjects whereas additional N-domain blockade 
was required to fully block this conversion in plasma of II subjects. Both domains 
contributed equally to the hydrolysis of bradykinin in plasma of DD and II subjects. 
The lack of Ang II accumulation in DD subjects might thus relate to the fact that in II 
subjects both the C- and N-domain generate Ang II whereas in DD subjects only the 
C-domain converts Ang I. As a consequence, the increase in ACE observed in DD 
subjects will not result in an increase in Ang I-II conversion, although it may result in 
enhanced bradykinin degradation.
Angiotensin receptors (Chapter 4, 5 and 6)
Ang II concentration-dependently decreased coronary fl ow (CF) and left ventricular 
systolic pressure (LVSP) in the mouse coronary vascular bed. Blockade of the AT2 
receptor and/or nitric oxide synthase (NOS) enhanced the Ang II-induced constrictor 
and inotropic responses, suggesting that Ang II exerts opposite effects on coronary 
and cardiac contractility via activation of AT1A and AT2 receptors. No Ang II-induced 
effects were however found during AT1 receptor blockade or in hearts of mice 
defi cient for the AT1A receptor. Thus, the AT2 receptor-induced, nitric oxide (NO)-
mediated effects occur only in conjunction with AT1A receptor activation.
Knock-out (KO) mice defi cient in either one, two or all three Ang II receptors are 
an ideal tool to study the receptor-specifi c functions and the putative AT receptor-
independent effects of Ang II and its metabolites. Mice lacking the AT1A receptor 
were characterized by a reduced heart rate, mean arterial blood pressure (MAP) 
and increased Ang II plasma levels. Triple KO mice showed an impaired survival and 
increased Ang II levels in plasma similar to that found in AT1A-defi cient mice whereas 
deletion of the AT2 receptor increased MAP. MAP of mice lacking both AT1 receptor 
subtypes dropped comparable to that observed in triple KO mice. In vivo, the Ang 
II pressor response in AT1A defi cient mice was impaired whereas defi ciency for the 
AT1B and/or AT2 receptor alone had no impact. The additional deletion of AT1B in AT1A-
defi cient mice further impaired the vasoconstrictive capacity of Ang II. Despite the 
fact that the general vasoconstrictor responses to endothelin-1 and phenylephrine 
were unchanged in triple KO mice, Ang II failed to affect MAP in these mice. This 
indicates that receptors other than the three known AT receptors are not involved in 
the Ang II-mediated pressor responses. 
In the rat coronary circulation, Ang III and Ang IV caused constriction via AT1 
receptor stimulation, although at lower potency than Ang II. Ang III, but not Ang 
IV, simultaneously induced vasorelaxation via AT2 receptors, and this was already 
apparent at subnanomolar Ang III concentrations, as opposed to the submicromolar 
concentrations of Ang II that were required to observe such relaxation. Ang-(1-7) 
did not exert effects of its own in the coronary circulation, but blocked AT1 receptor-
induced constriction at high concentrations. The relative constrictor potencies of the 
Chapter 8
124
3 angiotensin metabolites in rat iliac arteries and abdominal aortas were identical to 
those in the coronary vascular bed. These fi ndings suggest that in the rat coronary 
vascular bed AT2 receptor activation results in vasodilation, and that Ang III rather 
than Ang II is the endogenous agonist of these receptors. Ang III, Ang IV and Ang-(1-
7) do not exert effects through non-classical AT receptors in the rat coronary vascular 
bed, iliac artery or abdominal aorta.    
Renin inhibition (Chapter 7)
Spontaneously hypertensive rats (SHR) were treated with the renin inhibitor 
aliskiren, the AT1 receptor blocker irbesartan or the ACE inhibitor captopril at various 
doses, and monitored for a period of 3 weeks using radiotelemetry. All three RAS 
blockers lowered MAP in a dose-dependent manner without affecting heart rate. 
Irbesartan 15 mg/kg/day and captopril 3 mg/kg/day were equi-potent to aliskiren 
100 mg/kg/day in their ability to lower blood pressure. Treatment with the three RAS 
blockers at these doses increased coronary endothelial function (i.e., reactivity to 
bradykinin), whereas only aliskiren and irbesartan decreased the coronary response 
to Ang II. Simultaneously, at these doses, all 3 drugs decreased HW/BW ratio 
and cardiomyocyte area, although signifi cance was reached for the latter only. In 
conclusion, for a given decrease in blood pressure, aliskiren is as least as effective as 
AT1 receptor blockade and ACE inhibition with regard to improvement of endothelial 
function and cardiac hypertrophy.  
General Discussion
ACE
The active centers of the ACE C- and N-domain contribute equally to bradykinin 
hydrolysis.32,153 In contrast, selective inhibition of the N-domain did not affect the 
blood pressure responses to angiotensin (Ang) I bolus injections in mice,154 nor did 
targeted inactivation of the N-domain in mice affect blood pressure or plasma Ang 
II levels.155 This suggests that the ACE C-domain is the predominant site of Ang I 
conversion. The data in this thesis fully support this view, and a recent study in mice 
with targeted inactivation of the C-domain further confi rmed our fi ndings.308 Carriers 
of the ACE D allele display higher ACE levels than ACE I allele carriers. This is most 
likely due to the fact that the D allele leads to higher ACE mRNA expression.182 
Remarkably, the higher ACE levels in subjects with the DD genotype (as compared 
to II’s) do not result in a higher regional conversion rate nor in an alteration in the 
levels of circulating Ang II in DD’s.183-185,309 Ang II levels also did not differ between 
mice with different numbers of Ace gene copies,187,188  and compensatory renin 
regulation, as well as changes in the levels of Ang I-degrading enzymes, have 
been shown to explain the lack of effect of ACE titration on Ang II in mice. D allele-
related changes in renin or differences in Ang I degradation have however not been 
observed in humans184,189 and, thus, alternative explanations must be put forward for 
the absence of a D allele-related change in Ang II in man. Our observation in serum 
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that the N-domain contributes to Ang II generation in I allele carriers, on top of the C-
domain, offers an explanation for this phenomenon. This fi nding, if confi rmed in vivo, 
has multiple implications.
Clearly, I allele carriers should be treated with ACE inhibitors that block both domains. 
Since virtually all of the currently marketed ACE inhibitors do not make a distinction 
between the C- and N-domain (i.e., they block both domains when used at regular 
doses), this probably is already the case. For DD subjects, a C-domain selective 
ACE inhibitor might be suffi cient. Such selective ACE inhibitors most likely have less 
bradykinin-related side-effects.
Furthermore, given the absence of an effect of the D allele on Ang II generation, it 
is now understandable that no conclusive data have been obtained with regard to 
ACE genotyping and ACE inhibitor effi cacy. Future studies should therefore either 
make use of haplotypes,310,311 or apply an even simpler approach, i.e. perform ACE 
‘phenotyping’191 as a fi rst step toward personalized medicine for ACE inhibitors. In 
other words: to measure the concentration of ACE in circulating blood as a starting 
point. Plasma (or serum) ACE concentrations are stable within one individual,312 
and reasonably refl ect tissue ACE.181 Measuring ACE allows one to take into 
consideration the full variation range of ACE, and not just the <20% that is accounted 
for by the ACE I/D polymorphism.309 By measuring the response (e.g., the decrease 
in blood pressure) to a standard dose of an ACE inhibitor in patients with a wide 
range of ACE concentrations, one should be able to fi nally settle the question 
whether patients with high ACE levels respond better or worse than patients with low 
ACE levels.
Ace gene titration studies in mice do not necessarily refl ect the functional 
consequences of the ACE I/D polymorphism. Based on the present data, it appears 
that such studies should also incorporate the varying contribution of the two ACE 
domains. Finally, the molecular mechanism underlying the contributions of the 2 
ACE domains in I- and D-allele carriers should be unraveled. Since the insertion 
concerns a 287 base pair Alu repeat in intron 16 of the ACE gene, no molecular 
differences are to be expected between I and D ACE, and thus a factor in serum 
capable of interfering with ACE activity, e.g., an endogenous N-domain inhibitor, 
might be involved.   
Angiotensin receptors
In concordance with previous studies,45,46 our data show that mice lacking the AT1A 
receptor are hypotensive and display a reduced cardiac weight/body weight ratio.313 
In vivo, the pressure response to Ang II was almost completely abolished in AT1A 
receptor defi cient mice, whereas selective deletion of the AT1B - or AT2 receptor 
did not alter the response to Ang II. These fi ndings are in line with our (ex-vivo) 
Langendorff studies which demonstrated that the AT1A subtype is the only receptor 
subtype mediating vasoconstriction in the mouse coronary vascular bed.62 In vivo, 
deletion of the AT1B receptor on top of AT1A receptor defi ciency further decreased 
baseline blood pressure, and in such animals the pressor response to Ang II was 
absent. In-vitro studies by others have demonstrated that the AT1B receptor is the 
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most important regulator of Ang II-induced contractile responses in the mouse 
aorta and femoral artery.50 The fact that we did not fi nd a role for the AT1B receptor 
in the mouse coronary vascular bed can be explained by the lack of AT1B receptor 
expression in the heart.44 Humans express only one AT1 receptor subtype, and thus 
knowledge on the relative roles of both subtypes in rats and mice is of limited clinical 
importance. 
In vivo, deletion of the AT2 receptor increased blood pressure, whereas ex vivo, 
blockade of the AT2 receptor in the mouse and rat heart enhanced the AT1 receptor-
mediated vasoconstrictor response to Ang II. This effect was NO-dependent. These 
data confi rm that the AT2 receptor mediates vasodilatation, thus counteracting the 
contractile effects of the AT1 receptor.
57-60 Enhanced AT1 receptor-mediated effects, 
either in the coronary vascular bed or the systemic circulation, did not occur in AT2 
receptor KO mice, nor did we observe AT2 receptor-mediated vasodilatation in mice 
lacking AT1A and/or AT1B receptors. The former was not due to a selective upregulation 
of AT1A receptors in AT2 receptor KO mice, as suggested by others.
82,314,315 It could 
relate, at least in the systemic vascular bed, to the fact that only one (relatively high) 
dose of Ang II was tested, whereas an enhanced response will of course only be 
seen at lower, submaximal doses. However, in the coronary vascular bed, a whole 
range of Ang II concentrations was tested, and still no enhanced effect occurred 
in the absence of AT2 receptors. The most likely explanation of these fi ndings 
is therefore that AT2 receptor-mediated effects occur only in conjunction with AT1A 
receptor activation.62 Data supporting the existence of AT1/AT2 receptor heterodimers 
supports this idea.61 Further studies, preferably under pathological conditions (when 
AT2 receptors are upregulated
316) are required to fully unravel this phenomenon.  
Our studies in triple KO mice provided no evidence for hemodynamic effects of 
Ang II that are mediated via non-AT1/AT2 receptors, e.g., the Mas receptor or the 
AT4 receptor. Given the rapid in-vivo metabolism of Ang II to metabolites like 
Ang III, Ang IV and Ang-(1-7), these data suggest that also these metabolites do 
not induce (major) hemodynamic effects via non-AT1/AT2 receptors, although 
obviously additional studies infusing these metabolites in vivo are required to further 
substantiate this view. In-vitro studies with Ang III, Ang IV and Ang-(1-7) in both 
isolated rat hearts and blood vessels indeed did not provide evidence for non-AT1/
AT2 receptor-mediated effects of these metabolites. Both Ang III and Ang IV induced 
constrictor effects in an AT1 receptor-dependent manner, although at much lower 
potency than Ang II. This is not surprising given the current knowledge on Ang II-
AT1 receptor interaction.
280-282 In particular the concentrations of Ang IV that were 
required to obtain contractile responses were many orders of magnitude above its in-
vivo concentrations, thus making it unlikely that this metabolite exerts hemodynamic 
effects under normal physiological conditions. Unexpectedly, Ang III appeared to be 
a stronger AT2 receptor agonist than Ang II, with dilator effects already occurring at 
concentrations in the low nanomolar range. Possibly therefore, Ang III rather than 
Ang II is the preferred ligand for the AT2 receptor. Recent studies by others on Ang III-
induced natriuresis via AT2 receptor stimulation support this view.
97,283,317 
Ang-(1-7) exerted no effects in the coronary circulation, iliac artery or abdominal 
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aorta of the rat, but did act as an AT1 receptor agonist at micromolar concentrations. 
This mimics previous fi ndings in the rat renal vascular bed89,285 and the human 
forearm169, and suggests that Ang-(1-7), at pharmacological concentrations, acts as 
an AT1 receptor antagonist. Ang-(1-7) also exerts ACE-inhibitory effects,
32 and thus 
the benefi cial effects of Ang-(1-7) infusions in rats174 may be due, at least in part, to 
combined ACE inhibition and AT1 receptor blockade. 
The question remains whether AT2 receptor stimulation is of clinical relevance. The 
animal work in this thesis, as well as human in-vitro data58 support the idea of AT2 
receptor-mediated vasodilation. A wide range of animal studies suggest that the 
benefi cial effects of AT1 receptor antagonists actually depend on the AT2 receptor 
stimulation that will occur during such treatment,64,211 possibly even involving Ang-(1-
7) as an agonist.91 Given the lack of AT2 receptor-induced effects in the absence of 
AT1 receptors, and taking into consideration that the effectiveness of ACE inhibitors 
and AT1 receptor blockers is identical, one might speculate that, at most, AT2 receptor 
stimulation results in additional AT1 receptor blockade, and that no AT2 receptor-
induced effects will be observed once complete AT1 receptor blockade is obtained. 
Renin inhibition
Due to the species-specifi ty of the renin-angiotensinogen reaction, human renin 
inhibitors like aliskiren are relatively weak inhibitors of renin isoforms from non-
primate species, including rat, rabbit, and pig.290 Thus, testing aliskiren in rats 
requires the use of much higher doses (per kg body weight) than in humans. Yet, 
in order to get a better understanding of the mechanism of action of renin inhibitors, 
in particular of its effects on tissue angiotensin production, animal studies are 
required. Indeed, high doses do lower blood pressure effectively in spontaneously 
hypertensive rats (SHR).293 Obviously, much lower (human-like) doses can be applied 
successfully when using so-called double transgenic rats, i.e., rats that express both 
the human renin and angiotensinogen genes.318 These rats were actually designed 
to test human renin inhibitors, as they develop severe hypertension and end-organ 
damage due to the human renin-human angiotensinogen reaction. Thus, it is not 
surprising that renin inhibitors are highly effective in this model.292,319 In fact, without 
treatment these rats die within 6-7 weeks. The advantage of using SHR is that this is 
a well-established physiological model displaying the normal feedback mechanisms 
during RAS inhibition. Moreover, the use of SHR has contributed greatly to a 
better understanding of the mechanisms behind ACE inhibition and AT1 receptor 
blockade.297,300,320 It is for this reason that we have started to make a comparison 
between the 3 types of RAS blockade in SHR. Theoretically, various differences are 
expected to exist between the 3 groups of drugs.
First, renin inhibitors might have a pharmacokinetic advantage as compared to 
ACE inhibitors and AT1 receptor blockers, related to the fact that tissue angiotensin 
production depends on renin of renal origin. Thus, renin inhibitors may already bind 
to renin in the circulation, on its way to tissue sites, whereas the other blockers 
fi rst have to penetrate into the tissues to exert their effects. As a consequence of 
its binding to circulating renin, the renin-inhibitor complex will eventually replace 
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unbound “free” renin at tissue sites, thereby preventing angiotensin generation. 
Thus, the blood pressure-lowering effect of aliskiren may last for a considerable 
amount of time after stopping treatment (i.e., the time it takes to replace all aliskiren-
bound tissue renin by free renin), a phenomenon which has indeed been observed 
in humans321 and animals293. However, other mechanisms explaining this long-
lasting effect should also be considered. Aliskiren has a long half-life, of more than 
30 hours.322,323 Furthermore, it is conceivable that aliskiren accumulates at renal 
tissue sites, possibly even in renin storage granules, thus allowing the release of 
blocked renin even when treatment has stopped. This concept can be tested using 
renin-synthesizing cells in vitro. Finally, aliskiren may bind to prorenin, the inactive 
precursor of renin, either in blood (i.e., on its way to tissue sites) or at the tissue 
level. Recent studies suggest that prorenin gets activated at tissue sites, through its 
binding to the (pro)renin receptor. In fact, given its high levels, it might be prorenin 
rather than renin which is responsible for local angiotensin generation.110,324 Thus, a 
blocker which prevents prorenin-induced angiotensin generation might be an ideal 
tool to suppress tissue angiotensin generation.
Second, it is well-known that during RAS blockade renin levels will rise due to 
compensatory feedback mechanisms.1,147,325,326 Of course, such a rise in renin 
will also occur during renin inhibition. However, because of the presence of the 
renin inhibitor this renin cannot be enzymatically active, and thus the circulating 
angiotensin levels will remain low.289,327 Whether this is also true for tissue angiotensin 
levels remains to be proven. It has been suggested that the renin rise during renin 
inhibition with aliskiren is larger than during other types of RAS blockade.328 Given 
the aliskiren/renin stoichiometry during aliskiren therapy,329 it is highly unlikely that 
this renin is enzymatically active. However, such elevated renin levels might activate 
the (pro)renin receptor,15,186,330 and thus induce direct, angiotensin-independent 
effects. The same applies to prorenin, which will also rise during renin inhibition. 
(Pro)renin receptor-induced effects include an increase in DNA synthesis, activation 
of the mitogen-activated protein kinase p38, p42 and p44, stimulation of the 
release of transforming-growth factor-β1 and plasminogen activator-inhibitor-1, 
and phosphorylation of heat shock protein 27.14,288,331 In-vitro studies have already 
indicated that renin inhibitors do not interfere with (pro)renin-(pro)renin receptor 
interaction.332 The consequence of such (pro)renin receptor overstimulation is 
currently unknown. However, since such a (pro)renin rise also occurs during other 
types of RAS blockade, its detrimental effects, if present, should have been observed 
by now. A possible explanation comes from the work of Schefe et al.,333 who showed 
that, on activation of the receptor, the transcription factor promyelocytic zinc fi nger 
is translocated to the nucleus and represses transcription of the (pro)renin receptor 
itself, thus creating a short negative feedback loop. In other words: high (pro)renin 
levels, as occurring during RAS blockade, will suppress (pro)renin receptor 
expression, thereby preventing excessive receptor activation. Furthermore, the 
members of a family with a mutated renin allele, resulting in high plasma prorenin 
levels, were phenotypically normal.334  Future studies, applying (pro)renin receptor 
antagonists on top of aliskiren, should settle this issue.
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Third, during ACE inhibition and AT1 receptor blockade, the levels of various 
angiotensin metabolites (in particular Ang-(1-7) and Ang II) will rise, and a series of 
preclinical studies suggests that part of the benefi cial effects of these drugs involves 
either Mas receptor activation by Ang-(1-7) or AT2 receptor stimulation by Ang II.
335,336 
Obviously, given the decrease in the levels of all angiotensin metabolites during 
renin inhibition, such effects cannot occur during aliskiren treatment. So far, this does 
not appear to diminish the effects of renin inhibitors, at least on blood pressure,152 
possibly because a more complete RAS blockade induces the same effect as AT2 
receptor stimulation during AT1 receptor blockade, as discussed above. A similar 
explanation may apply to the potential benefi cial effects of Ang-(1-7) mediated by the 
Mas receptor, which is also known to form heterodimers with the AT1 receptor.
92,93,337 
Finally, given the many feedback mechanisms within the RAS, it seems unlikely that 
renin inhibitors will fully suppress the RAS. Thus, a combination of aliskiren with other 
RAS blockers might induce an even better blockade. With regard to blood pressure, 
this has already been observed150,291,338, and future studies should now address to 
what degree this is true with regard to end-organ damage. In this aspect, one might 
also consider aliskiren combination therapies with beta-adrenoceptor antagonists 
(which lower renin release) and/or (pro)renin receptor blockers.  
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Introductie en doel (Hoofdstuk 1)
Het renine-angiotensine systeem (RAS) speelt een belangrijke rol bij de regulatie 
van de water- en zouthuishouding en de bloeddruk. Vroeger werd het RAS gezien 
als een circulerend systeem (“circulerend” RAS) maar het is inmiddels algemeen 
bekend dat angiotensine (Ang) produktie ook plaatsvindt in weefsels (“weefsel” RAS). 
Angiotensinogeen (een voorloper gevormd in de lever) wordt door renine (enzym 
gevormd in de nieren) omgezet tot Ang I wat op zijn beurt kan worden omgezet in Ang 
II door het angiotensine I-converterend enzym (ACE). Als belangrijkste component 
van het RAS medieert Ang II zijn effecten via de angiotensine type 1 (AT1) en type 
2 (AT2) receptoren. In knaagdieren zijn er twee subtypen van de AT1 receptor 
geїdentifi ceerd: AT1A en AT1B. AT1 receptoren mediëren de welbekende effecten van 
Ang II zoals vasoconstrictie (vernauwing van bloedvaten), inotropie (beïnvloeding 
van de kracht van de samentrekking van de hartspier), chronotropie (beïnvloeding 
van de frequentie van de samentrekking van de hartspier), groeistimulatie en de 
afgifte van onder andere aldosteron en noradrenaline, en van AT2 receptoren 
wordt aangenomen dat deze over het algemeen een tegenovergesteld effect 
bewerkstelligen. Oorspronkelijk dacht men dat alle Ang II metabolieten inactief waren 
maar inmiddels is het duidelijk dat verschillende metabolieten, zoals Ang III, Ang IV 
en Ang-(1-7), zelf ook een functie hebben die mogelijk wordt gemedieerd door non-
AT1/AT2 receptoren. Onder pathofysiologische condities kan een overmatige RAS 
activiteit leiden tot een verhoogde bloeddruk en cardiale/renale hypertrofi e wat kan 
resulteren in eind-orgaanschade. Het RAS kan tegenwoordig worden geblokkeerd 
op drie verschillende niveaus: renine, ACE en de AT1 receptor. ACE remmers en 
AT1 receptor blokkers hebben hun effectiviteit al bewezen bij de behandeling van 
hypertensie (hoge bloeddruk) en andere cardiovasculaire ziekten. ACE remmers 
blokkeren de formatie van Ang II terwijl AT1 receptor blokkers voorkomen dat Ang 
II zijn effecten medieert via de AT1 receptor. Het is aannemelijk dat tenminste een 
deel van de voordelige effecten van AT1 receptor blokkers is te wijten aan stimulatie 
van de ongeblokkeerde AT2 receptor. Men denkt dat behandeling met de nieuw 
ontwikkelde renine remmers zal leiden tot een meer complete onderdrukking van 
het RAS omdat deze remmers aangrijpen op de eerste,  snelheids-beperkende stap. 
Het is duidelijk dat het RAS nog niet al zijn geheimen heeft geopenbaard. Stap voor 
stap vallen de stukjes van de puzzel op zijn plaats en een meer complete kennis 
van het RAS en zijn componenten zou kunnen leiden tot de ontdekking van nieuwe 
therapeutische doelen en verbeterde behandelingsmethoden.
ACE (Hoofdstukken 2 en 3)
Somatisch ACE bevat twee homologe domeinen (het C- en N-domein) die in staat 
zijn om Ang I en bradykinine te hydrolyseren. Selectieve remming van het C-domein 
leidde tot een rechtsverschuiving van de Ang I concentratie-respons curve (CRC) 
in de  arteriën van varkens, terwijl selectieve remming van het N-domein de door 
Ang I-geїnduceerde constrictie niet beїnvloedde. In humaan bloed werd de Ang 
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I-II conversie pas volledig geblokkeerd door remming van beide domeinen. De 
degradatie van bradykinine door membraan-gebonden ACE daarentegen was 
afhankelijk van beide domeinen; omdat zowel selectieve remming van het C- als 
N-domein leidde tot een verschuiving naar links van de bradykinine CRC, waarbij 
een maximale verschuiving naar links werd waargenomen na blokkade van beide 
domeinen. Dit betekent dat de Ang I-II conversie in weefsels afhankelijk is van het 
C-domein terwijl beide domeinen een rol spelen bij de conversie door ongebonden 
“soluble” ACE en bij de degradatie van bradykinine in weefsel. 
Het ACE insertie/deletie (I/D) polymorfi sme bepaalt een deel van de variabiliteit in 
ACE tussen verschillende individuen: dragers van het D allel hebben hogere ACE 
concnetraties in weefsel en bloed. Tegen de verwachtingen in, leiden de hogere ACE 
concentraties die worden gevonden in DD individuen niet tot een hogere regionale 
Ang I-II conversie snelheid en/of hogere Ang II levels. Met behulp van bloed van 
DD en II personen kon worden aangetoond dat selectieve remming van het C-
domein de Ang I-II conversie in het bloed van DD individuen volledig blokkeerde 
terwijl additionele remming van het N-domein nodig was om de conversie in bloed 
van II individuen volledig te remmen. Beide domeinen zijn gelijk in hun bijdrage aan 
de hydrolyse van bradykinine in plasma van DD en II individuen. Het uitblijven van 
een Ang II ophoping in DD personen wordt mogelijk veroorzaakt door het feit dat 
bij II individuen zowel het C- als N-domein Ang II genereren terwijl alleen het C-
domein Ang I converteert in DD individuen. Dit heeft tot het gevolg dat de toename 
in ACE die wordt gevonden in DD individuen niet zal resulteren in een toename van 
Ang I-II conversie, alhoewel deze wel kan zorgen voor een verhoogde bradykinine 
degradatie. 
Angiotensine receptoren (Hoofdstukken 4, 5 en 6)
Ang II zorgde voor een concentratie-afhankelijke verlaging van de coronaire fl ow 
(CF) en linker ventrikel systolische druk (LVSP) in het hart van de muis. Blokkade 
van de AT2 receptor en/of stikstof monoxide synthase verhoogde de Ang II-
geїnduceerde constrictoire en inotrope effecten wat de suggestie wekt dat Ang II 
tegenovergestelde effecten medieert op coronaire - en hartcontractiliteit via activatie 
van AT1A en AT2 receptoren. Er werden echter geen Ang II-geїnduceerde effecten 
gevonden tijden AT1 receptor blokkade of in harten van muizen die defi ciënt waren 
voor de AT1A receptor. Dus de AT2 receptor-geїnduceerde, stikstof monoxide-
gemedieerde effecten kunnen alleen plaatsvinden na activatie van de AT1A receptor.
Knock-out (KO) muizen defi ciënt voor een, twee of alle drie de Ang II receptoren 
zijn ideaal voor het bestuderen van de receptor-specifi eke functies en mogelijke AT 
receptor-onafhankelijke effecten van Ang II en zijn metabolieten. Muizen defi ciënt 
voor de AT1A receptor werden gekarakteriseerd door een lagere hartslag en 
bloeddruk, en een verhoogde Ang II concentratie in hun bloed. De overleving van 
triple KO muizen was afgenomen en deze dieren hadden een toegenomen Ang II 
concentratie in bloed, vergelijkbaar met die in AT1A-defi ënte muizen. Uitschakeling 
van de AT2 receptor verhoogde de bloeddruk. De daling in bloeddruk van muizen 
defi ciënt voor beide AT1 receptor subtypen was vergelijkbaar met die in triple KO 
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muizen. In vivo was het bloeddrukverhogende effect van Ang II afgenomen in AT1A 
defi ciënte muizen, maar niet in muizen met een defi ciëntie voor de AT1B en/of AT2 
receptor. De additionele deletie van de AT1B receptor in AT1A-defi ciënte muizen leidde 
tot een verdere afname van de vasoconstrictoire effecten van Ang II. Ondanks het 
feit dat de algemene vasoconstrictoire effecten op endotheline-1 en fenylefrine 
onveranderd waren in triple KO muizen, was Ang II niet in staat de bloeddruk te 
beïnvloeden in deze muizen. Dit geeft aan dat er geen andere receptoren dan de drie 
bekende AT receptoren betrokken zijn bij de Ang II-gemedieerde pressor effecten. 
Zowel Ang III als Ang IV zorgden voor een vasoconstrictoire response in de 
coronaire circulatie van de rat, hoewel hun potentie lager was dan die van Ang II. 
Tegelijkertijd induceerde Ang III, maar niet Ang IV, ook een vasorelaxatie via de AT2 
receptoren en dit was al duidelijk zichtbaar bij subnanomolaire concentraties van 
Ang III in tegenstelling tot de submicromolaire concentraties van Ang II die nodig 
waren om een dergelijke relaxatie waar te nemen. Ang-(1-7) medieerde geen 
effecten in de coronaire circulatie maar blokkerde wel de AT1 receptor-geïnduceerde 
constrictie bij hoge concentraties. De relatieve constrictoire eigenschappen van 
de drie angiotensine metabolieten in de arteria iliaca en abdominale aorta van de 
rat waren identiek aan de effecten die werden gevonden in de coronaire circulatie. 
Deze bevindingen suggereren dat AT2 receptor activatie in het coronaire vasculaire 
bed resulteert in vasodilatatie en dat Ang III in plaats van Ang II de endogene agonist 
is van deze receptoren. Ang III, Ang IV en Ang-(1-7) medieerden geen effecten door 
niet-klassieke AT receptoren in het coronaire vaatbed, arteria iliaca en abdominale 
aorta van de rat. 
Renine remming (Hoofdstuk 7)
Spontaan hypertensieve ratten (SHR) werden behandeld met verschillende doses 
van de renine remmer aliskiren, de AT1 receptor blokker irbesartan of de ACE remmer 
captopril, en gevolgd voor een periode van 3 weken met behulp van radiotelemetrie. 
Alle RAS blokkers verlaagden de MAP op een dosis-afhankelijke manier zonder 
hierbij de hartslag te beïnvloeden. Irbesartan 15 mg/kg/dag en captopril 3 mg/kg/
dag waren equi-potent in vergelijking met aliskiren 100 mg/kg/dag in hun vermogen 
de bloeddruk te verlagen. Behandeling met deze doses van de drie RAS blokkers 
verbeterde de coronaire endotheel functie (de reactiviteit op bradykinine), terwijl 
alleen aliskiren en irbesartan leidden tot een verlaagde coronaire respons op Ang 
II. Tegelijkertijd verlaagden alle drie de medicijnen de hartgewicht/lichaamsgewicht 
ratio en cardiomyocyt grootte, alhoewel signifi cantie alleen voor de laatste parameter 
werd bereikt. In conclusie kunnen we stellen dat, voor een gegeven daling in 
bloeddruk, aliskiren tenminste zo effectief is als AT1 receptor blokkade en ACE 
remming met betrekking tot de verbetering van de endotheel functie en de cardiale 
hypertrofi e.
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Dankwoord
Na lange tijd van data verzamelen, analyseren en proberen te beredeneren wat dit 
dan wel allemaal betekent is het er dan toch van gekomen, mijn proefschrift! Dit 
gehele proces was uiteraard absoluut onmogelijk geweest zonder de hulp van 
collega’s, vrienden en familie. Ik wil daarom de laatste bladzijden van dit proefschrift 
graag gebruiken om deze mensen, en ik hoop dat ik niemand vergeet, te bedanken. 
Daarom zijn we dan nu aangeland bij het, vaak eerst en meest gelezen hoofdstuk 
van het proefschrift, het dankwoord. 
Jan, als mijn promotor (en “RAS-goeroe”) ben jij natuurlijk de eerste die ik wil 
bedanken. Ze zeggen wel eens “alle begin is moeilijk” en ik denk dat dit ook zeker 
opgaat voor de eerste twee jaar van mijn AIO carriere. Je vertrouwen, positieve kijk 
en verhelderende blik hebben er mede toe bijgedragen dat ik vandaag hier sta en dit 
boekje heb kunnen afronden. Indrukwekkend dat jij in een oog opslag altijd meer uit 
een grafi ek weet te halen dan ik na uren staren. Bedankt dat ik altijd bij je aan kon 
kloppen voor steun, discussie of gewoon een praatje. 
Prof.dr. Jaap. Verweij, Prof.dr. Cock van Duijn, Prof.dr. Gerjan Navis wil ik bedanken 
voor bereidheid deel te nemen in de kleine commissie en de beoordeling van mijn 
proefschrift. Prof.dr. Carlos Villalon, Dr. Ton van den Meiracker en Prof.dr. Maarten 
Schalekamp wil ik bedanken  deelname in de grote commissie. Carlos, I am very 
happy that you were willing to combine your trip to Europe with being a member of my 
committee. Although we never really worked together we had some very interesting 
discussions (both work as non-work related) during your visits to our department. 
Ton, bedankt voor de interessante discussies en natuurlijk het gezelschap tijdens het 
camper avontuur/congres in Arizona. Prof.dr. Maarten Schalekamp, indrukwekkend 
hoe u alles binnen het RAS kunt verklaren met ingewikkelde formules die u zo uit uw 
mouw weet te schudden.  
Ik ben blij dat ik tijdens mijn promotie word bijgestaan door mijn twee kamergenoten 
van het eerste uur, Richard en Saurabh. Richard, je hebt een hele belangrijke rol 
gespeeld bij de tot standkoming van dit proefschrift. Je hebt me de afgelopen jaren 
ontzettend geholpen bij het opzetten en uitvoeren van de vele experimenten, mijn 
computerproblemen maar ook als ik een keertje op zoek was naar een leuke fi lm 
of wat muziek. Je bent altijd in voor een geintje en ik denk niet dat er nog ooit een 
weekje cursus komt dat kan tippen aan ons avontuur in Center Parcs. Als er ooit 
nog een vervolg komt rij jij! Saurabh, after I managed to clear the confusion that 
Saurabh and “Amu” in fact were one and the same person sitting in the same room 
with me, we quickly became good friends. You always have been there for me during 
good and bad times. We had a great time both in- as outside the lab and I am happy 
that we are still in such good contact after you moved to Denmark to continue your 
career. I am convinced I will have to call you Professor Gupta one day. 
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Wendy, vanaf dag een heb je me wegwijs gemaakt op het lab. Zeg nou zelf, van wie 
kon ik nu beter les krijgen dan de “Empress of Mulvany”? Ik kon altijd bij je terecht 
voor raad, advies of gewoon een praatje over van alles en nog wat. We hebben 
samen inmiddels heel wat congressen bezocht en naast de wetenschappelijke lading 
was er altijd tijd voor ontspanning en gezelligheid, ik hoop dat er nog vele zullen 
volgen! Trouwens, je mag het nu best eens vertellen hoor van die vingerhoedjes...... 
Manne (“Mr. Money” voor Arizona campertrip veteranen), jij hebt het strijken van 
congres-bloesjes toch wel echt tot een hogere dimensie verheven. Bedankt voor de 
gezellige tijd zowel binnen als buiten het werk. Ik denk dat je zelf inmiddels lekker op 
weg bent met het vullen van je eigen boekje en na mijn promotie ben jij de volgende, 
succes!
“Mijn studenten”, wil ik bedanken voor het vertrouwen, geduld en natuurlijk de 
gezelligheid. Voor mij was dit een hele leerzame periode en ik hoop dat jullie iets 
van mij hebben kunnen opsteken. Beste Chantal, hoofdstuk 6 is zeker “jouw ding”. 
Ik weet zeker dat dit hoofdstuk geen onderdeel van mijn boekje zou zijn geweest 
zonder je inzet en enthousiasme. Succes met het afronden van je studie Farmacie 
en ik hoop dat deze stage je toch nog een beetje warm heeft gemaakt voor het 
onderzoek. Els, ik vind het harstikke leuk dat ik de kans heb gekregen je op weg te 
helpen met je onderzoek tijdens je master-opleiding. Als sportfanaten onder elkaar 
hebben we altijd wel iets om over te kletsen. Ik vind het super dat we inmiddels 
collega’s en kamergenoten zijn geworden. 
Ingrid, ik ben altijd weer verbaasd wat er is te vinden in de zakken van jouw labjas; 
rekenmachientjes, buisjes, dopjes, roervlootjes, alles is daar te vinden! Harstikke 
bedankt voor het meten van al die bloed en orgaan “prutjes”. Ik weet dat hiervoor 
soms heel wat spierballen nodig waren! 
Kayi (“ontzettende vrouw”), ik hoop dat 3 juni voor jou een onvergetelijke dag word 
en veel succes met je verdere promotie onderzoek. 
De rest van mijn (ex-)collegas wil ik bedanken voor hun adviezen, hulp en gezellige 
tijd; Birgitte, Ria, René (de Vries), Wenxia, Antoinette, Anton, Mieke Suneet, Jan 
Heiligers† Jasper, Aloys, Hari, Thomas, Sylvia, Florian, Wang Yong, Jialin, Michaela, 
Vijay, Uday, Irene, Serge, Mellisa, Martin, Beril en Prof.dr. Saxena. Dit geld ook voor 
de “nieuwe” collegas van het hypertensie lab van Interne Geneeskunde; René (de 
Bruin), Pieter, Mariette, Joost, Leon, Gooitzen, Jeanette, Usha, Angelique, Marcel, 
Bianca, Evelien, Marjolein, Joyce, Edith en Frans Boomsma.
Mijn “schoonfamilie” Peter, Anja, Boet en Lobke wil ik bedanken voor al hun hulp en 
interesse tijdens mijn promotietraject. Peter en Anja, super dat jullie je reisschema 
konden aanpassen om hier vandaag bij te kunnen zijn. Boet veel succes met het 
afronden van je promotie onderzoek.
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En dan natuurlijk ons pap en ons mam! Jullie hebben me vrij gelaten en gestimuleerd 
om te gaan studeren wat ik zelf wilde en me geleerd dingen “geen halve bak” te 
doen. Bedankt voor jullie onvoorwaardelijke steun en vertrouwen. Inhoudelijk was 
het misschien een beetje moeilijk uitleggen wat ik nou precies uitvoerde op het lab, 
maar ik hoop dat dit boekje hier toch een beetje duidelijkheid in kan scheppen. Mijn 
“kleine” zusje Caroline en Maurice wil bedanken voor al hun steun en interesse. Voor 
jullie is juni, net als voor mij, een belangrijke maand in jullie leven. Ik weet zeker dat 
jullie op 13 juni een geweldig mooie dag gaan beleven!
Als laatste wil ik eindigen met mijn lieve vriendinnetje, Debby. Mijn dank aan jou is 
moeilijk in woorden uit te drukken. Ondanks je eigen drukke programma, stond je als 
geen ander altijd voor me klaar. Bedankt dat je het hebt volgehouden met mijn niet 
altijd even makkelijke persoontje. Zonder jouw steun en liefde had dit boekje er nooit 
gelegen. Ik weet zeker dat we heel erg gelukkig gaan worden in ons nieuwe droom-
huisje in Schiedam. 
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Curriculum Vitae
De auteur van dit proefschrift werd geboren op 3 mei 1979 te Oisterwijk, waar hij 
zijn HAVO diploma behaalde aan het Durendael College. In 1996 begon hij aan 
de studie Hoger Laboratorium Onderwijs aan Hogeschool Brabant te Etten-leur. 
In het laatste jaar liep hij 12 maanden stage op de afdeling Farmacologie bij TNO 
Prins Maurits Laborarium te Rijswijk. Onder supervisie van Dr. H.P.M. van Helden 
deed hij hier onderzoek naar surfactant-schade en longoedeem veroorzaakt 
door het longtoxische agens perfl uorisobutylene (PFIB). Na het behalen van 
zijn diploma in de specialisatie biochemie in 2000,  vervolgde hij zijn studietraject 
datzelfde jaar met de opleiding medische Biologie aan de Katholieke Universiteit 
Nijmegen. Zijn eerste stage liep hij op de afdeling Moleculaire biologie te Nijmegen 
waar hij onder leiding van Prof.dr. H.G. Stunnenberg en Dr. A. Vermunt onderzoek 
deed naar de expressie van de malaria vaccin kandidaat pfs48/45 door middel 
van het eukaryote vaccinia expressie systeem. Zijn tweede stage liep hij op de 
afdeling psychoneurofarmacologie te Nijmegen waar hij de hartslag, bloeddruk, 
lichaamstemperatuur en locomotor activiteit in APO-SUS en APO-UNSUS ratten 
bestudeerde met behulp van radiotelemetrie onder leiding van Prof.dr. A.R. Cools 
en Dr. A. Ellenbroek. In zijn doctoraalscriptie behandelde hij de rol van dopamine in 
de synaps, waarna hij in 2003 zijn diploma behaalde. 
Vanaf november 2003, is hij werkzaam geweest als assistent in opleiding op de 
afdeling Inwendige geneeskunde - sector Farmacologie, vasculaire en metabole 
ziekten (voorheen afdeling Farmacologie) van het Erasmus MC te Rotterdam 
onder supervisie van Prof.dr. A.H.J. Danser. Dit heeft uiteindelijk geresulteerd in dit 
proefschrift. Sinds november 2007, zet hij zijn werk voort als post-doc opdezelfde 
afdeling gesubsidieerd door Nederlandse Hartstichting (NHS).
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Abbreviations
ACE   Angiotensin converting enzyme
ACEi   ACE inhibitors
ACE2   Angiotensin converting enzyme 2
Ang   Angiotensin
Ang I   Angiotensin I  / Angiotensin-(1-10)
Ang II   Angiotensin II / Angiotensin-(1-8)
Ang III   Angiotensin III / Angiotensin-(2-8)
Ang IV   Angiotensin IV / Angiotensin-(3-8)
Ang-(1-7)  Angiotensin-(1-7)
ANOVA   Analysis of variance
AT1   Angiotensin type 1
AT1A   Angiotensin type 1A
AT1B   Angiotensin type 1B
AT2   Angiotensin type 2
AT4   Angiotensin type 4
A-779   D-ala7-Ang (1-7)
B2   Bradykinin type 2
BK   Bradykinin
Bpm   Beats per minute
BW   Body weight
CF   Coronary fl ow
cGMP   Cyclic Guanosine 3’, 5’ monophosphate
CRC   Concentration response curve
ERK   Extracellular signal-regulated kinase
ET-1   Endothelin-1
GPCR   G-protein-coupled receptor
L-NAME  Nω-nitro-L-arginine methyl ester HCl
LVSP   Left ventricular systolic pressure
HHL   Hip-His-Leu
HW   Heart weight
HR   Heart rate
IGFII   Insulin-like growth factor II
i.p.   Intraperitoneal
IU   International units
KH   Krebs Henseleit
KO   Knock-out
KW   Kidney weight
M6P   Mannose-6-phosphate
MAP   Mean arterial pressure
MAPK   Mitogen-activated protein
mmHg   Millimetres of mercury
NO   Nitric oxide
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NOS   Nitric oxide synthase
PCMA   Porcine coronary microarteries
PE   Phenylephrine
PFA   Porcine femoral artery
RAS   Renin angiotensin system
SHR   Spontaneously hypertensive rat
WKY   Wistar Kyoto
WT   Wildtype
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